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Abstract 
Irwin AD. The Diagnosis of Serious Bacterial Infections in the Children’s Emergency Department 
 
Background 
Acute febrile illness is a common presentation to the children’s Emergency Department (ED). 
Difficulty discriminating between Serious Bacterial Infections (SBI) and self-limiting infections 
results in delayed treatment of SBI, and over-treatment of self-limiting infections. 
 
Aims/Objectives 
To define the aetiology of bacteraemia in the children’s ED, to evaluate a universal molecular 
diagnostic for the diagnosis of bacteraemia, and to derive and validate risk prediction models 
for SBI in this setting. 
 
Methods 
A prospective diagnostic accuracy study of clinical and biomarker variables in febrile children 
presenting to the ED which incorporated a case-control study evaluating 16S rRNA followed by 
sequencing for the diagnosis of bacteraemia. An 11 year retrospective time series analysis 
described the aetiology of bacteraemia presenting to the children’s ED. The study had full 
ethical approval. 
 
Results 
Time series analysis of bacteraemia presenting to the ED between 2001 and 2011 (n=575) 
estimated an annual 10.6% reduction in vaccine-preventable infections, and an annual 6.7% 
increase in Gram-negative infections. The rate of healthcare-associated bacteraemia increased 
from 0.18 to 0.50 per 1000 ED attendances, and the proportion of isolates susceptible to 
empirical antibiotics declined from 96.3% to 82.6%. Episodes of Gram-negative bacteraemia 
received antibiotics 1h later than episodes of vaccine-preventable bacteraemia. 
1101 children were recruited to the diagnostic accuracy study. 146 children were included in an 
evaluation of 16S rRNA PCR in whole blood (SepsiTest) followed by sequencing for the diagnosis 
of bacteraemia. 120 ‘high-risk’ children were selected alongside 26 ‘low-risk’ children. SepsiTest 
identified 9/16 (56%) cases of bacteraemia. Combination with blood culture yielded a sensitivity 
of 75%, and specificity of 66%. SepsiTest identified 17/120 bloodstream infections with Viridans 
Group Streptococci in the high-risk group, and none in the low-risk group (p=0.06). 
A risk prediction model combining clinical variables with the biomarkers CRP, Procalcitonin and 
Resistin discriminated well between Pneumonia, ‘other SBIs’ and no SBI (AUC 0.84 and 0.77 
respectively). External validation of published models was performed and improvements in 
classification achieved by the addition of Procalcitonin and Resistin. The addition of biomarkers 
had particular value in ruling-out ‘other SBIs’ (NRI for non-events 5.3%). 
 
Conclusion 
Serious Bacterial Infections in the children’s ED are increasingly healthcare-associated, and 
remain difficult to recognise. Broad-range molecular tests which are culture independent may 
have a role as adjuncts to conventional microbiology but require ongoing evaluation. 
Meanwhile, risk prediction models improve discrimination between SBI and self-limiting 
infections and should be tested in robust impact studies.   
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 Chapter 1: Introduction 
1 
1.1. Synopsis of thesis 
The febrile child presents a common diagnostic dilemma. Most children presenting 
to the Emergency Department (ED) with an acute febrile illness will have a self-
limiting viral illness. A small number, however, will have a Serious Bacterial 
Infection (SBI), and will benefit from the prompt administration of antibiotics. 
Recognition of those children with SBI is often difficult, and poor discrimination 
between SBI and self-limiting illnesses may result in both delayed treatment of SBI, 
and over-treatment of self-limiting illness. This thesis seeks to address the challenge 
of improving diagnostic discrimination in febrile children in the ED.  
 
1.2. Overview of the chapter 
In this Chapter I aim to describe the burden of acute febrile illness in children 
presenting to the ED, the importance of identifying SBI in these children, and the 
difficulty of doing so. I set out the current diagnostic approach to the febrile child, 
including the use of clinical findings and laboratory tests. With reference to the host 
immune response to serious infection, I describe the existing evidence for newer 
markers of SBI in the children’s ED, and highlight the challenges associated with 
undertaking diagnostic accuracy studies in this field. Finally, I set out in detail the 
aims and objectives of the thesis. 
 
1.3. Background 
1.3.1. Acute febrile illness in the children’s Emergency Department 
In the UK in 2013, approximately 4 million children under the age of 16 attended 
the ED1. Acute febrile illnesses are the most common of all medical presentations to 
the children’s ED, the majority of which are caused by acute self-limiting infections2. 
Data from a single UK ED estimated that fever as a primary reason to attend ED 
accounted for 14% of all childhood medical presentations, and that acute infections 
(of which fever may have been a part) accounted for more than one half3. The same 
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study estimated that the number of medical presentations to the children’s ED 
increased by 40% between 2001 and 20113,4. Though there are no equivalent data 
from the UK, recent national data from the US reveal that almost one third of all 
childhood presentations to the ED are infection-related, of which 59% are upper 
respiratory or ear infections5. 
1.3.2. Serious Bacterial Infection in the children’s Emergency Department 
SBI is a heterogeneous term representing a group of infections requiring prompt 
and definitive antimicrobial therapy. Diagnoses reported as SBI in diagnostic 
accuracy studies in children are listed in Table 1. In young children in highly 
resourced settings SBI account for an estimated 7% of acute febrile illnesses 
presenting to the ED6.  
 
Category of SBI 
Bacteraemia/septicaemia 
Meningitis 
Pneumonia 
Urinary tract infection/pyelonephritis 
Osteomyelitis 
Septic arthritis 
Bacterial gastroenteritis 
Mastoiditis 
Table 1: Diagnoses reported as SBI in diagnostic accuracy studies in children7-10 
 
SBI are associated with significant morbidity and mortality in children. 
Meningococcal disease (MCD) - septicaemia or meningitis caused by Neisseria 
meningitidis - is the most common fatal bacterial infection in UK children11. Whilst 
its incidence in the UK has declined following the introduction of the conjugate 
vaccine against serogroup C12, it remains higher than that of other European 
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countries13. Delays in the treatment of MCD and other severe sepsis increase 
mortality, and the likelihood of long term disability14-17. 
Pneumonia and urinary tract infection (UTI) are the most common SBIs seen in the 
children’s Emergency Department6. Whilst the introduction of effective vaccines 
against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae has 
reduced the contribution of these bacterial pathogens to the burden of bacterial 
pneumonia18,19, complications from pneumonia remain an important cause of 
hospital admission in the UK20. Globally, pneumonia remains the single most 
important cause of childhood death21. 
Childhood UTI exerts a significant and increasing burden on hospital services. In the 
UK, hospital admission rates of children with UTI increased by 39% between 2001 
and 201122. UTI may be associated with septicaemia and meningitis, particularly in 
young infants or immunocompromised children. Approximately one third of 
children with UTI involving the upper urinary tract subsequently develop renal 
scars23. 
1.3.3. Epidemiology of Serious Bacterial Infection in children 
1.3.3.1. The global burden of Serious Bacterial Infection in children 
Globally, SBI remains a substantial contributor to child mortality. Pneumonia alone 
is estimated to cause 1.5 million deaths in children under 5 each year21,24. Child 
deaths attributable to invasive Streptococcus pneumoniae and Haemophilus 
influenzae type b infections are estimated to equal those collectively attributable to 
HIV, Tuberculosis and malaria18,19. In malaria endemic regions, the diagnosis of 
malaria frequently leads to a failure to recognise and treat SBI25,26. Simultaneously, 
World Health Organisation (WHO) guidelines for the management of childhood 
febrile illness in these regions encourage the use of antibiotics in often self-limiting 
non-malarial febrile illness26, reflecting a failure both to recognise SBI when it is 
present, and to rule it out when it is absent. 
‘Sepsis’ (which I will discuss in more detail in Section 1.6.2) describes the systemic 
manifestations of the inflammatory response to serious infection. Recently, a large 
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international study of paediatric intensive care units (PICUs) estimated the point 
prevalence of ‘severe sepsis’ to be 8.2% of all PICU patients. More than three 
quarters of cases of severe sepsis occurred in children with comorbidities. Mortality 
was approximately 25%, and 17% of survivors developed a significant disability27. 
Evidence from both North America and Australasia suggests that its frequency has 
increased over the last decade28,29 
1.3.3.2. Serious Bacterial Infection in children in the UK 
In the UK, SBI caused by Hib30, Neisseria meningitidis12,31,32, and Streptococcus 
pneumoniae20,33 have declined dramatically following the introduction of effective 
conjugate vaccines. Other invasive bacterial pathogens for which effective 
immunisations have yet to be implemented continue to cause significant disease 
however. Outbreaks of invasive Group A Streptococcus (iGAS) infections associated 
with substantial mortality have been reported in the UK in recent years34,35. Toxic 
shock syndrome caused by both iGAS and Staphylococcus aureus is rare – with an 
estimated incidence of 0.38 per 100000 children in the UK – but often requires 
intensive care support, and carries a significant risk of death36. Overall, SBI are 
estimated to cause 20% of all child mortality in the UK37.  
The UK’s NHS Hospital Episode Statistics database provides publicly available 
national data for all clinical episodes (http://www.hscic.gov.uk/hes). In the year to 
April 2013, there were approximately 39 000 clinical admissions of children under 
the age of 16 years old with SBI as a primary diagnosis. Figure 1 illustrates the most 
common SBI diagnoses requiring admission to hospital. 
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Figure 1: Number of hospital admissions in children (<16y) with SBI in the UK in 2013
38
. Pneu: 
Bacterial pneumonia and empyema. Bact: Bacteraemia. BJI: Bone and joint infection. GI: Bacterial 
enteric infection. CNS: Bacterial meningitis. ENT: Mastoiditis. 
 
1.3.3.3. Bacteraemia in children in the UK 
Bacteraemia in children in the UK is now uncommon in previously healthy children. 
A study of bacteraemia and meningitis in hospitals in south London between 2009 
and 2011 estimated the population incidence of ‘community-acquired’ bacteraemia 
or meningitis – that is, bacteraemia and meningitis diagnosed within 48 hours of 
presentation to hospital – to be 18 per 100 000. Two thirds of these cases occurred 
in children with significant comorbidities. In children with no comorbidities, the 
estimated incidence of community-acquired bacteraemia was 5.3 per 100 00039. 
Low estimates of age standardised hospital admission rates for bacteraemia and 
meningitis caused by N.meningitidis, S.pneumoniae and Hib have similarly been 
reported in the UK, alongside longitudinal data demonstrating the impact of 
immunisation on declining rates12. 
Whilst the incidence of childhood bacteraemia in the UK caused by vaccine-
preventable organisms has declined, a 10 year study of data from NHS microbiology 
databases revealed an increase in both Gram-negative infections (such as 
Enterobacteraeciae), and less virulent Gram-positive infections such as Coagulase 
negative Staphylococci and non-pyogenic Streptococci40. 
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In summary, acute febrile illnesses make up a significant proportion of all 
presentations to the children’s ED. Of these, SBI are a small but important 
component. Not only are SBI relatively uncommon, but the presentation of SBI is 
evolving as immunisation reduces the incidence of the most common invasive 
childhood pathogens. Furthermore, children presenting to the ED with SBI are 
increasingly those with significant comorbidities. Understanding changes in the 
aetiology of, and risk factors associated with, childhood SBI is necessary in order to 
improve its recognition and treatment. Improving the ability of clinicians to 
discriminate between SBI and self-limiting febrile illness would allow prompt 
intervention and therapy in those who need it, whilst supporting rational decision-
making regarding antimicrobial use and the need for hospital admission. 
 
1.4. Diagnosing Serious Bacterial Infection in children 
1.4.1. The importance of prompt identification: ‘Ruling in’ SBI 
The prompt recognition and treatment of SBI improves outcomes, and forms the 
basis of management in sepsis. Clinical guidelines commonly refer to the ‘golden 
hour’ of sepsis management. This is the recommendation that antibiotics are 
commenced within one hour of recognition of severe sepsis, based upon the 
demonstration of increasing mortality for every hour of delayed therapy41. 
In children with suspected sepsis in the ED, average time to administration of 
antibiotics is more than 2 hours from arrival42. In the case of MCD, delays to 
antibiotic administration are associated with increased mortality43, while pre-
hospital antibiotics reduce the likelihood of death44. The signs and symptoms of 
MCD are non-specific early in the disease process and rapidly progressive45. 
Approximately one half of children with MCD are not identified at first contact with 
medical services14,45.  
Prompt and appropriate antimicrobial therapy for other SBIs is intuitively 
important. Though there is little evidence to associate delayed antibiotics with 
adverse outcomes in children with pneumonia in the ED, a small study of children in 
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paediatric intensive care reported that longer time to appropriate antibiotics was 
associated with an increased duration of mechanical ventilation 46. Delays in the 
treatment of UTI in infants have been associated with the development of 
subsequent renal scarring47. 
1.4.2. Rational diagnosis: ‘Ruling out’ SBI 
The consequences of poor diagnostic discrimination are not limited to a failure to 
‘rule in’ serious infection. Faced with diagnostic uncertainty, and difficulty ‘ruling 
out’ serious infection in the ED, clinicians are committed to prolonged clinical 
observation, including the possibility of unnecessary admission to hospital and 
antimicrobial treatment. For those children discharged home, appropriate 
strategies to allow the recognition of a deteriorating condition (‘safety-netting’) are 
necessary48. 
An increase in short-stay uncomplicated hospital admissions in children suggests 
that clinicians are adopting an increasingly risk-free approach to the febrile 
child22,49. Over the last decade, the likelihood of a young child being admitted to 
hospital with an acute infection categorised as ‘primary care sensitive’ – one which 
may be appropriately managed in the community – has approximately doubled22. 
An increasing burden of medical attendances to ED3, associated with changes to 
medical training and working patterns50 may all have contributed to this minimum 
risk approach. Improving the ability of clinicians to confidently rule out SBI has 
significant potential to rationalise hospital admission. 
Alongside decisions relating to the need for hospital admission, diagnostic 
uncertainty in acute febrile illness may also result in the overuse of antibiotics. 
Guidelines from both the National Institute for Health and Care Excellence (NICE) 
and the British Thoracic Society advocate the use of antibiotics for the management 
of respiratory infections in children where ‘the patient is systemically very unwell’, 
or has ‘signs and symptoms suggestive of serious illness’51,52. The subjectivity of 
these assessments may partly underlie the substantial geographical variation in 
antibiotic prescribing observed across even highly immunised populations. Large 
ecological studies from Europe identified a threefold variation in antibiotic 
8 
prescribing between the highest and lowest prescribing nations53,54. This prescribing 
is strongly associated with the occurrence of antibiotic resistant organisms54. 
Improving rational prescribing is a central component of the World Health 
Organisation global strategy for the containment of antimicrobial resistance55.  
 
In view of the substantial difficulty faced by clinicians in ruling in, or ruling out SBI, 
the value of clinical signs and adjunctive diagnostic tests has been extensively 
evaluated in diagnostic accuracy studies. 
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1.5. Methodological issues in diagnostic accuracy studies 
Before summarising diagnostic accuracy studies of SBI in febrile children presenting 
to the ED, I will describe the importance of robust methods in the undertaking and 
reporting of such studies. 
 
Diagnostic accuracy measures the agreement between the test of interest (the 
‘index test’) and the target condition as determined by a pre-defined reference 
standard. The validity of the findings of diagnostic accuracy studies, and their 
applicability to clinical care are dependent upon the methodology applied. Poorly 
designed studies are associated with biased, often optimistic assessments of 
diagnostic performance56,57. Furthermore studies in which the population, test and 
outcome of interest are ill-defined are difficult to interpret.  
 
1.5.1. Standards for Reporting of Diagnostic Accuracy (STARD) guidelines 
Concern regarding the design and reporting of diagnostic accuracy studies 
prompted the Cochrane diagnostic and screening test methods working group to 
develop a checklist of items to be included in diagnostic accuracy studies, resulting 
in the Standards for Reporting of Diagnostic Accuracy (STARD, Table 2)58. The 
objectives of the STARD initiative were to improve the clear reporting of diagnostic 
accuracy studies in order to allow readers to evaluate potential bias in a study 
(which determines the internal validity of the study), as well as to assess the 
generalisability of the findings (that is, its external validity). 
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Section and Topic Item 
# 
 On 
page # 
TITLE/ABSTRACT/ 
KEYWORDS 
1 Identify the article as a study of diagnostic accuracy (recommend MeSH 
heading 'sensitivity and specificity'). 
 
INTRODUCTION 2 State the research questions or study aims, such as estimating diagnostic 
accuracy or comparing accuracy between tests or across participant groups. 
 
METHODS 
Participants 
3 The study population: The inclusion and exclusion criteria, setting and 
locations where data were collected. 
 
 4 Participant recruitment: Was recruitment based on presenting symptoms, 
results from previous tests, or the fact that the participants had received the 
index tests or the reference standard? 
 
 5 Participant sampling: Was the study population a consecutive series of 
participants defined by the selection criteria in item 3 and 4? If not, specify 
how participants were further selected. 
 
 6 Data collection: Was data collection planned before the index test and 
reference standard were performed (prospective study) or after 
(retrospective study)? 
 
Test methods 7 The reference standard and its rationale.  
 8 Technical specifications of material and methods involved including how and 
when measurements were taken, and/or cite references for index tests and 
reference standard. 
 
 9 Definition of and rationale for the units, cut-offs and/or categories of the 
results of the index tests and the reference standard. 
 
 10 The number, training and expertise of the persons executing and reading the 
index tests and the reference standard. 
 
 11 Whether or not the readers of the index tests and reference standard were 
blind (masked) to the results of the other test and describe any other clinical 
information available to the readers. 
 
Statistical methods 12 Methods for calculating or comparing measures of diagnostic accuracy, and 
the statistical methods used to quantify uncertainty (e.g. 95% confidence 
intervals). 
 
 13 Methods for calculating test reproducibility, if done.  
RESULTS 
Participants 
14 When study was performed, including beginning and end dates of 
recruitment. 
 
 15 Clinical and demographic characteristics of the study population (at least 
information on age, gender, spectrum of presenting symptoms). 
 
 16 The number of participants satisfying the criteria for inclusion who did or did 
not undergo the index tests and/or the reference standard; describe why 
participants failed to undergo either test (a flow diagram is strongly 
recommended). 
 
Test results 17 Time-interval between the index tests and the reference standard, and any 
treatment administered in between. 
 
 18 Distribution of severity of disease (define criteria) in those with the target 
condition; other diagnoses in participants without the target condition. 
 
 19 A cross tabulation of the results of the index tests (including indeterminate 
and missing results) by the results of the reference standard; for continuous 
results, the distribution of the test results by the results of the reference 
standard. 
 
 20 Any adverse events from performing the index tests or the reference 
standard. 
 
Estimates 21 Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 
95% confidence intervals). 
 
 22 How indeterminate results, missing data and outliers of the index tests were 
handled. 
 
 23 Estimates of variability of diagnostic accuracy between subgroups of 
participants, readers or centers, if done. 
 
 24 Estimates of test reproducibility, if done.       
DISCUSSION 25 Discuss the clinical applicability of the study findings.  
Table 2: Standards for Reporting of Diagnostic Accuracy (STARD) checklist. http://www.stard-
statement.org. Accessed 11th December 2013.  
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1.5.2. Evaluating diagnostic accuracy in the absence of a ‘gold’ standard 
A significant methodological challenge in diagnostic accuracy studies is that of 
establishing appropriate reference standards against which to evaluate the index 
test of interest. A ‘gold’ reference standard would establish the presence or 
absence of the target condition, reliably identifying the true state of each study 
subject. In the context of infectious disease diagnostics, few such ‘gold’ standards 
exist. Reference standards based upon microbiological confirmation of infection are 
limited by their own lack of sensitivity59. In children, even obtaining microbiological 
samples for respiratory infections60,61, or bone and joint infections may be 
difficult62. As a result, surrogate measures such as radiological evidence of bacterial 
pneumonia or osteomyelitis are often used, despite their limitations63. This can lead 
to misclassification of cases which may have an impact on the estimated 
performance of the index test under investigation64,65. 
1.5.2.1. Misclassification 
In the classical diagnostic accuracy paradigm, disagreement between index test and 
reference test is considered to be a ‘false’ result of the index test, while 
classification of the target condition by the reference standard is considered error 
free. Classification errors of the target condition by the reference standard will thus 
affect estimates of the accuracy of the index test. The impact of this 
misclassification is hard to predict. If errors of classification occur at random and 
are independent of the index test, then misclassification is said to be ‘non-
differential’. Such non-differential misclassification results in estimates of diagnostic 
accuracy which are biased towards the null – it under-estimates the diagnostic 
accuracy of the index test. Conversely, where misclassification errors are correlated 
with errors in the index test (‘differential misclassification’), this results in 
erroneous agreement between the index and reference tests and inflated estimates 
of diagnostic accuracy64,65. 
In order to remedy the impact of imperfect reference standards on estimates of 
diagnostic accuracy, various approaches have been described. These have been 
extensively reviewed64.  
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1.5.2.2. Adjustments to the reference standard 
One approach to the problem of an imperfect reference standard is to adjust 
estimates of diagnostic accuracy of the index test based upon external data 
describing the accuracy of the reference standard. If reliable estimates of diagnostic 
accuracy of the reference standard are available, and if the error inherent in the 
reference standard is independent of error in the index test, then statistical 
corrections to the accuracy of the index test can be made to account for known 
error in the reference test. Often however, little is known about the ‘true’ accuracy 
of the reference standard. In this case sensitivity analyses may be undertaken which 
adjust for the accuracy of reference test across a range of plausible estimates. 
Where the assumption of conditional independence between the errors is false, a 
correlation parameter may be included, and if the degree of correlation is unknown 
this too may be varied across a range of plausible values in order to adjust 
estimates for the index test66. 
1.5.2.3. Composite reference standard 
An alternative approach to the use of an imperfect reference standard is to seek a 
consensus outcome from a number of ‘expert’ investigators. These approaches 
have proved popular, but risk incorporation bias whereby index tests under 
investigation are used as part of the rule to determine outcome64,65. In this context, 
the incorporation of the index test may result in inflated estimates of index test 
accuracy. One solution to this is to use a pre-defined rule to define the composite 
reference standard in terms of a number of imperfect reference standards. While 
the use of expert panels may bring together significant expertise in order to define 
a reference standard, this lacks a formal data-driven methodology. 
1.5.2.4. Latent class analysis 
Latent class analysis is a formal statistical approach that combines multiple pieces 
of information in order to construct a composite reference standard. In this case, an 
unknown ‘latent’ variable (for example, the presence or absence of SBI) can be 
modelled against observed ‘manifest’ variables, including any imperfect reference 
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standards. The probabilities of observing true and false positive and negative test 
results can be described in terms of the (unknown) sensitivity and specificity of 
each test and the (observed) prevalence. Using maximum likelihood methods, the 
solution (the estimates of sensitivity and specificity for each of the latent variables) 
which best describes the observed data can be obtained67. 
While the use of latent class models is well established, and the statistical solution 
satisfying, latent class models may be criticised for failing to define the latent 
variable clinically - it can be hard to understand what exactly the target condition 
defined by the latent variable is. Furthermore, the incorporation of the index test 
into the definition of the target condition is inherent to the latent class method, 
though it could be argued that this is a less significant problem than in other 
methods which define a composite reference standard.  
1.5.2.5. Evaluating improvements to the reference standard 
When the limitations of an existing reference test are recognised, disagreement 
between the results of a new index and the existing reference test may represent 
an improvement in diagnostic accuracy. Evaluating a molecular method of 
infectious disease diagnosis based on PCR against a culture based reference 
standard with limited sensitivity, for example, may yield new positive ‘cases’. These 
may represent false positive results or an improvement in sensitivity against the 
existing standard. Importantly, these new identifications may represent a new 
definition of the target condition. Are these new cases associated with less severe 
disease, and what are the consequences of their identification? Understanding the 
implications of discordant cases is necessary in order to determine whether the 
new index test is an improvement on the reference standard. 
Evaluating discordance between index and reference tests may be achieved using a 
third test. This test, which has been called an ‘umpire’ test, must be related to the 
target condition, but independent of both the index and reference tests under 
evaluation. It may be a related exposure, another diagnostic test, or a response to 
treatment. Inevitably an imperfect diagnostic test for the outcome of interest, it 
only matters that its errors are unrelated to those of the other tests68.  
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An example of this approach was given in the evaluation of the interferon gamma 
release assay, ELISPOT, for the diagnosis of latent Tuberculosis infection (LTBI) in 
the context of a school TB outbreak69. This study compared the use of ELISPOT to 
the established, but recognisably imperfect reference standard of the Tuberculin 
skin test (TST). Though there was substantial agreement between the two tests, in 
approximately 11% (61/535) of children, the tests were discordant. The authors 
used a third measure – that of exposure to the index TB case – as an independent 
adjudicator. In identifying that the ELISPOT correlated more closely with TB 
exposure, it concluded that the method was an improvement on the TST for the 
identification of LTBI. This assertion was tested further by the follow up of children 
identified to have positive and negative tests to look at subsequent development of 
TB disease, which in this case is the clinical condition of most consequence.  
1.5.3. Diagnostic accuracy studies in paediatric SBI 
Diagnostic accuracy studies in paediatric SBI present particular problems. As 
described above, misclassification of study subjects caused by imperfect reference 
standards may impact the accuracy, and internal validity of published studies. The 
external validity of studies meanwhile is frequently limited by restrictive inclusion 
criteria such as those based upon age, or temperature at presentation. These 
inclusion criteria may themselves be associated with the likelihood of SBI. External 
validity is limited too by the heterogeneity of studied populations, and by the use of 
various definitions of SBI. Evidence of this heterogeneity can be seen as variation 
between studies in the proportion of subjects with a diagnosis of SBI8. 
Finally, studies which incorporate the use of invasive tests, including simple blood 
tests in children, may be considered ethically justifiable only if undertaken in 
children already undergoing invasive clinical investigations. In the ED, this results in 
the study of a population of children at higher risk of SBI. Applying findings from 
such a population to a lower risk group may not be appropriate. 
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An understanding of the requirements of diagnostic accuracy studies is important 
both in the design of high quality studies and in their interpretation. 
Methodologically robust studies ensure that reliable estimates of diagnostic 
accuracy can be made, upon which to consider the implications for clinical practice. 
 
1.6. Current approaches to the diagnosis of SBI in the children’s ED 
Here I aim to describe the current diagnostic approach to SBI in children in the ED, 
moving from the ideal scenario of rapid, accurate pathogen identification, to the 
use of indirect evidence of SBI based upon clinical or biomarker variables. 
 
1.6.1. Pathogen identification  
1.6.1.1. Culture-based methods of identification 
The ideal diagnostic test for SBI would allow rapid, accurate identification of the 
causative organism in order to guide timely and effective antimicrobial treatment. 
In children, obtaining appropriate samples is the first challenge to overcome. 
Sampling for possible UTI is relatively straightforward, but the process of obtaining 
adequate samples for the diagnosis of pneumonia, meningitis and bacteraemia are 
all associated with significant difficulty. Sputum samples from children with 
suspected pneumonia require the child to be able expectorate, while the 
identification of an organism, particularly if from the upper respiratory tract, does 
not attribute causation70. Obtaining adequate samples of CSF and blood may also 
be a technically demanding, particularly in unwell children. For the diagnosis of 
bacteraemia the volume of blood obtained is directly associated with the culture 
yield59. 
Culture-based methods of pathogen identification are limited most obviously by the 
time they require. Following the initial identification of a positive isolate in a clinical 
sample, conventional pathogen identification involves a process of phenotypic 
testing designed to characterise the isolate71. This process of analysis may take 
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several days to complete. An alternative to this phenotypic approach uses a 
technique called matrix-assisted laser desorption ionisation-time of flight (MALDI-
TOF) mass spectrometry (MS). In this, a sample taken from a positive culture isolate 
is mixed with a matrix material before ablation using a pulsed laser. The resultant 
peptides are ionised and accelerated into a mass spectrometer. Identification of the 
organism is achieved by comparing the peptide spectrum of the sample with 
reference spectra72. Positive evaluations of MALDI-TOF MS in terms of the reliability 
of pathogen identification, time taken, and cost involved have encouraged uptake 
into clinical practice73. Other platforms at a more exploratory stage of development 
are discussed in Chapter 4. 
Though techniques such as MALDI-TOF MS promise to reduce the time from 
positive culture to pathogen identification, culture-based methods are insufficiently 
timely to impact treatment decisions at the time of diagnosis.  
1.6.1.2. Molecular methods of identification  
Culture independent methods of pathogen identification are of substantial interest. 
Polymerase chain reaction (PCR) is now a well-established technique which allows 
the amplification of specific regions of – in this context – bacterial DNA 
complementary to the primers used in the assay74 (see Section 4.2.2). PCR-based 
testing may be completed within a few hours. For the diagnosis of bacteraemia, the 
technique requires smaller volumes of blood than culture, and is less affected by 
prior antibiotic treatment75. Specific PCR assays for the identification of individual 
organisms, such as N.meningitidis are highly sensitive and specific76, but only 
provide information about the presence or absence of the target organism. For the 
diagnostic assessment of the febrile child, the molecular approach would need to 
identify a broad range of potential pathogens. 
In recent years, a number of broad-range molecular tests for the diagnosis of SBI 
have been developed and evaluated77. These tests are largely based upon 
identification and amplification of highly conserved regions of 16S ribosomal RNA 
(rRNA), and can be considered in two groups. ‘Multiplex’ PCR assays target a range 
of likely causative organisms using a panel of pathogen-specific probes, whilst 
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‘universal’ PCR assays achieve speciation with the use of a post-PCR process such as 
DNA sequencing or mass spectrometry78. Commercially available broad-range 
molecular tests are detailed in Chapter 4. 
The first broad-range molecular test to achieve the European CE mark for the 
diagnosis of bacteraemia was SeptiFast (Roche Diagnostics, Mannheim, Germany). 
Pathogen identification using SeptiFast is based upon the use of species-specific 
probes for 25 of the most common bloodstream pathogens. In vitro it has been 
found to be highly sensitive and specific79. In clinical diagnostic accuracy studies, 
however, its performance has been more variable. A recent systematic review 
funded by the National Institute for Health Research (NIHR) highlighted substantial 
methodological weaknesses of the published evidence and failed to reach clear 
conclusions about its clinical utility80. 
The use of broad-range PCR assays in whole blood samples is a technical challenge. 
Host DNA is present in whole blood in much greater quantities than pathogen DNA, 
and inhibitory to the PCR reaction necessary for pathogen detection77. One solution 
to this is to selectively lyse host cells and degrade host DNA, recovering intact 
pathogens before isolation of pathogen DNA81. MolYsis (Molzym, Bremen, 
Germany) is a commercially available pre-analytical process designed in this way to 
selectively extract pathogen DNA. The method has been demonstrated to 
substantially reduce host DNA contamination, and increase the sensitivity of 
pathogen detection in clinical whole blood samples82. 
In adults, PCR amplification of variable regions of the 16S rRNA gene followed by 
sequence analysis (using SepsiTest, Molzym) has proven a sensitive method for 
detecting and identifying a broad range of aetiologies of sepsis and infectious 
endocarditis83,84. The sensitivity of this approach in small volume blood samples 
from children has yet to be demonstrated however. 
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1.6.2. Clinical indicators of SBI in children 
In the absence of timely, direct pathogen identification, clinicians are required to 
look for indirect evidence of the presence of SBI. The systemic response to serious 
infection is termed ‘sepsis’. More accurately, sepsis describes manifestations of a 
dysregulated host immune response associated with severe infection and organ 
dysfunction85. Sepsis in children was defined at an international conference in 
200586, modifying criteria established in adults87. Age appropriate clinical (and 
biomarker) variables determine the presence of the Systemic inflammatory 
response syndrome (SIRS), while sepsis requires the presence of SIRS alongside 
evidence of a causative pathogen which may be microbiologically proven or 
strongly suspected on clinical grounds. As a consensus definition, the term is not 
without limitations. A large recent study of adult intensive care patients found that 
the use of SIRS criteria to determine the presence of sepsis excluded 1 in 8 patients 
with ‘severe sepsis’88. 
Whilst primarily designed to address the challenge of sepsis in a critical care setting, 
the definition highlights some of the clinical features consistent with systemic 
infection (such as temperature, heart rate and respiratory rate) and is relevant to 
the diagnosis of SBI in the ED. Extensive investigation has been undertaken in the 
paediatric ED to identify those clinical features that delineate SBI from self-limiting 
infection, or illnesses of a non-infectious nature.  
The value of clinical signs in the diagnosis of serious infections in children was 
comprehensively summarised in a recent systematic review 10. Most of the 
published studies were undertaken in EDs where the likelihood of SBI was 
moderate (5-20%)89-96 or high (>20%)97,98. Table 3 details the performance 
characteristics of individual clinical signs for the diagnosis of SBI in children 
presenting to the ED. Though a number of clinical signs were associated with the 
presence of SBI, few were sufficiently discriminatory to either rule in or rule out SBI. 
An explanation of the terms used to quantify diagnostic accuracy (such as the 
likelihood ratios presented in the table) is given in Section 2.6.1. 
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Much of the published evidence was of a modest quality. In particular the challenge 
of attributing outcome diagnosis in the absence of a well-defined reference 
standard, and issues relating to blinding of investigators to outcome diagnosis 
limited the value of the published evidence. Moreover, many of the studies 
evaluated children suspected of a specific diagnosis (such as meningitis or MCD), 
limiting their generalisability to the population of children presenting to the ED. 
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Indicator   Reference Outcome 
diagnosis 
Proportion 
with SBI (%) 
Age range/ 
months 
LR+ LR- 
Ill appearance 
 
Waskerwitz 198189 Bacteraemia 5.8 0-24 2.75 (1.56 – 4.86) 0.64 (0.41 – 1.00) 
Haddon 199999 Bacteraemia 3.4 3-36 1.05 (0.15 – 7.48) 1.00 (0.9 – 1.11) 
Wells 200195 Bacteraemia 11.0 0-180 4.27 (2.98 – 6.11) 0.26 (0.12 – 0.56) 
Bleeker 200797 All SBI 26.0 0-36 1.40 (1.15 – 1.71) 0.67 (0.50 – 0.88) 
Nijman 201396 Pneumonia 14.5 1-180 1.55 (1.22 – 1.97) 0.86 (0.78 – 0.95) 
Nijman 201396 Other SBI 14.5 1-180 1.68 (1.34 – 2.10) 0.83 (0.75 – 0.93) 
 
Abnormal cry Oostenbrink 200198 Meningitis 38.7 1-180 1.34 (0.75 – 2.38) 0.95 (0.85 – 1.06) 
Bleeker 200797 All SBI 26.0 0-36 0.74 (0.56 – 0.96) 1.30 (1.07 – 1.60) 
 
Drowsiness Offringa 199291 Meningitis 7.4 3-72 1.99 (1.29 – 3.08) 0.65 (0.42 – 1.00) 
Oostenbrink 200198 Meningitis 38.7 1-180 2.43 (1.82 – 3.26) 0.37 (0.25 – 0.66) 
 
Cyanosis Oostenbrink 200198 Meningitis 38.7 1-180 50.2 (2.97 – 846) 0.88 (0.81 – 0.95) 
Nijman 201396 Pneumonia 14.5 1-180 5.24 (3.33 – 8.25) 0.89 (0.84 – 0.94) 
Nijman 201396 Other SBI 14.5 1-180 0 1.03 (1.02 – 1.03) 
 
Poor circulation Oostenbrink 200198 Meningitis 38.7 1-180 3.71 (2.32 – 5.93) 0.56 (0.44 – 0.73) 
Bleeker 200797 All SBI 26.0 0-36 2.39 (1.50 – 2.83) 0.83 (0.73 – 0.94) 
Nijman 201396 Pneumonia 14.5 1-180 1.14 (0.54 – 2.43) 0.99 (0.96 – 1.03) 
Nijman 201396 Other SBI 14.5 1-180 2.14 (1.22 – 3.75) 0.96 (0.92 – 1.00) 
 
Abnormal chest signs Mahabee-Gittens 200592 Pneumonia 8.6 2-59 2.21 (0.89 – 5.50) 0.93 (0.84 – 1.04) 
Table 3: Performance characteristics of individual clinical signs for the diagnosis of SBI in children presenting to the ED. LR+: Positive likelihood ratio, LR-: Negative 
likelihood ratio. ‘Other SBI’ are SBI other than pneumonia. LRs were calculated using the epiR package in R
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Indicator   Reference Outcome 
diagnosis 
Proportion 
with SBI (%) 
Age range/ 
months 
LR+ LR- 
Increased work of 
breathing 
Taylor 199593 Pneumonia 7.3 0-24 3.08 (2.41 – 3.94) 0.37 (0.23 – 0.60) 
Mahabee-Gittens 200592 Pneumonia 8.6 2-59 1.11 (0.70 – 1.74) 0.96 (0.78 – 1.18) 
Bleeker 200797 All SBI 26.0 0-36 3.60 (2.06 – 6.28) 0.81 (0.72 – 0.91) 
Nijman 201396 Pneumonia 14.5 1-180 1.95 (1.32 – 2.88) 0.92 (0.87 – 0.98) 
Nijman 201396 Other SBI 14.5 1-180 0.16 (0.04 – 0.63) 1.07 (1.05 – 1.09) 
 
Meningism Offringa 199291 Meningitis 7.4 3-72 275 (16.7 – 4526) 0.52 (0.35 – 0.76) 
Oostenbrink 200198 Meningitis 27.5 1-180 2.57 (2.16 – 3.06) 0.01 (0 – 0.15) 
Nielsen 200194 MCD 18.8 1-192 13.9 (5.41 – 35.60) 0.61 (0.47 – 0.79) 
 
Petechial rash Offringa 199291 Meningitis 7.4 3-72 83.7 (4.50 – 1475) 0.86 (0.73 – 1.01) 
Oostenbrink 200198 Meningitis 27.5 1-180 6.18 (2.68 – 14.3) 0.81 (0.73 – 0.91) 
Nielsen 200194 MCD 18.8 1-192 9.00 ( 5.26 – 15.3) 0.28 (0.16 – 0.48) 
Wells 200195 Bacteraemia 11.0 0-180 7.00 (4.60 – 10.7) 0.19 (0.08 – 0.46) 
Thayyil 2005101 All SBI 11.1 1-36 8.90 (2.63 – 30.4) 0.75 (0.63 – 0.91) 
 
Seizures Joffe 198390 Meningitis 5.4 6-72 5.90 (1.79 – 19.0) 0.80 (0.59 – 1.08) 
Offringa 199291 Meningitis 7.4 3-72 3.50 (1.69 – 7.17) 0.76 (0.58 – 1.00) 
Oostenbrink 200198 Meningitis 27.5 1-180 1.68 (0.66 – 4.27) 0.96 (0.90 – 1.04) 
 
Reduced conscious 
level 
Offringa 199291 Meningitis 7.4 3-72 155 (9.03 – 2677) 0.73 (0.57 – 0.93) 
Table 3 (cont): Performance characteristics of individual clinical signs for the diagnosis of SBI in children presenting to the ED. LR+: Positive likelihood ratio, LR-: Negative 
likelihood ratio. MCD: Meningococcal Disease. LRs were calculated using the epiR package in R
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1.6.3. Biomarkers of SBI in children 
The limitations of clinical variables in diagnosing SBI in children have encouraged 
the use of biomarkers to support the diagnostic process. A biomarker is defined as 
“a characteristic that is objectively measured and evaluated as an indicator of 
normal biologic processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention”102. Strictly speaking, the clinical variables described in the 
previous section could be termed biomarkers, but I will use the term with specific 
reference to laboratory-measured biomarkers from clinical samples. Biomarkers 
may be used alone or in combination to allow classification of an individual to a 
group with defined characteristics. 
An improved understanding the complexity of the host response to serious 
infection has driven the development of biomarkers to provide diagnostic or 
prognostic information. Almost 200 such biomarkers have now been related to 
sepsis103. I will summarise current understanding of the host response before 
describing biomarkers of SBI currently used in children, and concluding with 
discussion of the small number of newer biomarkers of SBI which have been 
evaluated in the children’s ED. 
 
1.6.4. The host response to serious infection 
The interaction between host and pathogen results in a complex and dynamic 
cascade of pro-inflammatory and regulatory anti-inflammatory signals (Figure 2), 
the outcome of which is one of pathogen eradication, colonisation, or otherwise 
overwhelming infection and host demise. The likelihood of each of these possible 
outcomes depends upon both host (genetic or environmental) and pathogen 
factors (such as virulence). Key mediators of the host response are described below. 
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Figure 2: A schematic of the host inflammatory response
104
. 
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1.6.4.1. Toll like receptors 
Toll like receptors (TLRs) are one of a family of pattern recognition receptors which 
act as a first line of the innate immune system. They recognise pathogen-associated 
molecular patterns, such as lipopolysaccharide (LPS), as well as endogenous 
peptides released by tissue damage. TLR expression is up-regulated in sepsis105. 
TLRs induce Interleukin-1β (IL-1β), an inflammatory cytokine, and activate 
“inflammasomes” such as caspases. Caspases regulate apoptosis - that is, 
programmed cell death - induce other pro-inflammatory cytokines, and also 
contribute to host defence by up-regulating the production of reactive oxygen 
species106. Various signal transduction enzymes act as downstream regulators of 
TLR signalling. Depending on target cell type, phosphoinositide 3-kinase (PI3K) can 
act both positively, to induce pro-inflammatory cytokines such as IL-1β, IL-6, and IL-
8 from monocytes, and negatively, inhibiting their production from neutrophils107. 
TLRs also act through Rho GTPases to mediate leucocyte migration, to activate NF-
κB and thereby to up-regulate inflammatory cytokine transcription108. NF-κB is an 
important transcription factor which regulates inflammation, cell survival and 
proliferation109.  
1.6.4.2. Leucocytes 
Leucocytes such as neutrophils and macrophages are important cells of the innate 
system with the capacity to degrade internalised pathogens by generating reactive 
oxygen species110, and are recruited to sites of infection. Migration of neutrophils 
to extravascular sites requires interaction with activated endothelium via adhesion 
molecules such as beta-2 integrin (CD11/CD18 complexes)111. Activation of 
neutrophils is a necessary and effective mechanism to achieve intracellular killing of 
pathogens, but neutrophil activation also has the potential for injury to the host. 
Extracellular neutrophil elastase can impair fibrinolysis and influence the 
coagulation cascade112. Neutrophil-mediated injury is well described, and the 
inflammatory response is mitigated by neutrophil apoptosis. In sepsis, however, 
inflammatory cytokines induce prolonged neutrophil survival and activation113.  
Neutrophil Gelatinase-associated Lipocalin (NGAL) is a component of neutrophil 
granules and has a role in innate immunity through its ability to bind siderophores 
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required by many bacterial pathogens to scavenge iron from the host 114. It is highly 
upregulated by inflammatory stimuli via NF-κB 115 and is considered to have an 
antibacterial iron depletion role116 as part of the innate immune response. CD64 is a 
membrane receptor expressed on macrophages and monocytes. In sepsis, it is 
highly upregulated on neutrophils117. 
1.6.4.3. Inflammatory cytokines 
Inflammatory cytokines such as IL-1β, Tumour Necrosis Factor-α (TNF-α), IL-6, IL-8 
may be released directly from leucocytes, or via the above ‘inflammasome’ or TLR 
signalling pathways. Their effects are to induce further leucocyte migration and 
activation, and to activate endothelial surfaces by up-regulating the expression of 
adhesion molecules and increasing vascular permeability118,119.  
Cytokines with a particular role in stimulating leucocyte migration are termed 
chemokines120. IL-8 (termed CXCL8 according to chemokine nomenclature) is a 
potent chemoattractant of neutrophils, causing neutrophil migration to sites of 
infection, and inducing phagocytosis121. Other significant chemotactic proteins 
include Monocyte Chemoattractant Protein-1 (MCP-1, or CCL2), Macrophage 
Inflammatory Protein 1-β (MIP-1β, or CCL4) and RANTES (CCL5), all of which act 
primarily on monocytes and macrophages122, but also recruit T-lymphocytes123.  
High Mobility Group Box-1 (HMGB-1) is a nuclear protein which has a role in 
maintaining chromosomal DNA stability124. It also contributes to angiogenesis and 
tissue repair125. In response to inflammatory stimuli (such as IFN-γ), HMGB-1 is 
released by macrophages and monocytes. This release occurs late in the 
inflammatory response, increasing to a steady state at 16-32h and persisting in 
adults with septic shock126. Another important nuclear protein in the regulation of 
sepsis is Peroxisome Proliferator-activated Receptor-γ (PPARγ). In mouse models, 
PPARγ modulates inflammation by preventing the release of inflammatory 
cytokines IL-1β, IL-6 and TNF-α via the TLR signalling pathway127. Furthermore, the 
use of PPARγ agonists reduces levels of HMBG-1 and improves survival in mice with 
septic shock128,129. Both HMGB-1 and PPARγ are involved in the subsequent 
expression of Resistin. Resistin is an adipokine first related to insulin resistance in 
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mice130. In humans, Resistin expression occurs predominantly in macrophages, 
monocytes and neutrophils131,132. Circulating Resistin levels peak 8-16h after the 
administration of LPS in healthy subjects, mediated by pro-inflammatory cytokines 
and NF-κB 133. HMGB-1 is a potent inducer of Resistin in monocytes, and mediates 
the persistence of elevated Resistin levels in patients with sepsis on ICU134, while 
PPARγ activity is increased and correlates with Resistin levels in children with 
sepsis135. 
1.6.4.4. Anti-inflammatory cytokines 
Anti-inflammatory cytokines are important mediators of the inflammatory 
response. IL-10 is released by leucocytes, and suppresses the production of the pro-
inflammatory cytokines IL-1β, TNF-α, IL-6 and IFN-γ136. Further, IL-10 stimulates 
production of IL-1 receptor antagonist (IL-1Ra) and soluble TNF receptors (sTNFRs) 
which act to neutralise their pro-inflammatory effects137. Transforming Growth 
Factor –β (TGF-β) has also been shown to attenuate the inflammatory response by 
suppressing the release of pro-inflammatory cytokines, and by stimulating the 
production of IL-1Ra and sTNFRs138.  
The observation that the early administration of IL-10 and TGF-β improved survival 
in murine models of sepsis illustrated the importance of anti-inflammatory 
cytokines in the host response to severe infection. Consistent with this, 
immunoneutralisation of IL-10 led to elevated IL-6 and TNF-α, and was associated 
with worse outcomes139. Interestingly, however, late inhibition of IL-10 in this 
model improved survival140, suggesting that the balance between pro- and anti-
inflammatory cytokines is dynamic. In adults presenting to the ED with acute febrile 
illnesses an anti-inflammatory cytokine profile (characterised by a high IL-10 to TNF-
α ratio) is associated with mortality141. In children with MCD, an anti-inflammatory 
profile (high IL-1Ra to TNF and IL-6 ratios) is associated with more severe disease142. 
It is hypothesised that following the initial hyperinflammatory state of early sepsis, 
patients enter a more protracted state of immunoparesis and immunosuppression 
which is an important contributor to late mortality143. 
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1.6.4.5. Acute phase reactants 
Acute phase reactants are typically induced by inflammatory cytokines. C-reactive 
Protein (CRP) is the best known acute phase reactant and is in widespread clinical 
use as a diagnostic test. The name was derived from its discovery, bound to the C 
polysaccharide of the pneumococcal cell wall in adults with pneumonia144. It is a 
‘pentraxin’, a secreted pattern recognition receptor synthesised in the liver 
following induction by pro-inflammatory cytokines, particularly IL-6145,146. It binds 
microbial peptides and damaged cells and mediates their destruction through its 
interaction with the core complement component C1q145. Levels of CRP peak at 36-
50h in response to an inflammatory signal147. 
Procalcitonin (PCT) is a 116 amino acid protein derived most commonly from 
neuroendocrine cells including the C-cell of the thyroid with which it was first 
associated148. Whilst Calcitonin is thought to have a role in calcium metabolism, and 
bone resorption through its action on the osteoclast149, the action of PCT remains 
unclear. In normal conditions the Calcitonin gene CALC-I, located on chromosome 
11, is selectively expressed in neuroendocrine tissues, and transcribes the 
prohormone PCT. In these circumstances, Calcitonin is then produced by the action 
of proteolytic enzymes on PCT. PCT and its constituent proteins are present in low 
concentrations in normal subjects, and become markedly elevated in a number of 
conditions (see Table 4). Under such conditions, including sepsis, CALC-I is 
expressed systemically and Calcitonin mRNA detected in a wide of variety of 
tissues150. The resultant increase in the level of PCT occurs in the absence of the 
enzymatic pathways which control Calcitonin and its precursors in neuroendocrine 
tissue, and is not mirrored by a corresponding increase in the Calcitonin level. Its 
role in sepsis is unclear though it has been a target of immunomodulation in animal 
models151 
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Infection Bacterial 
Parasitic 
Fungal 
Viral 
Neoplasm Neuroendocrine tumours 
Medullary Thyroid Carcinoma 
Small Cell Lung Cancer 
Carcinoid tumour 
Inflammation Pancreatitis 
Burns 
Heat Stroke 
Trauma  
Surgery  
Table 4: Conditions which elevate PCT
152
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Ferritin is an iron storage protein whose synthesis is increased by the pro-
inflammatory cytokines IL-6 and IL-8. It is elevated in systemic inflammation, and is 
associated with mortality in children with severe sepsis153. Mannose Binding Lectin 
(MBL) is synthesised primarily by the liver, and binds carbohydrates on the surface 
of pathogens before activating complement via MBL-associated serine proteases154. 
This “pattern recognition” role is an important feature of innate immunity. 
Mutations in the MBL2 gene have been associated with frequent and recurrent 
infections155, and low levels of MBL in paediatric sepsis have been associated with 
severity of illness156. 
Serum amyloid A is another acute phase protein produced in the liver in response 
to inflammatory stimuli. It has multiple functions relating to inflammatory 
modulation, and cholesterol metabolism157. Haptoglobin scavenges cell free 
haemoglobin and heme, which are increased in sepsis and mediate tissue 
damage158. In animal models this scavenging attenuates the inflammatory response 
and decreases mortality159. Haemoglobin-haptoglobin complexes are endocytosed 
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by macrophages via the haemoglobin scavenger receptor CD163160. The soluble 
form of the receptor (sCD163) is shed from the cell membrane in response to 
inflammatory stimuli161, and levels have been found to predict prognosis in 
pneumococcal bacteraemia162. 
1.6.4.6. Complement 
Complement is a sophisticated and highly regulated network of enzyme pathways. 
In the classical pathway, presentation of microbial peptides to C1q initiates a 
cascade which results in the production of C3a and C5a145. The effects of this 
complement activation are multitude, including chemotaxis of leucocytes, 
endothelial activation, and induction of phagocytosis through opsonisation of 
microbial peptides and apoptotic cells. Complement interacts with other 
components of the innate immune system, including TLRs and the coagulation 
cascade, as well as priming the adaptive immune system, in particular the humoral 
response145.  
1.6.4.7. Coagulation and the endothelium 
The inflammatory milieu in sepsis is prothrombotic163. The endothelium, which in 
normal conditions acts to prevent thrombus formation, is activated by 
inflammatory cytokines, LPS and complement164. Activated endothelium stimulates 
platelet adhesion and platelet aggregation, and releases von Willebrand factor 
(vWF) into the circulation165. Activated endothelial cells are more likely to undergo 
apoptosis, and along with vWF, release angiopoietins into the circulation. 
Angiopoietins are endothelial growth factors. Ang-1 has a role in enhancing 
endothelial survival and barrier integrity. Ang-2, by contrast, propagates 
inflammatory pathways by sensitising endothelial cells to TNF-α, including an up-
regulation of adhesion molecules166. The ratio of Ang-1 to Ang-2 has been 
suggested as a prognostic marker of serious infection167,168. 
Other inflammatory mechanisms tip the balance of coagulation in favour of 
thrombosis. Complement induces the expression of tissue factor on endothelial 
cells, and inhibits fibrinolysis169. Neutrophils prevent inhibitors of the tissue factor 
pathway, localising coagulation to small vessels, thereby preventing pathogen 
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dissemination170. Various mechanisms inhibit anticoagulant pathways. In particular 
the protein C pathway, which limits coagulation by the inactivation of clotting 
factors Va and VIIIa, is impaired. Production of protein C is reduced, consumption 
increased, and activation limited by a reduction in the expression of 
thrombomodulin on endothelial surfaces mediated by TNF-α171. 
In return, coagulation pathways influence inflammation through protease-activated 
receptors (PARs). Thrombin induces IL-6 from endothelium via PAR-1 and PAR-2172. 
Activated Factor VII can also induce IL-6 and IL-8 production173. Clotting factors 
cleave C1 and activate complement174, while thrombin activates C5175. In response 
activated protein C down-regulates pro-inflammatory signals via PAR-1176, while 
promoting endothelial integrity177. 
Adhesion molecules play a critical role in leucocyte migration to sites of infection, 
and across the vascular endothelium. Those most closely associated with the host 
response to sepsis are the selectins (E-selectin, L-selectin and P-selectin) along with 
intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 
(VCAM-1). With the exception of L-selectin (which is expressed on leucocytes) these 
molecules are expressed on the endothelium and mediate endothelial adhesion, 
leucocyte rolling, and migration across endothelial surfaces. All are up-regulated by 
inflammatory stimuli TNF-α, IL-1β, IL-6 and LPS178. Upon endothelial activation, 
these adhesion molecules are promptly shed from the surface, and soluble isoforms 
become detectable in the plasma. It is proposed that this shedding limits leucocyte-
endothelial interaction, exerting a protective effect by mitigating the inflammatory 
cascade locally179. Elevated levels of E-selectin and L-selectin have been associated 
with improved outcomes in sepsis in children180 and adults181. A similar pattern of 
shedding in sepsis has been observed with ICAM-1 and VCAM-1. In both cases, 
shedding is postulated to be a protective mechanism limiting local inflammation182. 
Whilst the highest levels of ICAM-1 are associated with improved outcome in septic 
children180, adults with the most elevated levels of VCAM-1 had the highest 
mortality from sepsis183. To date the relationship between soluble adhesion 
molecules and diagnosis and prognosis in sepsis remains unclear. 
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1.6.4.8. Summary of the host response 
The complexity and heterogeneity of the host response to serious infection underlie 
the many and varied presentations of children to the ED. It is this heterogeneity 
that makes the identification of reliable diagnostic tools so challenging. Of the many 
mediators of the host response described above, few have been demonstrated to 
be sufficiently specific to infection to provide adequate diagnostic accuracy. 
 
In the subsequent section, I will discuss the current use of biomarkers of SBI in the 
children’s ED, before summarising the evidence for newer potential markers in this 
context. 
 
1.6.5. Biomarkers of childhood SBI in current clinical practice 
Few biomarkers are in routine clinical use for the diagnosis of SBI in children. In its 
“Feverish illness in children” guideline, NICE recommends the use of CRP and WCC 
in the evaluation of febrile children under the age of 5 years. The most recently 
updated guideline includes a meta-analysis suggesting that PCT may perform 
moderately better than CRP in the diagnosis of childhood SBI, but that the 
availability and cost of the test currently preclude its widespread 
implementation184. 
Table 5 summarises the performance characteristics of prospective studies of CRP, 
WCC and PCT for the diagnosis of SBI in children in the ED. For an explanation of 
terms used to quantify diagnostic accuracy, including the likelihood ratios used in 
Table 5, see Section 2.6.1.Few studies included children older than 3 years. A 
number specifically considered young infants less than 3 months of age. Most of 
the biomarker evaluations were performed in populations of children with a 
substantial risk of SBI (only one had a rate of SBI of less than 10% of participants). 
Together these characteristics limit the applicability of the findings in all children 
presenting to the ED with acute febrile illness.  
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1.6.5.1. C-reactive Protein 
CRP is commonly used in clinical practice in the UK, as recommended by the NICE 
“Feverish Illness in Children” guidelines. As such, it has been extensively 
investigated as a marker of SBI in children in the ED. Quantitative point of care 
tests, such as the Afinion CRP (Alere, Waltham, USA) are now commercially 
available, increasing access to the use of the test. Despite this widespread use, the 
value of CRP in discriminating between SBI and self-limiting infections is limited 
when used in isolation. Meta-analysis included in the NICE guideline estimated a 
pooled positive likelihood ratio (PLR) of 3.1 (95% CI 2.5 to 3.7) and negative 
likelihood ratio (NLR) of 0.27 (95% CI 0.18 to 0.42) for the diagnosis of SBI in 
children184. These estimates are comparable to those reported by van den Bruel et 
al185. 
1.6.5.2. White cell count 
White cells (or leucocytes) are a central component of the host response. 
Abnormalities of the WCC are associated with a range of immune, inflammatory 
and haematological conditions and so its measurement as part of the full blood 
count is a common part of the evaluation of the unwell child. For the purposes of 
diagnosing SBI, however, white cell count is insufficiently discriminatory. The largest 
single study of its diagnostic accuracy in children under the age of 5 estimated a PLR 
of 1.93 (95% CI 1.75 to 2.13) and NLR of 0.70 (95% CI 0.65 to 0.75) at a WCC 
threshold of 15 x109/l, consistent with NICE guidance186. Despite its limitations, it 
has been incorporated into clinical rules aimed at identifying young infants at risk of 
serious infection, such as the Rochester criteria (Section 1.6.8)187. 
The Neutrophil count is a subset of the WCC. As an important cell of the innate 
immune response, abnormalities of the Neutrophil count have been evaluated as a 
marker of SBI in children. Perhaps unsurprisingly, its diagnostic accuracy appears 
comparable to that of WCC186. 
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1.6.5.3. Procalcitonin 
PCT has been extensively evaluated in children since its first description in 
hospitalised children with suspected sepsis188. Its rapid increase in response to 
serious infection, and resolution with appropriate therapy suggest a valuable 
diagnostic test. PCT performs moderately better than CRP in studies of children 
presenting to the ED101,189-192. In particular it may have a role in children presenting 
with a short history (<12h) of fever, when CRP is unreliable190,191. Like CRP, it 
remains insufficiently discriminatory to use in isolation. A pooled PLR of 4.1 (95% CI 
2.9 to 5.7), and NLR of 0.25 (95% CI 0.16 to 0.38) were estimated by the NICE meta-
analysis184. Near patient testing is available in the semi-quantitative PCT-Q assay 
and more recently the quantitative PCT Direct (both Thermo Fisher Scientific, 
Waltham, USA). 
 3
4 
Biomarker   Reference Proportion 
with SBI (%) 
Threshold Age range/ 
months 
LR+ LR- 
CRP Berger 1996193 23.9 20 <12 2.53 (1.82 – 3.50) 0.25 (0.11 – 0.56) 
Pulliam 2001194 18.2 70 1-36 8.30 (3.8 – 27.3) 0.24 (0.09 – 0.65) 
Lacour 2001189 22.6 40 <36 3.57 (2.47 – 5.17) 0.14 (0.05 – 0.42) 
Isaacman 2002195 11.3 44 3-36 3.28 (2.21 – 4.85) 0.47 (0.29 – 0.75) 
Galetto-Lacour 2003196 29.2 40 <36 3.70 (2.28 – 6.01) 0.26 (0.13 – 0.54) 
Fernandez-Lopez 2003190 42.6 27.5 1-36 3.15 (2.44 – 4.07) 0.29 (0.21 – 0.40) 
Thayyil 2005101 11.1 50 1-36 2.40 (1.40 – 4.12) 0.36 (0.11 – 1.22) 
Hsiao 2006197 10.3 9.8 2-6 2.61 (1.81 – 3.76) 0.61 (0.44 – 0.83) 
Andreola 2007191 23.0 40 <36 3.79 (2.92 – 4.94) 0.35 (0.26 – 0.49) 
Galetto Lacour 20087 26.7 40 <36 3.35 (2.45 – 4.57) 0.25 (0.14 – 0.43) 
Olaciregui 2009198 23.6 30 <3 5.35 (3.63 – 7.89) 0.47 (0.36 – 0.60) 
Manzano 2011199 16.4 17.1 1-36 3.01 (2.50 – 3.63) 0.08 (0.03 – 0.24) 
 
Procalcitonin Lacour 2001189 22.6 0.9 <36 4.24 (2.87 – 6.28) 0.09 (0.02 – 0.35) 
Galetto-Lacour 2003196 29.2 0.5 <36 3.62 (2.40 – 5.46) 0.09 (0.02 – 0.36) 
Fernandez-Lopez 2003190 42.6 0.59 1-36 14.19 (8.37 – 24.1) 0.09 (0.06 – 0.16) 
Thayyil 2005101 11.1 0.5 1-36 1.75 (1.22 – 2.50) 0.25 (0.04 – 1.59) 
Andreola 2007191 23.0 0.5 <36 3.11 (2.47 – 3.93) 0.35 (0.25 – 0.49) 
Galetto Lacour 20087 26.7 0.5 <36 2.96 (2.33 – 3.80) 0.08 (0.03 – 0.25) 
Maniaci 2008192 17.9 0.12 <3 1.28 (1.15 – 1.42) 0.19 (0.05 – 0.74) 
Olaciregui 2009198 23.6 0.5 <3 4.94 (3.47 – 7.04) 0.42 (0.31 – 0.56) 
Manzano 2011199 16.4 0.2 1-36 2.81 (2.28 – 3.47) 0.21 (0.11 – 0.40) 
Woelker 2012200 8.4 0.26 <2 2.57 (1.96 – 3.37) 0.12 (0.02 – 0.79) 
Table 5: Performance characteristics of biomarkers for the diagnosis of SBI in children in the ED. LRs were calculated using the epiR package in R
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Biomarker Reference Proportion 
with SBI (%) 
Threshold Age range/ 
months 
LR+ LR- 
White cell count Berger 1996193 23.9 15 <12 1.67 (1.08 – 2.60) 0.70 (0.48 – 1.02) 
Pulliam 2001194 18.2 15 1-36 1.93 (1.14 – 3.26) 0.54 (0.26 – 1.11) 
Lacour 2001189 22.6 15 <36 2.96 (1.89 – 4.63) 0.42 (0.24 – 0.72) 
Nademi 2001201 29.1 15 0-192 1.95 (0.55 – 6.90) 0.95 (0.85 – 1.06) 
Fernandez-Lopez 2003190 42.6 17.1 1-36 2.27 (1.70 – 3.03) 0.60 (0.50 – 0.73) 
Thayyil 2005101 11.1 15 1-36 1.07 (0.51 – 2.24) 0.94 (0.45 – 1.95) 
Trautner 2006202 19.4 15 0-204 0.87 (0.51 – 1.47) 1.14 (0.72 – 1.80) 
Hsiao 2006197 10.3 15.7 2-6 2.43 (1.73 – 3.43) 0.61 (0.44 – 0.83) 
Andreola 2007191 23.0 15 <36 2.08 (1.58 – 2.75) 0.65 (0.52 – 0.80) 
Galetto Lacour 20087 26.7 15 <36 1.92 (0.55 – 6.90) 0.66 (0.49 – 0.89) 
Olaciregui 2009198 23.6 15 <3 2.39 (1.61 – 3.53) 0.74 (0.62 – 0.88) 
Manzano 2011199 16.4 14.1 1-36 2.79 (2.23 – 3.49) 0.26 (0.15 – 0.46) 
De 2013186 18.3 15 0-60 1.93 (1.75 – 2.13) 0.70 (0.65 – 0.75) 
 
Neutrophil count Pulliam 2001194 18.2 10.2 1-36 3.00 (1.73 – 5.21) 0.38 (0.16 – 0.87) 
Fernandez-Lopez 2003190 42.6 9.9 1-36 2.66 (1.96 – 3.61) 0.56 (0.47 – 0.68) 
Trautner 2006202 19.4 10 0-204 1.06 (0.68 – 1.66) 0.93 (0.55 – 1.59) 
Andreola 2007191 23.0 10 <36 1.38 (0.95 – 2.00) 0.90 (0.62 – 1.00) 
Manzano 2011199 16.4 5.2 1-36 2.17 (1.82 – 2.59) 0.22 (0.11 – 0.44) 
De 2013186 18.3 10 0-60 1.87 (1.68 – 2.09) 0.75 (0.71 – 0.80) 
Table 5 (cont): Performance characteristics of biomarkers for the diagnosis of SBI in children in the ED. .LRs were calculated using the epiR package in R
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1.6.6. Alternative markers of SBI in the children’s ED 
Despite significant interest in the use of biomarkers to predict serious infection, 
relatively few have been investigated in children in the Emergency Department. 
Here, I will summarise the evidence for alternative markers of SBI in the children’s 
ED. 
1.6.6.1. Interleukins (IL-1, IL-6, IL-8) 
The inflammatory cytokines IL-1, IL-6, and IL-8 have long been considered potential 
biomarkers of serious infection in view of their central role in the host inflammatory 
response. Studies of adults with sepsis on ICU which focussed on the prognostic 
role of the inflammatory cytokines reached varying conclusions. Whilst the 
cytokines were found be elevated in non-survivors of sepsis, the prognostic value 
was not greater than that achieved by the use of clinical variables alone203-205. 
Numerous studies have evaluated cytokines in the diagnosis of neonatal sepsis. 
Following the observation that IL-1Ra (a competitive antagonist of IL-1 at the IL-1 
receptor) is present systemically at much higher concentrations than IL-1β206, most 
have evaluated IL-1Ra instead of IL-1. Though an early study suggested superior 
diagnostic accuracy of IL-1Ra and IL-6 to CRP207, no subsequent studies have 
validated this finding208.  
In the children’s ED, a limited evidence base describes these inflammatory 
cytokines in the diagnosis of SBI. A small case-control study compared IL-6 to CRP 
and PCT for the purpose of differentiating viral from bacterial infections, and 
concluded that IL-6 was inferior to PCT209. A study of 124 children under 3 years 
evaluated IL-1Ra, IL-6 and IL-8 alongside PCT, CRP and a clinical score. It concluded 
that IL-1Ra and IL-8 failed to differentiate SBI from self-limiting infection, and that 
IL-6 was inferior to PCT and CRP189. A subsequent study by the same authors 
corroborated these findings196. 
1.6.6.2. Neutrophil Gelatinase-associated Lipocalin 
NGAL was first identified as a marker of acute kidney injury in patients on the 
intensive care unit210. It was subsequently found to be more significantly elevated 
in sepsis than in other inflammatory states211-213. In adults presenting to the ED with 
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suspected sepsis, an optimal biomarker panel included NGAL, protein C, and IL-1Ra. 
The area under the curve for this ‘sepsis score’ was 0.80 for severe sepsis, 0.77 for 
septic shock, and 0.79 for death214 Using transcriptomic analysis in Malawian 
children presenting with signs of pneumonia and meningitis, NGAL, along with PCT 
and Resistin were found to be differentially expressed in children with SBI and 
measurement of the protein products discriminated between those with SBI and 
those without. Combination of the three markers achieved an AUC of 0.90 for the 
diagnosis of SBI215. In Kenyan children, the combination of NGAL with haptoglobin 
achieved an AUC of 0.82 for the diagnosis of bacterial pneumonia216.  
1.6.6.3. Resistin 
Resistin is significantly elevated in intensive care patients with sepsis217. Two small 
case-control studies in the neonatal unit demonstrated differences between 
neonates with proven sepsis and healthy neonates, though to date no high quality 
diagnostic accuracy studies have been done in this setting218,219. A single study of 37 
adults with sepsis in ED identified that persistent elevation of Resistin, NGAL and IL-
8 beyond 24h after presentation predicted the presence of severe sepsis and septic 
shock220. The only published study to describe the performance of Resistin in 
children in the ED is the above study of Malawian children presenting with signs of 
pneumonia and meningitis, in which Resistin, together with PCT and NGAL 
predicted the presence of SBI221. 
1.6.6.4. Neutrophil CD64 
CD64 expression on neutrophils is increased in neonates with culture proven sepsis 
compared with culture negative neonates who undergo a sepsis evaluation222. A 
small study of 82 critically unwell children and neonates concluded that CD64 
expression was superior to CRP and PCT in the diagnosis of ‘sepsis’223. A further 
study of 38 pre-term infants quantified the ‘proportionate reduction in uncertainty’ 
of the presence of infection and suggested that CD64 expression performed better 
than CRP or PCT in the diagnosis of infection224. Only one study of 70 febrile 
children (under the age of 3 years) has evaluated CD64 expression in the ED, 
reporting a sensitivity of 95% for SBI, with a specificity of 47%225. 
38 
 
1.6.6.5. Soluble urokinase plasminogen activator receptor (suPAR) 
Soluble urokinase plasminogen activator receptor (suPAR) is the cleaved form of 
the membrane bound urokinase plasminogen activator receptor, expressed on 
neutrophils, and macrophages226. suPAR has to date demonstrated only limited 
value in the identification of sepsis in critically ill adults227,228. Two small studies of 
suPAR for the prediction of SBI in NICU revealed modest performance229,230. A single 
study evaluated the use of suPAR in the prediction of severity of pneumonia in 
children, though did not report diagnostic accuracy231, whilst another evaluated the 
prognostic value of suPAR to predict upper urinary tract involvement in children 
with UTI232. It concluded that the use of suPAR could predict those children who 
may have upper urinary tract involvement and require further investigation with 
DMSA following a UTI. 
 
1.6.7. The combination of variables in clinical prediction 
Considerable diagnostic uncertainty remains when individual clinical signs or 
biomarkers are used to diagnose SBI in the children’s ED. The combination of 
clinical and biomarker variables in the form of a clinical prediction rule (CPR, or 
clinical prediction model) may enhance the ability of clinicians to identify serious 
infection. Clinical risk prediction such as this has the potential to provide valuable 
diagnostic information, but requires a robust approach to development and 
validation233. The diagnosis of serious infection in febrile children has been a 
common question addressed by CPRs in children, but very few have undergone 
external validation and impact analysis234.  
I will summarise the evidence supporting the use of CPRs in the diagnosis of SBI in 
the children’s ED. 
 
1.6.8. Clinical prediction rules for SBI in the children’s ED 
An early CPR, widely adopted as the “Yale Observation Scale” (YOS) was developed 
in young children and combined six characteristic of children with fever235. The 
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score evaluated the “quality of cry”, “reaction to parental stimulation”, “state 
variation”, “colour”, “hydration”, and “social response” on categorical scales. The 
study recruited 312 children under the age of 2 years, of whom 37 had SBI. Using a 
threshold of 10 points, the score demonstrated a positive likelihood ratio of 3.8 
(95% CI 2.75 – 5.37), and an encouraging negative likelihood ratio of 0.15 (95% CI 
0.03 – 0.44). External validation studies however, mostly in children up to 3 years of 
age, failed to reproduce these results101,189,191,196,197,236-238. 
A number of early studies examined the value of CPRs in ruling out SBI in young 
infants. These infants, less than 3 months of age, were considered at high risk of SBI 
and had conventionally been admitted to hospital and treated with empirical 
antibiotics. The first of these, which established the ‘Rochester’ criteria, determined 
that in previously healthy young infants a ‘normal’ clinical examination alongside a 
normal white cell count, and urinalysis could be used to identify ‘low-risk’ infants 
suitable for observation. The low-risk criteria performed well in this regard. Only 
1/144 infants considered at low risk was found to have a serious infection, and no 
adverse outcomes were reported187. These findings were subsequently validated in 
a different population239.  
 
Validation studies of the Rochester criteria and modifications of these (which 
incorporated the use of CRP or Erythrocyte Sedimentation Rate), similarly 
suggested the safety of this approach239-245. An alternative approach to young 
infants over one month of age utilized the YOS first evaluated in older children235. In 
this age group, the YOS alone failed to be sufficiently sensitive to rule out SBI236. A 
later study however combined the YOS with WBC, urinalysis and CSF microscopy to 
yield a low-risk group (the Philadelphia protocol)237, and in 3 studies which used this 
approach, the criteria safely ruled out SBI (negative LR <0.2)237,244,246. Only 2/422 
(0.5%) of low-risk infants were misclassified, and none had adverse outcomes. A 
further variation of this approach - the Milwaukee protocol - failed to demonstrate 
the safety of their approach (negative LR 0.15, 95% CI 0.02 - 1.02)247. 
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A large study of more than 5000 young infants derived a novel prediction model 
combining clinical variables along with urinalysis, white blood cell count, and CSF 
microscopy. The sensitivity of the model for SBI was 82%. Nearly one fifth of SBI 
was misclassified as low-risk, including 14/59 infants with bacteraemia, and a 
further infant with meningitis. No external validation has since been performed248. 
Details of the low-risk criteria applied are detailed in Table 6, and the performance 
characteristics of the use of low-risk criteria for SBI in young infants are summarized 
in Table 7. 
 
Low-risk protocol Age 
group / 
days 
Criteria 
Rochester187 0-90 Normal clinical exam 
5 < WCC < 15 x109/litre 
Urine microscopy <10 WCCs per high 
power field 
Philadelphia237 28-56 YOS ≤10 
WCC <15 x109/litre 
Urine microscopy <10 WCCs per high 
power field 
CSF <8 WCCs per high power field 
CXR no infiltrate 
Milwaukee247 28-56 Normal clinical exam 
CSF<10 WCCs per high power field 
Negative CSF Gram stain 
WCC <15 x109/litre 
Urine microscopy <10 WCCs per high 
power field 
Negative urine Gram stain 
Decision tree248 0-90 Urinalysis (LE or nitrite) negative 
Urine microscopy <5 WCCs per high 
power field 
4.1<WCC <20 x109/litre 
Temp <39.6°C 
Age >13 days 
Table 6: Low-risk criteria applied to young infants in order to rule out SBI. WCC: Peripheral blood 
White cell count. YOS: Infant observation Score. CSF: Cerebrospinal fluid. CXR: Chest Xray. LE: 
Leucocyte esterase 
 
41 
 
Few CPRs for the diagnosis of SBI in older children feature commonly in clinical use. 
In the UK, the management of children with fever is based upon expert guidance - 
the NICE “Feverish illness in children” guideline, designed for use in children under 
the age of 5184. The guideline identifies clinical signs which may predict the 
presence of serious infection, and allocates each to a “traffic light” based risk 
category. Recently, the value of the NICE guideline has been evaluated in two large 
prospective studies in the children’s ED249,250. In each, the absence of any ‘amber’ or 
‘red’ signs had some value in ruling out serious infection, though the presence of 
the same features had little role in ruling in serious infection. 
The Manchester triage system (MTS) is a well-established triage tool, though not 
designed to detect SBI in children. In common with the NICE guidelines, the MTS 
demonstrates limited ability to discriminate between SBI and self-limiting infection. 
In one study, the two most urgent categories appeared to have some value for the 
ruling in of serious infection (where the outcome was ‘serious or intermediate’ 
infection)249, though was of limited value for the diagnosis of SBI in a second study 
with a lower proportion of serious outcomes251. 
Recent studies have sought to derive new risk prediction models combining clinical 
variables and laboratory tests7,9,96. The performance characteristics of these are 
summarised in Table 8. Though encouraging diagnostic performance has been 
demonstrated in the populations in which the models have been derived, few have 
performed as well in external validation studies252. 
A large UK based study9 derived (n=1664) and internally validated (n=287) a 
prediction rule based on clinical variables. Using a low-risk threshold the model 
demonstrated a negative likelihood ratio of 0.4 (95% CI 0.3 – 0.6), and a negative 
predictive value of less than 2%. The analysis was undertaken on a historic dataset, 
prior to the introduction of the pneumococcal conjugate vaccine, and with a low 
prevalence of SBI.  
 
42 
 
A small study7 in children less than 3 years derived (n=135) and internally validated 
(n=67) a prediction rule (“Lab score”) combining C-reactive protein (CRP), 
Procalcitonin (PCT) and urine dipstick. In this study the likelihood of SBI was 
approximately 25%. At a low-risk threshold, the negative likelihood ratio of 0.07 
(95% CI 0.02 – 0.21), is promising. The authors suggested that use of the Lab score 
would have reduced antibiotics by an estimated one third. External validation was 
undertaken in a historical dataset from another European country, demonstrating 
similar performance characteristics253. In a further validation study of more than 
1000 young infants less than 3 months of age, the Lab score demonstrated value in 
ruling in SBI, but limited ability to rule out SBI254.  
 
The largest study to derive a clinical prediction model for SBI in children included 
more than 15000 children under the age of 5 years6. The study used multinomial 
regression to develop risk prediction models for each diagnosis of UTI, pneumonia, 
and bacteraemia. The models were derived before internal validation in more than 
5000 children. The models demonstrated reasonable discrimination in the 
validation samples, with areas under the ROC curve of 0.78, 0.84, and 0.74 for the 
diagnosis of UTI, pneumonia and bacteraemia respectively. The authors proposed 
that the identification of appropriate rule out thresholds as part of a computer 
based decision tool could be used to rationalise decision-making, though to date no 
evaluation of the impact of the model upon clinical decision-making has been 
published. 
 
A large study across three populations in Europe used a similar model building 
approach, and included an external validation population96. The authors derived 
models for the prediction of pneumonia, and ‘other SBIs’. The overall performance 
of the models showed good discrimination with an AUC 0.81 and 0.86 for the 
prediction of pneumonia and ‘other SBIs’ respectively, and good calibration. 
Discrimination of ‘other SBIs’ was less good in the external validation population 
(AUC 0.69). In the validation group, it proved possible to identify low-risk thresholds 
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below which it was possible to rule out pneumonia (negative LR of 0.12) though a 
low-risk threshold of <2.5% for other SBIs only achieved a negative LR of 0.59. The 
study demonstrated the additive value of CRP on a model based upon clinical 
variables alone. 
 
The above published CPRs for the diagnosis of SBI were recently evaluated in a 
validation study252. In this, the authors applied CPRs derived in one published study, 
to other prospectively recruited cohorts. In general, the performance of the 
published rules was less good in the validation samples. In particular, the YOS failed 
to demonstrate adequate sensitivity, while the NICE guideline appeared to be 
sensitive, but at a cost of identifying many false positives (non-specific). The 
authors concluded that the use of such guidelines as NICE in low and intermediate 
risk settings (including primary care) may allow clinicians to rule out serious 
infection, but that their value in the higher risk setting of the ED was less clear252. 
 
 4
4 
Score Reference Number of 
subjects 
Proportion 
with SBI (%) 
Age range/ 
days 
LR+ LR- 
Yale IOS Baker 1990236 126 29.4 28-56 2.27 (1.32 – 3.90) 0.68 (0.49 – 0.93) 
Rochester Dagan 1985187 233 9.9 0-90 3.00 (2.42 – 3.72) 0.06 (0.01 – 0.44) 
Dagan 1988239 237 8.9 0-60 3.21 (2.63 – 3.91) 0 
Jaskiewicz 1994240 802 7.1 0-60 1.85 (1.68 – 2.03) 0.15 (0.07 – 0.35) 
Chiu 1994241 254 17.7 0-31 2.07 (1.67 – 2.57) 0.29 (0.16 – 0.56) 
Chiu 1997242 119 16.4 4-28 2.58 (2.15 – 3.09) 0.04 (0.01 – 0.27) 
Byington 2004243 1378 9.4 0-90 1.41 (1.32 – 1.51) 0.26 (0.15 – 0.45) 
Garra 2005244 259 25.9 0-56 1.54 (1.37 – 1.73) 0.08 (0.02 – 0.32) 
Marom 2007245 386 24.0 0-28 2.44 (2.11 – 2.81) 0.02 (0 – 0.11) 
Philadelphia Baker 1993237 747 8.7 28-56 1.70 (1.58 – 1.82) 0.04 (0.01 – 0.26) 
Baker 1999246 422 10.2 28-56 1.36 (1.28 – 1.45) 0 
Garra 2005244 181 21.5 28-56 1.27 (1.14 – 1.41) 0.11 (0.02 – 0.78) 
Milwaukee Bonadio 1993247 534 4.5 28-56 1.33 (1.20 – 1.47) 0.15 (0.02 – 1.02) 
Decision tree Bachur 2001248 5279 7.1 0-90 3.70 (3.45 – 3.97) 0.23 (0.18 – 0.28) 
‘Lab score’ Bressan 2012254 1012 28.3 0-90 10.5 (7.46 – 14.7) 0.51 (0.45 – 0.57) 
Table 7: Clinical prediction rules to identify young infants at low risk of SBI. LRs were calculated using the epiR package in R
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5 
Score Reference Outcome 
diagnosis 
Proportion with 
outcome (%) 
Age range/ 
months 
LR+ LR- 
NICE traffic light Thompson 2009249 ‘Serious infection’ 44.7 3-192 1.20 (1.10 – 1.30) 0.50 (0.40 – 0.70) 
De 2013250 All SBI 7.1 0-60 1.08 (1.04 – 1.11) 0.77 (0.68 – 0.87) 
Manchester 
triage score 
Thompson 2009249 ‘Serious infection’ 44.7 3-192 3.40 (2.20 – 5.20) 0.8 (0.8 – 0.9) 
Nijman 2011251 All SBI 10.4 1-192 1.35 (1.08 – 1.69) 0.84 (0.73 – 0.98) 
Yale Observation 
score 
McCarthy 1982235 All SBI 11.9 0-24 3.84 (2.75 – 5.37) 0.15 (0.03 – 0.44) 
Teach 1995238 Bacteraemia 2.9 3-36 1.58 (0.85 – 2.93) 0.98 (0.95 – 1.01) 
Galetto-Lacour 2001189 All SBI 22.6 0-36 1.60 (0.66 – 3.78) 0.91 (0.74 – 1.12) 
Galetto-Lacour 2003196 All SBI 29.2 0-36 1.30 (0.58 – 2.92) 0.93 (0.74 – 1.18) 
Thayyil 2005101 All SBI 11.1 1-36 2.70 (1.72 – 4.13) 0.19 (0.03 – 1.17) 
Hsiao 2006197 All SBI 10.3 2-6 1.10 (0.62 – 1.98) 0.97 (0.82 – 1.15) 
Andreola 2007191 All SBI 23.0 0-36 1.80 (1.38 – 2.35) 0.68 (0.55 – 0.85) 
SBI score 
(various) 
Bleeker 2001255  All SBI 25.1 1-36 5.97 (3.08 – 11.54) 0.66 (0.54 – 0.81) 
Bleeker 200797 All SBI 26.0 1-36 2.07 (1.72 – 2.51) 0.38 (0.27 – 0.55) 
Brent 20119 All SBI 3.8 1-180 11.0 (5.33 – 22.7) 0.86 (0.78 – 0.85) 
Nijman 201396 Pneumonia 14.5 1-180 11.1 (6.57 – 18.7) 0.85 (0.79 – 0.92) 
Nijman 201396 Other SBI 14.5 1-180 9.12 (5.54 – 15.0) 0.83 (0.76 – 0.91) 
‘Lab score’ Galetto-Lacour 20087 All SBI 26.7 0-36 4.66 (3.66 – 6.46) 0.07 (0.02 – 0.21) 
Galetto-Lacour 2010253 All SBI 22.7 0-36 5.09 (3.93 – 6.59) 0.17 (0.10 – 0.28) 
Table 8: Performance characteristics of risk prediction scores for the diagnosis of SBI in children presenting to the ED. LR+: Positive likelihood ratio, LR-: Negative likelihood 
ratio. LRs were calculated using the epiR package in R
100
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1.7. Summary 
Acute febrile illnesses are a common presentation to the children’s Emergency 
Department. A failure to recognise SBI in febrile children and initiate prompt 
therapy is associated with adverse outcomes. Conversely, the inability to rule out 
SBI in a majority of febrile children results in the overtreatment of self-limiting 
illnesses. The consequences of this approach are an excess of hospital admissions, 
and an overuse of antibiotics, associated with the development of antibiotic 
resistance. 
Serious bacterial infections caused by vaccine-preventable organisms are in decline, 
and the aetiology of SBI is evolving as a consequence. The changing aetiology of the 
most invasive infections, such as bacteraemia, may further challenge the ability of 
clinicians to recognise and initiate treatment with effective antibiotics.  
Improved diagnostic testing using clinical or biomarker variables, and combinations 
thereof, may improve the assessment of risk of SBI, rationalising decision-making 
with regard to empirical treatment and hospital admission. Molecular methods of 
pathogen identification may also speed the identification of causative organisms 
and guide definitive antimicrobial therapy. 
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1.8. Hypothesis 
The prediction of SBI in febrile children of all ages presenting to the ED can be 
improved by the combination of clinical and biomarker variables in risk prediction 
models. 
 
1.9. Aims and objectives 
a) To describe the changing aetiology of bacteraemia presenting to the 
children’s ED, and to examine the impact of aetiology on clinical recognition 
of disease. 
b) To evaluate the use of a universal 16S rRNA PCR with sequencing method 
for the diagnosis of bacteraemia in the children’s ED. 
c) To derive and internally validate a clinical predication rule for the diagnosis 
of SBI in the children’s ED, incorporating recently described biomarkers of 
SBI.  
d) To externally validate the performance of published prediction rules in a 
prospectively recruited sample of children presenting to the ED with acute 
febrile illness, and to estimate the improvement in diagnostic accuracy 
obtained by the addition of multiple biomarkers. 
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Chapter 2: Methods 
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2.1. Overview of the chapter 
The work presented in this thesis is the result of the analysis of two large datasets 
designed to describe the aetiology of bacteraemia and other Serious Bacterial 
Infection (SBI) presenting to the children’s Emergency Department (ED), and to 
evaluate the diagnostic accuracy of molecular tests, clinical and biomarker variables 
for the diagnosis of SBI in this setting. In this chapter I will set out the methods used 
in the large, prospective diagnostic accuracy study which provided the context for 
the work. Though detailed statistical methods are located in the relevant results 
chapters, in this chapter I also detail conventional methods for quantifying 
diagnostic accuracy. 
 
2.2. Setting 
All of the work presented was undertaken in the Alder Hey Children’s Hospital NHS 
Foundation Trust ED. This is the busiest children’s ED in the UK, with approximately 
60 000 attendances per year. Alder Hey is situated in Liverpool and provides a range 
of secondary and tertiary paediatric services to children throughout the North West 
of England. It has been the focus of research into Meningococcal Disease (MCD) for 
over 20 years. 
 
2.3. Contributors 
Professor Enitan Carrol developed the study protocol for the Salivary Procalcitonin 
in Children presenting to the Emergency Department (SPICED) study and secured 
funding from the National Institute for Health Research (NIHR). As my PhD 
supervisor, Professor Carrol supported me to identify further funding from the 
Alder Hey Children’s Charity and the University of Liverpool in order to carry out 
further biomarker analysis, and the evaluation of a broad-range molecular 
diagnostic, SepsiTest.  
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The work benefitted greatly from a highly motivated clinical staff working in the ED, 
and a long established commitment to clinical research in the department, 
overseen by Dr Omnia Marzouk, a co-investigator on the SPICED study. Guidance 
was given by the Steering Committee, Drs Paul McNamara, Ruwanthi Kolamunnage-
Dona, and Paul Newland, and Ms Kim Williams, Ms Rachel Breen, Ms Sarah Olsen, 
Ms Jenny Newman, and Ms Dot Lambert. I undertook the day to day management 
of the SPICED study, establishing the mechanisms for recruitment into the study, 
communicating with and providing feedback to clinical staff, and revising the initial 
protocol and case report form (CRF) into the final versions used. Together with the 
research nurses Ms Alison Grant and Ms Rhian Williams, we directly recruited 
children in to the study, and having organised the provision of Good Clinical 
Practice training in the department, supported clinical staff to appropriately recruit 
to the study throughout the working week. This research team completed data 
entry onto paper CRFs. Together with Dr Duncan Appelbe, I developed and revised 
a Microsoft Access database, and I was responsible for data entry into the 
database, and for the cross checking of all CRFs. I was responsible for liaising with 
the UK Clinical Research Network (UKCRN) Coordinating Centre, and uploading 
recruitment data on a monthly basis. Outcome diagnoses for children recruited to 
the SPICED study were attributed by Professor Carrol, Dr Stephane Paulus and I. 
Clinical samples obtained in the ED were prepared and stored with the help of the 
Biochemistry and Microbiology departments at Alder Hey, and in particular Ms 
Christine Chesters, Ms Elaine Hanmer and Ms Teresa Barton. Procalcitonin (PCT) 
measurement was performed on the B.R.A.H.M.S Kryptor platform (Thermofisher 
scientific, Hennigsdorf) and was carried out by Ms Chester. I was supported in the 
performance of Neutrophil Gelatinase-associated Lipocalin (NGAL) and Resistin 
analysis by Mr Graham Jeffers, while the performance of the broad-range molecular 
test (SepsiTest) was undertaken by the Molzym laboratory in Bremen, with the 
oversight of Professor Michael Lorenz. 
Statistical analysis was undertaken with the support of Professor Peter Diggle. I also 
received training from Drs Rob Christley and Jon Read as part of the Advanced 
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Statistics for Epidemiology course at the University of Liverpool, and from Ms Sally 
Eagle who together taught me to programme using the R statistical package. 
The study of bacteraemia was conceived by Dr Richard Drew, Professor Carrol and I. 
Informatics support was provided by Ms Laura Medway and Ms Gemma Boydell 
who exported data from the Alder Hey Trust microbiology and biochemistry 
databases. I was supported in the process of data entry and cleaning by the 
Research Fellow Dr Kha Nguyen, and by a group of final year undergraduate 
medical students who I co-supervised as part of a Paediatric Infectious Disease 
‘Selective in Advanced Medical Practice’. 
 
2.4. The Salivary Procalcitonin in Children presenting to the Emergency 
Department (SPICED) study 
2.4.1. Background 
The measurement of biomarkers in saliva is a non-invasive approach to diagnostic 
testing which has particular appeal in the study of children. Saliva has been 
demonstrated to be an appropriate sample for the measurement of protein 
biomarkers, as well as molecular diagnostics, and salivary biomarkers may reflect 
both local and systemic disease256. Salivary Procalcitonin has previously been 
detected in adults with diabetes and periodontitis257. 
2.4.2. Objectives 
The primary objective of the SPICED study was to evaluate the diagnostic accuracy 
of Procalcitonin, measured in saliva samples, for the diagnosis of SBI in febrile 
children presenting to the ED. Recognising the limitations of individual markers of 
SBI in children, and building upon earlier work which identified markers of SBI in 
Malawian children215, the study incorporated the measurement of NGAL and 
Resistin in blood samples, and the comprehensive collection of clinical data with 
which to evaluate multivariable risk prediction models. The study also provided the 
infrastructure in which to evaluate the molecular diagnostic SepsiTest in whole 
blood in children. 
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2.4.3. Study design 
The SPICED study was a prospective observational diagnostic accuracy study of 
febrile children presenting to the Emergency department. It was funded by the 
NIHR Research for Innovation, Speculation and Creativity stream (Project ID: RC-PG-
0309-10053).  
2.4.4. Identification of eligible patients 
Children less than 16 years of age with fever (>38°C) or history of fever were eligible 
for inclusion in the study if they required blood tests as part of routine clinical 
management. At triage, nursing staff were prompted by an electronic triage screen 
to record a ‘fever, or history of fever’. Children who met this criterion received a 
SPICED study ‘tag’ which was attached to the clinical notes. Simultaneously they 
were electronically flagged to the study research team. At clinical review, if the 
attending clinician decided to undertake blood tests, the research team would 
approach the child and family with written information relating to the study (see 
Appendix 1 for an example of age appropriate patient information provided to 
eligible children). 
All documentation required to recruit children to the study was included in 
numbered study packs which were available in the busy clinical observation area of 
the ED. 
2.4.5. Exclusion criteria 
Children with an underlying immunodeficiency or with significant periodontal 
disease were excluded. 
2.4.6. Ethics approval 
Written informed consent was obtained from those with parental responsibility for 
the study subjects (Appendix 2). Where appropriate in older children, the assent of 
study subjects was also recorded. Ethical approval for the study was granted by the 
Greater Manchester West Research Ethics Committee (10/H1014/53), and site 
approval granted by the Alder Hey Children’s NHS Foundation Trust Research and 
Development department. Specific ethical approval was obtained for a process of 
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deferred written consent whereby in the context of an acute clinical emergency, or 
on occasions where the attending clinical team felt unable to give adequate 
information to allow parents to make an informed decision, parents were able to 
give verbal consent for clinicians or study staff to store excess clinical samples. 
Following a later discussion regarding the objectives of the study, parents could 
give written consent for their child to be included, and for the stored clinical 
samples to be salvaged for analysis 
2.4.7. Timescale 
Recruitment to the study commenced in November 2010 and was completed in 
April 2012.  
2.4.8. Data collection and storage 
Potential markers of SBI were identified from published data10,185. The full list of 
clinical and biomarker variables investigated is detailed in the pre-designed CRF 
(Appendix 3). Clinical data were entered onto CRFs at or shortly after the clinical 
assessment. Where possible, this was done by the attending clinician. When clinical 
information was not fully entered onto the CRF at the time of assessment, the 
missing clinical information was taken from the clinical notes, where explicitly 
referenced. Paper CRFs were collected by the study team on a daily basis, and 
stored in a locked office. All data recorded on the CRFs were cross checked against 
the clinical notes which had been electronically scanned and stored. 
2.4.9. Data entry 
Data from the paper CRFs were transcribed into a password protected Microsoft 
Access database. Information stored electronically on Trust databases (such as 
demographic data, admission and discharge dates, and results of blood tests) was 
imported directly into the study database. A random selection of approximately 
10% (120) of CRFs was cross checked against the electronic record to identify 
transcription errors. None were identified. 
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2.4.10. Standards for Reporting of Diagnostic Accuracy (STARD) 
The study was reported in line with the STARD initiative guidelines, detailed in the 
Introduction (Section 1.5.1). 
 
2.4.11. Outcome diagnoses 
Outcome diagnoses were determined independently by Professor Carrol, or 
another Paediatric Infectious Disease Consultant (Dr Paulus) and I, according to pre-
determined criteria (Table 9). These criteria were agreed with reference to 
previously published diagnostic accuracy studies of SBI in children 9,10,185,253. 
Outcome diagnoses were blinded to the results of the biomarkers analysed (PCT, 
NGAL and Resistin), though not to the clinical information including routine clinical 
tests. Routine clinical tests were requested at the discretion of the clinical team, 
and not all tests were performed in all children. In the event of disagreement, a 
final outcome diagnosis was attributed by consensus with the involvement of all 
three investigators. Subjects were followed up to 28 days post discharge to 
minimise the risk of misclassification. 
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Diagnosis Criteria 
Pneumonia Respiratory symptoms and signs and focal consolidation on X-ray 
reported by a paediatric radiologist 
Other SBI  
 Bacteraemia Identification of a significant bacterial pathogen in blood using culture 
or molecular methods,  
 Urinary tract 
 infection 
Growth of a single bacterial urinary tract pathogen at ≥105 colony-
forming units/ml in an appropriate urine sample in the context of 
clinical signs of systemic involvement. 
 Meningitis Identification of a bacterial pathogen in CSF using culture or molecular 
methods, or clinical meningitis plus a cerebrospinal fluid 
polymorphonuclear leucocytosis 
 Osteomyelitis Clinical signs, and radiological confirmation or identification of a 
pathogen in the bloodstream 
 Septic 
 arthritis 
Isolation of a bacterial pathogen from a joint 
 Probable 
 bacteraemia 
Identification of a plausible pathogen, in the context of a compatible 
clinical syndrome and/or clinical signs of bacteraemia (see Table 10 
and below for definition of clinical signs) 
 Probable SBI Prolonged admission and administration of intravenous antibiotics 
beyond 72h despite negative culture results.  
Table 9: Pre-defined criteria for the diagnosis of SBI
9,10,185,253
 
 
‘Clinical signs’ of bacteraemia were considered to be signs of sepsis on presentation 
(including fever, tachycardia, tachypnoea, poor perfusion), associated with elevated 
markers of infection (White Cell Count and C-Reactive Protein) and the prolonged 
administration of intravenous antibiotics, and prolonged hospital stay despite 
negative culture results. Supportive microbiological evidence of infection was also 
considered, such as a serological response to a clinically plausible organism (for 
example an elevated anti-Streptolysin O titre in a clinical presentation consistent 
with a Streptococcal infection). Criteria for the outcome of bacteraemia are 
detailed in Table 10.   
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Culture Specific 
PCR 
SepsiTest Clinical 
signs 
Additional 
microbiology 
Outcome 
Pathogen ± ± ± ± Bacteraemia 
± Pathogen ± ± ± Bacteraemia 
± ± Pathogen ± ± Bacteraemia 
Possible pathogen: 
 
Single isolation 
 
 
 
Repeated isolation 
 
 
-ve 
-ve 
 
-ve 
-ve 
 
 
Same organism 
-ve 
 
-ve 
± 
 
 
± 
+ve 
 
-ve 
± 
 
 
± 
± 
 
± 
± 
 
 
Bacteraemia 
Probable 
bacteraemia 
No bacteraemia 
Bacteraemia 
Negative 
 
 
-ve 
 
 
Possible pathogen 
 
 
+ve 
 
-ve 
± 
 
± 
Probable 
bacteraemia 
No bacteraemia 
Negative 
 
 
-ve 
 
 
Negative 
 
 
+ve 
 
-ve 
+ve 
 
± 
Probable 
bacteraemia 
No bacteraemia 
Table 10: Outcome diagnosis of bacteraemia according to microbiological and clinical evidence 
 
 
2.5. Laboratory methods 
2.5.1. Sample collection and preparation 
Alongside routine clinical samples, study samples were collected by trained clinical 
or research staff using a conventional aseptic non-touch technique. 
2.5.1.1. Plasma 
A sample of 0.5-1.0ml of blood collected into Lithium Heparin was transported to 
the laboratory at ambient temperature, and centrifuged at 13,000 rpm for 5 
minutes using a Heraeus Biofuge Pico centrifuge. The plasma was removed and 
stored in Sarstedt 0.5ml microtubes at -80°C. Sample freezing occurred within 1 
hour. Samples were tracked using the hospital laboratory tracking system. 
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2.5.1.2. EDTA 
A sample of 0.5-1.0ml of whole blood was collected into paediatric EDTA bottles. 
Samples were inverted at the bedside to prevent clotting. In the microbiology 
laboratory, samples were transferred in sterile conditions into DNA-free Universal 
Microbe Detection (UMD) tubes containing glycerol (Molzym, Bremen). These were 
then vortex mixed for 15 seconds. Samples were labelled with a study ID and stored 
at -80°C until analysis.  
2.5.1.3. Saliva 
Saliva samples were collected using plain cotton swab ‘Salivettes’ (Sarstedt, 
Numbrecht). Children were encouraged to chew or suck the swab for 45 seconds as 
described in the product instructions for use. The swab was then returned to the 
Salivette container and centrifuged for 2 minutes at 13 000 rpm, allowing the 
collection of the saliva sample in the extended tip of the collection chamber. Up to 
1ml of saliva was stored at -80°C until analysis. Sample freezing occurred within 1 
hour, and samples were tracked using the hospital laboratory tracking system.  
Prior to analysis the samples were thawed, mixed thoroughly by vortex mixer and 
centrifuged again to remove bubbles and particulate matter. 
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2.5.2. Enzyme-linked immunosorbent assay (ELISA) 
The ELISA is a well –established method for quantifying an unknown substance in 
clinical samples. The general principle involves the specific binding of antibody to 
the antigen of interest, followed by an enzyme reaction causing a detectable signal 
(such as a colour change). In the sandwich ELISA technique, the antigen of interest 
in the sample is bound first to antibody on a pre-treated plate (the ‘capture 
antibody’), and this bound antigen is then ‘sandwiched’ by the addition of a second, 
complementary detection antibody to which an enzyme is conjugated. Following 
the addition of the enzyme substrate the resultant colour change may be quantified 
by an absorbance reader. Accurate quantification of the antigen requires the 
production of a standard curve. For this, absorbance readings from samples with a 
known concentration of antigen (‘standards’) are used to plot the curve that relates 
absorbance to antigen concentration for each assay. Absorbance readings taken 
from clinical samples can then be applied to the standard curve for that assay to 
allow the calculation of the antigen concentration. 
 
 
Figure 3: Schematic of a simple sandwich ELISA assay. 
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2.5.2.1. Neutrophil Gelatinase-associated Lipocalin (NGAL) 
Measurement of NGAL was undertaken using a commercially available ELISA, 
validated for use on plasma samples (R&D systems, Minneapolis) according to the 
supplied protocol. 
2.5.2.1.1. Reagent and sample preparation 
A serial dilution of the supplied human NGAL standard was prepared following 
reconstitution of the standard solution (100ng/ml) with deionised water. Standard 
concentrations ranged from 0.156ng/ml to 10ng/ml. The supplied wash buffer, 
calibrator diluents, and substrate solutions were prepared according to the 
instructions provided. 
Plasma samples were initially diluted 1:20 as per the protocol by mixing 20µl of 
plasma with 380 µl of calibrator diluent. In view of the high number of samples 
exceeding the upper limit of detection, subsequent assays were run at a dilution of 
1:50 (20µl plasma in 980µl diluent). 
2.5.2.1.2. Assay procedure 
The assay was performed on the supplied pre-coated 96-well NGAL microplate. 
100µl assay diluent was added to each well, before the addition of 50µl of prepared 
standard or sample. Initially, assays were undertaken in duplicate (n=80) and intra-
assay variability was measured by estimating the coefficient of variation (CV). For 
the NGAL assay CV was estimated to be 4.16%. Following the demonstration of 
adequate intra-assay precision, later samples were assayed individually. 
Standards and samples were incubated for 2 hours at 4°C before washing with the 
supplied wash buffer using an autowasher. 200µl human NGAL conjugate (stored at 
4°C) was then added to each well, and incubated for a further 2 hours at 4°C. 
Following a further wash cycle, 200µl substrate solution was added to each well and 
incubated in a dark room at room temperature for 30 minutes. Stop solution was 
then added to each well, and the optical density read by the ELx800 absorbance 
reader (Biotek instruments, Winooski) set to 450nm. A 4 parameter logistic curve 
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was constructed with each assay run, using the KC junior software package 
produced by Biotek. 
2.5.2.2. Resistin 
Plasma samples were analysed using a commercially available, validated Resistin 
ELISA (Assaypro, Missouri) according to the manufacturer’s instructions. 
2.5.2.2.1. Reagent and sample preparation 
A serial dilution of the supplied human Resistin standard was prepared following 
reconstitution of the standard solution (16ng/ml) with deionised water. Standard 
concentrations ranged from 0.25ng/ml to 8ng/ml. The supplied wash buffer, 
calibrator diluents, and substrate solutions were prepared according to the 
instructions provided. Plasma samples were diluted 1:20 by mixing 20µl of plasma 
with 380µl of calibrator diluent. 
2.5.2.2.2. Assay procedure 
The assay was performed on the supplied pre-coated 96-well Resistin microplate. 
50µl of prepared standard or sample was added to each well. Duplicate assays 
(n=80) again demonstrated acceptable intra-assay variability (CV 3.91%), so 
subsequent biomarker measurement was undertaken on individual samples. 
Standards and samples were incubated for 2 hours at room temperature before 
washing with the supplied wash buffer using an autowasher. 50µl of biotinylated 
Resistin antibody was then added to each well and incubated for a further 2 hours. 
Following a further wash cycle, 50µl of Streptavidin-Peroxidase conjugate was then 
added to each well, and incubated for a further 30 minutes. After washing, 50µl of 
Chromogen Substrate was added and incubated for approximately 12 minutes, 
tapping the microplate to ensure mixing. Stop solution was then added to each 
well, and the optical density read by the ELx800 absorbance reader (Biotek 
instruments, Winooski) set to 450nm. A 4 parameter logistic curve was constructed 
with each assay run, using the KC junior software package produced by Biotek. 
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2.5.3. Automated Procalcitonin assay (Kryptor) 
2.5.3.1. Assay procedure 
PCT analysis in plasma and saliva was undertaken on the B.R.A.H.M.S. Kryptor 
platform (Thermofisher scientific, Hennigsdorf) in the biochemistry department of 
the Alder Hey Children’s Hospital NHS Foundation Trust. The samples were 
analysed according to manufacturer’s instructions, in batches of 50. Quality control 
samples were analysed at the beginning and end of each run. 
 
2.5.4. SepsiTest 16S rRNA PCR with sequencing 
Frozen samples stored in UMD tubes were shipped in dry ice to be analysed by 
Molzym in Bremen. 
2.5.4.1. Assay procedure 
Thawed samples were analysed using the semi-automated broad-range real-time 
PCR, SepsiTest (Molzym, Bremen). The kit includes all reagents for automated DNA 
isolation and universal 16S and 18S rRNA PCR analysis of bacterial and fungal DNA, 
respectively. Amplifications were performed in a DNA Engine Opticon cycler 
(BioRad, Hercules, USA) following the recommended programme in the SepsiTest 
manual.  
2.5.4.2. Sequencing of amplicons 
In case of positive reactions, amplicons were sequenced as advised in the manual 
using supplied sequencing primers. Standard precautions for the avoidance of air 
and handling-borne DNA contamination were followed. Sequence chromatograms 
were carefully analysed and sequences were edited manually if necessary. Strains 
were identified using NCBI BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) and 
SepsiTest-BLAST (http://www.sepsitest-blast.net). A result was recorded negative if 
the melt curve analysis of the real-time PCR indicated absence of bacteria and 
fungi-specific peaks, respectively, or sequencing did not give a read-out. At 
sequence identities >97 and 99% genus and species names were filed, 
respectively. Mixed sequences (i.e., chromatograms showing overlapping 
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sequences of two or more different sequences) were analysed using the Ripseq 
mixed programme (Isentio, Bergen). Cases positive in the PCR assay and with mixed 
sequences that could not be resolved were assigned positive for bacteria. 
 
2.5.5. Routine microbiology and virology investigation 
Clinical tests were requested at the discretion of the clinical team. All samples were 
processed in Clinical Pathology Accredited (CPA) laboratories. Blood (0.5 to 1ml) 
was inoculated into blood culture bottles and monitored using the BacT/ALERT 3D 
system (Biomerieux, Marcy l’Etoile). Positive blood cultures were processed in line 
with the UK standard for Microbiology investigations developed by Public Health 
England258. 
Molecular identification of Streptococcus pneumoniae and Neisseria meningitidis 
was performed using specific PCR assays at the Meningococcal Reference Unit in 
Manchester259,260. Multiplex viral PCR was performed on respiratory (Respiratory 
Syncytial Virus, Influenza A and B, Parainfluenza 1, 2 and 3, Adenovirus, Rhinovirus 
and Metapneumovirus) and CSF (Herpes Simplex, Varicella Zoster and Enterovirus) 
samples in the regional virology laboratory at Manchester and subsequently the 
Royal Liverpool Hospital. 
Urinalysis was performed in the ED using Multistix 8 reagent strips (Siemens, 
Erlangen). Samples of urine and CSF underwent conventional microscopy and 
culture on agar gel plates, and were processed at Alder Hey in line with the relevant 
UK Standard for Microbiology Investigations261,262. 
 
  
65 
 
2.6. Statistical methods 
Statistical analysis was undertaken using the R statistical package263. Each chapter 
includes a detailed description of the statistical methods employed. 
 
2.6.1. Regression analysis 
The regression methods described here are drawn from the book “Regression 
modelling strategies” by Frank Harrell264 and course notes from the “Advanced 
Statistics for Epidemiology” MSc module led by Dr Rob Christley at the University of 
Liverpool.  
Regression analysis is a statistical method used to describe relationships between 
dependent (outcome) and independent (predictor) variables. Using sample data, a 
model relating outcome to a combination of explanatory predictors can be 
estimated.  
2.6.1.1. Linear regression 
The simplest such model is the linear regression model: 
y = α +βx 
where y is the outcome of interest, x are the observed values of an explanatory 
variable, and α and β represent unknown ‘parameters’ estimated to best fit the 
data. To reflect variability in the outcome variable, this mathematical model 
becomes the statistical model: 
 Yi = α + βxi + Zi, i=1.…n 
The statistical model includes the term Zi which quantifies the amount each 
measured xi deviates from the straight line. This is the ‘error’ or ‘residual’ term. i are 
the number of measured variables in the dataset, hence the ability to estimate the 
model parameters depends upon the size of the dataset, n. 
66 
 
Several assumptions are necessary for linear regression. These are that the 
residuals are an independent random sample (implying that the observations are 
independent), from a normal distribution with a mean of zero (the relationship 
between Y and x is linear) and constant variance. Under these assumptions, 
maximum likelihood estimates can be made for the parameters α and β. That is 
that, given the data, these are the parameter estimates that make the data most 
likely. 
The simple model relating outcome to a single explanatory variable can be 
extended to include more than one. The inclusion of multiple variables may 
improve the fit of the model to the data, helping to explain more of the variation in 
the observed outcome. It also allows an exploration of the effect of each variable in 
the model, whilst controlling for that of the other variables. 
 
2.6.1.2. Non-linear explanatory variables 
One of the key assumptions of linear regression is that the residuals have a mean of 
zero, and that the relationship between explanatory variable and outcome is linear. 
It may be apparent in the initial data exploration that this is not true. Various 
approaches to these non-linear associations are possible, including the use of 
polynomial and piecewise transformations of the explanatory variable.  
2.6.1.2.1. Polynomial transformations 
In settings where the assumption of linearity appears not to hold, alternative 
relationships can be explored by the use of polynomial terms, e.g. 
 
 Y= α +β1x+ β2x
2+ βix
i + Zi, i=1....n  
 
Though the relationship between Y and x is non-linear, the regression function 
remains linear in terms of the unknown parameters (α, β), and so polynomial 
models are considered an example of multivariable linear regression. Maximum 
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likelihood estimates for the unknown parameters can be made by considering each 
higher order polynomial as independent variables in the regression model.  
2.6.1.2.2. Piecewise transformations 
Instead of considering a non-linear relationship between outcome and explanatory 
variable as a polynomial function, non-linear variation can be viewed as a 
combination of more than one adjacent linear relationship. This use of more than 
one linear segment may allow the model to fit the data more closely. Identifying 
the most appropriate ‘breakpoint’ – the point at which the slope of the line changes 
in order to best fit the data – can be achieved statistically, that is, by iterating over 
all possible breakpoints to find the model which best fits the data, or 
mechanistically by choosing a breakpoint which explains an expected variation in 
the model.  
2.6.1.3. Generalised linear models 
So far, the methods described have maintained the necessary assumptions of 
normally distributed residuals (there is a linear relationship between explanatory 
variables and outcome), and of constant variance. However, in a number of 
situations these assumptions are clearly false. In the course of this thesis there are 
two such examples. These are the analysis of data where the outcome variable is 
binary (or categorical), and the analysis of count data.  
Generalised linear models (GLMs) relax the requirement for outcome and 
explanatory variable to be directly linear. Instead a GLM has the following 
properties to relate outcome to predictors: 
 an error structure 
 a linear predictor 
 a link function 
These properties will be illustrated with reference to the common GLMs used in the 
thesis.  
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2.6.1.3.1. Logistic regression 
Logistic regression may be used when outcome data are binary. In this setting, the 
relationship between outcome and explanatory variables is clearly not linear (the 
outcome is either 0 or 1). This is the context for much of the work of this thesis, 
where the outcome of interest is the presence or absence of disease (SBI). Even 
when the outcome is expressed as a probability of SBI (p), a simple linear regression 
would predict probabilities that are impossible (outside the range 0 to 1). Further, 
the variance of a binomial distribution (a distribution of the probability of obtaining 
a 1, where the data may be 0 or 1) varies (variance is proportional to p(1-p)), 
breaching the assumption of constant variance.  
Logistic regression overcomes these limitations of linear regression. As described, 
logistic regression as an example of a GLM specifies an error structure, and a link 
function which allows the predicted value of the outcome to be derived from the 
linear predictor – the linear sum of the effects of the explanatory variables.  
For logistic regression, the link function g(Y) is the logit function, ln (p/1-p). So,  
 
g (Y) = ln (p/1-p)= α +β1x1i + β2x2i + βpxpi + Zi, i=1....n   
 
The error structure specific to logistic regression limits the residual terms Zi to the 
binomial distribution. 
The results of a logistic regression model then can conveniently be transformed into 
the probability of the outcome of interest. From the equation above, the 
probability of the outcome can be written: 
 
 p= eg(Y)/1+eg(Y) 
with g(Y) calculated from the particular set of explanatory variables in the model.   
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2.6.1.3.2. Poisson log-linear regression  
The second example of a GLM used in the thesis is in the case of count data. For 
count data with frequent zero counts, the variance of the data is assumed to equal 
the mean, and thus increases with the mean (it is not constant). Once again, the 
error structure is non-normal, as count data are bounded by zero (it is not possible 
to have a negative count). In this setting, the link function is the log function (which 
ensures that data are bounded below), while the error structure follows the 
poisson distribution.  
 
2.6.1.3.3. Generalised additive models 
Generalised Additive Models (GAMs) are a form of GLM which provide a valuable 
method to explore the relationship between a non-linear explanatory variable and 
outcome. GAMs do not assume a linear relationship but instead apply non-
parametric smoother functions to local subsets of data265 and thus can describe 
complex non-linear relationships. For the purpose of this thesis, the use of GAMs 
has been limited to providing an illustration of the likely shape of the relationship 
between outcome and explanatory variable, in order to identify appropriate non-
linear relationships (such as piecewise or polynomial transformations) which better 
model the data. 
2.6.2. Imputation of missing data 
In the analysis of large datasets with multiple variables, missing data is a common 
problem. The handling of missing data has significant implications for the 
conclusions drawn from the data. The appropriate response to the problem of 
missing data depends upon the pattern of missingness. Where the probability of 
missingness of a given variable is independent of both the observed variables, and 
the unobserved, missing variables, the data is said to be missing completely at 
random (MCAR). This is an unusual case. More commonly, it is plausible to assume 
that the missingness depends upon observed variables, termed missing at random 
(MAR). This MAR assumption may be particularly appropriate where there are 
many predictor variables266. Where the probability of missingness is dependent 
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upon the missing variables, the problem is termed ‘non-ignorable’ or missing not at 
random (MNAR). The methods used to make efficient, unbiased use of incomplete 
data depend upon these assumptions267. 
2.6.2.1. Complete case analysis 
Analysis of only those cases in which data are completely recorded is both 
inefficient, as well as almost certainly leading to biased inferences. Only where the 
MCAR assumption holds does a complete case analysis yield unbiased inferences. 
The use of complete case analysis in datasets with many variables is inefficient as 
only those cases in which all variables of interest are complete can be included. 
2.6.2.2. Ad-hoc methods 
Ad-hoc methods include a variety of methods which either recode missing variables 
to some common value (such as in mean imputation), or drop those variables with 
a high proportion of missing values. Like complete case analyses, such approaches 
are generally considered to lead to biased inferences, and inefficient use of the 
available data268. 
2.6.2.3. Multiple imputation 
Multiple imputation is a statistical method in which missing data are replaced by 
random draws from a distribution of plausible values. The generation of plausible 
values requires the appropriate specification of an imputation model relating 
missing data to that of the observed data. For this model to be appropriate it 
should preserve both the structure of the observed data, and the uncertainty 
underlying it. From this distribution of plausible values, multiple imputations are 
made resulting in the generation of multiple, ‘completed’ datasets. These multiple 
datasets are analysed for the outcome of interest, and the results of each analysis 
pooled. The resultant pooled analysis generates estimates whose standard errors 
reflect the uncertainty inherent in the missing data269. 
2.6.2.4. Likelihood based methods 
In maximum likelihood methods, multiple imputations of missing values are 
entered, alongside the probability of obtaining each value, given the observed data. 
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This ‘augmented’ dataset is then used to undertake the regression analysis, 
accounting for the weight of each possible imputed value267. 
2.6.3. Statistical measures of diagnostic accuracy 
2.6.3.1. Evaluating dichotomous test results: the 2x2 table 
The diagnostic accuracy of a test – a clinical variable, a biomarker, or a prediction 
model – evaluates the agreement between the test and the outcome of interest, as 
determined by the reference standard. Tests should ideally be as ‘sensitive’ and 
‘specific’ as possible. Sensitivity is the proportion of individuals with the outcome of 
interest identified by a positive test, whilst specificity is the proportion of 
individuals without the outcome correctly identified by a negative test270. These, 
and other measures of the value of a test, can be illustrated by a ‘2x2 table’ (Table 
11) relating test outcomes to the ‘true’ diagnosis, in this case of SBI. 
 
 SBI 
+ - 
Test + a b 
- c d 
Table 11: A 2x2 table relating test results to outcome diagnosis (SBI). 
 
 
Sensitivity    =  a / a+c 
Specificity    =  d / b+d 
 
Positive predictive value  =  a / a+b 
Negative predictive value =  d / c+d 
 
Positive likelihood ratio  =  True positive rate / false positive rate 
     (a / a+c) / 1-(d / b+d) 
 
Negative likelihood ratio  =  False negative rate / true negative rate 
     (1-(a / a+c)) / (d / b+d) 
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The sensitivity and specificity of a test do not identify the likelihood that a subject 
with a positive test has the outcome of interest. This is described by the positive 
predictive value. Positive and negative predictive values are however, highly 
dependent upon the prevalence of the outcome. If the outcome of interest is rare, 
positive predictive values of sensitive and specific tests will remain low, whilst poor 
tests will achieve a high negative predictive value271. 
 
Likelihood ratios are the ratio of the probability of a given test result in a subject 
with the disease to that of a subject without the disease. The likelihood ratio allows 
the calculation of post-test odds from pre-test odds. Hence a discriminatory test 
will have a positive likelihood ratio significantly higher than 1, and a negative 
likelihood ratio significantly less than 1272. Various authors have suggested positive 
and negative likelihood ratios that respectively rule in and rule out diagnoses. In the 
diagnosis of SBI, a test with a positive likelihood ratio of more than 5 is proposed as 
a ‘red flag’ test capable of ruling in SBI, whilst one with a negative likelihood ratio of 
less than 0.2 is proposed to effectively rule out SBI8. 
2.6.3.2. Evaluating diagnostic risk prediction models 
An established approach to evaluating the diagnostic accuracy of multiple variables 
for a binary outcome is multivariable logistic regression. A logistic regression model 
provides a predicted probability of a binary outcome of interest for given values of 
the explanatory variables. For each threshold value of the predicted probability, the 
outcome may be dichotomised and summary statistics such as sensitivity, 
specificity, predictive values and likelihood ratios calculated as described above. A 
change in the threshold to increase sensitivity invariably reduces specificity, and 
various methods exist to ‘optimise’ this threshold value. Studies of biomarkers of 
SBI in children have commonly achieved this using the ‘Youden index’ which sums 
sensitivity and specificity273. This approach assumes equal weighting for positive 
and negative outcomes, and has been criticised. Increasingly, authors are 
identifying multiple thresholds at which important clinical decisions to rule in or 
rule out SBI can be made185.  
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A number of measures of the overall performance of logistic regression models 
exist. Broadly, these measures quantify the distance between predictions and 
observed outcomes, with better fitting models minimising this distance274. The 
most commonly reported summary statistic of a logistic regression model is the 
concordance (c) statistic.  The c statistic is the likelihood that a randomly selected 
subject with the outcome of interest will have a higher predicted probability than 
another randomly selected subject who does not have the outcome275. It is the 
overall measure of discrimination of the model. Conveniently, in logistic regression, 
the c statistic is equal to the area under the Receiver Operating Characteristic (ROC) 
curve (AUC) which plots sensitivity against (1-specificity) for each probability of an 
outcome. Though rarely undertaken, it is equally plausible to create ROC curves to 
summarise positive and negative predictive probabilities. 
Another important consideration in the evaluation of a logistic regression model is 
the calibration between predictions and observed outcomes. In simple terms, in a 
well calibrated model a predicted risk of 10% should result in 10 outcomes of 
interest per 100 subjects with this risk. This can be represented by a calibration 
plot. Subjects with similar predicted probabilities are grouped together and mean 
predictions plotted against observed outcomes. When subjects are grouped into 
deciles, this is a graphical representation of the Hosmer-Lemeshow ‘goodness of fit’ 
test274. 
2.6.3.3. Evaluating improvements in risk prediction models 
The increasing acceptance of risk prediction models in the context of diagnostics 
has prompted recognition of the need to evaluate improvements of one model over 
another. Quantifying improvement in traditional measures of model performance, 
such as the AUC, may be of value, but has been shown to be difficult. The addition 
of variables with a significant association with outcome to a baseline model with 
reasonable discrimination, may fail to produce a meaningful increase in the AUC. 
Such an increase often requires the addition of variables with unrealistically high 
effect size276. 
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Alternative approaches have been proposed. One attempts to quantify the 
improvement in classification achieved by the assignment of subjects into risk 
categories277. Improved classification occurs when subjects with the outcome of 
interest are re-classified into higher risk categories. Worse classification occurs 
when the new model re-classifies a subject with the outcome to a lower risk 
category. The converse is true for subjects without the outcome of interest and so 
reclassification is outcome specific. The Net Reclassification Improvement (NRI) is 
defined as the sum of differences of proportions of subjects with the event moving 
into a higher risk category minus those moving into a lower risk category, and of 
those without the event who move into a lower risk category minus those who 
move into a higher risk category. NRI provides a clinically relevant measure to 
evaluate the relative performance of two models277. 
Use of the NRI in this way assumes the existence of clinically meaningful risk 
categories. In cardiovascular disease clinical guidelines incorporate established risk 
thresholds to guide treatment decisions278, but in many clinical situations, including 
in febrile illness in children, this is not the case. In this situation, the identification of 
risk categories must be justified. Alternatively, the ‘category-free’ (or continuous) 
NRI eliminates the need for risk categories and defines any increase in probability in 
the new model as upward reclassification. The category-free NRI equals twice the 
difference in the probabilities of upward classification in events, minus non-
events276. 
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Chapter 3: Bacteraemia in the Alder Hey 
Children’s Hospital NHS Foundation Trust 
Emergency Department 2001-2011 
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3.1 Overview of the chapter 
This chapter describes the analysis of all positive blood cultures isolated from 
children presenting via the Alder Hey Children’s Hospital Emergency Department 
between 2001 and 2011. 
3.2 Background 
3.2.1 Bacteraemia presenting to the children’s Emergency Department 
Bacteraemia is estimated to occur in approximately 1 in 250 febrile children under 
the age of 5 years presenting to the ED6. Although relatively uncommon, 
bacteraemia is associated with significant morbidity and mortality. Meningococcal 
disease (MCD) remains the most common infectious cause of childhood death 
outside the neonatal period13. Prior to the introduction of the Pneumococcal 
vaccine in the UK, an estimated 20% of childhood mortality was infection related, 
with ‘septicaemia’ the most commonly documented cause of death37. 
3.2.2 Aetiology of paediatric bacteraemia in the UK 
The aetiology of paediatric bacteraemia in the UK has evolved following the 
introduction of effective vaccines against the important childhood pathogens 
Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae. 
Rates of admission to hospital with septicaemia caused by these organisms have 
substantially declined12. Over the same period, the recorded incidence of childhood 
bacteraemia caused by Gram negative infections (such as Enterobacteraeciae) and 
of Gram positive infections such as Staphylococci and non-pyogenic Streptococci 
has increased40. 
A recent study of septicaemia and meningitis in hospitals in south London 
estimated that two thirds of ‘community-acquired’ septicaemia or meningitis in 
2009-2011 – that is, septicaemia and meningitis diagnosed within 48 hours of 
presentation to hospital –occurred in children with significant comorbidities. In 
children with no comorbidities, the estimated incidence of community-acquired 
septicaemia was 5.3 per 100 00039.  
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3.2.3 Categorising paediatric bacteraemia 
Historically, serious infections such as bacteraemia have been categorized by the 
timing of their identification into ‘community-acquired’ and ‘hospital-acquired’ 
infection. These categories were used to inform the likely aetiology, and guide 
empirical therapy. There is an increasing awareness of patients who, though they 
acquire serious infections in the community, share the characteristics of patients 
with ‘hospital-acquired’ infections. Such infections have been termed ‘healthcare-
associated’279. Adult studies have indicated that healthcare-associated Gram 
negative bacteraemia is associated with delays in the administration of appropriate 
antibiotic therapy when compared with community-acquired infections280. To date 
no validated definition of healthcare-associated bacteraemia is in use in children.281 
3.2.4 Timely antimicrobial therapy in paediatric bacteraemia 
Timely, effective antimicrobial therapy alongside supportive therapy is fundamental 
to the management of serious infections in children. The Surviving Sepsis campaign 
recommends the administration of antibiotics within one hour of recognition of 
severe sepsis41. Delays in the recognition of MCD14, in administering antibiotics, and 
suboptimal resuscitation of septic shock contribute to mortality in children15,16. 
3.2.5 Appropriate empirical antimicrobial therapy 
Presently it is not possible to confirm the presence of, still less the aetiology of 
bacteraemia in the ED. Empirical antimicrobial therapy then is initiated prior to 
confirmation of infection, and must be based upon the likely causative organism, 
and an understanding of local susceptibilities of these organisms. Unsurprisingly, in 
order to improve outcomes, empirical antimicrobial therapy needs to be effective. 
In a large multicentre study of adults with bacteraemia in Spain, inadequate 
empirical antimicrobial therapy – therapy to which the isolated organism was not 
susceptible in vitro - was associated with increased mortality282. Another large 
retrospective analysis of 5715 adults with septic shock demonstrated that 
inadequate empirical antibiotics resulted in a 5 fold increase in mortality283.  
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3.3 Hypothesis 
The evolving aetiology of paediatric bacteraemia may impact the ability of ED 
clinicians to recognise the diagnosis and to initiate timely, effective antimicrobial 
therapy.  
 
3.4 Aims and objectives 
This study set out to describe the aetiology of childhood bacteraemia presenting to 
the Alder Hey Children’s Hospital NHS Foundation Trust ED between 2001 and 
2011. Specifically, the study objectives were to: 
I. Report temporal trends in the aetiology of bacteraemia in the Alder Hey 
Emergency Department between 2001 and 2011 
II. Describe the clinical characteristics of children presenting to the Alder Hey 
Emergency Department with bacteraemia between 2001 and 2011 
III. Explore the impact of temporal trends in aetiology upon the timeliness and 
appropriateness of empirical antibiotic therapy 
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3.5 Methods 
3.5.1 Study design 
This was a retrospective times series analysis of all clinically significant episodes of 
culture-positive bacteraemia presenting to the Alder Hey Children’s Hospital ED.  
3.5.2 Data collection 
All positive blood culture isolates recorded in the laboratory database between 
2001 and 2011 inclusive were identified. Isolates were excluded if they were not 
associated with a presentation to the ED within the 48h prior to the sample being 
taken.  
Clinical data relating to each episode of bacteraemia was extracted from clinical 
notes, and from the Hospital Trust electronic database. Data was recorded on 
demographics and significant comorbidities, including the presence or absence of a 
central venous line (CVL) or other prosthetic material. Commonly used markers of 
infection (White cell count, Neutrophil count, Platelets and C-reactive protein) were 
extracted electronically. Antibiotic susceptibility data on all significant isolates was 
retrieved from the microbiology database. 
In order to examine trends and to compare our data with published evidence, we 
grouped episodes of Streptococcus pneumoniae, Neisseria meningitidis and 
Haemophilus influenzae as ‘vaccine-preventable’ infections, and similarly grouped 
‘Gram negative’ infections. For the remaining Gram positive infections we 
differentiated between typically pathogenic organisms in healthy children such as 
Staphylococcus aureus (‘typical Gram positive’), and those considered to be 
associated with the healthcare setting such as Coagulase-negative staphylococcus 
(‘other Gram positive’).  
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3.5.3 Definitions 
Community-acquired (CA) bacteraemia was defined as the identification of a 
significant pathogen in a blood culture taken within 48 hours of presentation to the 
ED, in the absence of admission to hospital in the previous month, and in the 
absence of any features of healthcare-associated bacteraemia. 
Healthcare-associated (HCA) bacteraemia was defined as the identification of a 
significant pathogen in a blood culture taken within 48 hours of presentation to the 
ED, in the following children: 
 those with an indwelling device (such as CVL, ventriculo-peritoneal shunt or 
other prosthetic material) 
 those with primary or acquired immunodeficiency 
 those requiring regular hospital based intervention (such as haemodialysis, 
or intravenous therapies) 
 pre-term infants less than 12 months from discharge from the neonatal unit 
Hospital-acquired bacteraemia was defined as the identification of a significant 
pathogen in blood culture in a child who had been admitted to hospital in the 
previous month. Children with hospital-acquired bacteraemia were excluded from 
the analysis. 
The identification of on organism classified as a common commensal according to 
the US Centers for Disease Control, were considered contaminants unless cultured 
on more than one occasion within 48 hours284. 
Empirical therapy was defined as therapy instituted prior to microbiological 
evidence of infection, limited to 24 hours from presentation to the ED. Therapy 
instituted beyond this period, or where there was documentation of 
microbiological advice was termed ‘directed’. 
Susceptibility to empirical therapy was defined as susceptibility to the empirical 
therapy initiated by the clinical team. Susceptibility was determined by breakpoints 
in use at the time of isolation, according to the British Society for Antimicrobial 
Chemotherapy (BSAC) methodology.285 
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A significant comorbidity was any diagnosis requiring the ongoing care of a hospital 
paediatrician. 
 
3.5.4 Statistical methods 
Statistical analysis was undertaken in R, version 3.0.1.263  
 
3.5.4.1 Summary statistics 
Continuous data were described by median and interquartile range, and 
comparison between groups performed using the Kruskal-Wallis test. Categorical 
variables were expressed as percentages with 95% confidence intervals (95% CI) 
and groups compared by means of a χ2 test of association. In order to compare 
uncommon events between groups (such as death), a Monte Carlo simulation was 
used to check the accuracy of the asymptotic χ2 approximation to the null sampling 
distribution. 
 
3.5.4.2 Time series analysis 
Poisson log-linear regression was used to model weekly counts of bacteraemia 
using the glm() function in R, with weekly ED attendance as an offset. To test for 
over-dispersion in the data, an additional dispersion parameter was included in the 
model. Time, and a sine-cosine variable representing seasonal variation with an 
annual period, were included as covariates. In each case, the time series of 
residuals was examined for evidence of auto-correlation using the acf() function in 
R (see Figure 4 and Figure 5). 
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Logistic regression, again implemented in the glm() function in R, was used to 
model the probability over time that each clinical episode occurred: 
1) in a child with significant comorbidities 
2) in a child with an indwelling CVL 
3) with an isolate that was susceptible to empirical antibiotic therapy. 
Scatter plots and generalised additive model (GAM) plots286 of explanatory 
variables, fitted using the gam() function in the mgcv R package, were examined for 
evidence of non-linearity on the log-odds scale. 
  
84 
 
 
Figure 4: Standardised residuals (‘res.std’, top) and fitted values (‘fv’, bottom) for the modelled vaccine 
preventable bacteraemia data 
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Figure 5: Autocorrelation (top) and partial autocorrelation (bottom) functions of the time series 
model describing vaccine-preventable bacteraemia. Dashed lines are point-wise 95% limits for 
uncorrelated residuals. 
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In the CVL model, inspection of the GAM plot suggested an initial increase in the 
likelihood of a clinical episode occurring in a child with an indwelling CVL, and 
subsequent reduction from 2008. In parallel, there was an initial reduction in the 
likelihood of an isolate being susceptible to empirical antibiotics, with an increase 
after 2008 (Figure 6). Late in 2007 the hospital increased investment in specialist 
intravenous nurses, with responsibility for training in the management of CVLs. We 
considered this a plausible explanation of the observed variation, and implemented 
a piecewise fit of time with the breakpoint specified to occur at the time of the 
clinical intervention. Inclusion of the piecewise variable improved the fit of the 
model to the data (p=0.02, likelihood ratio test). 
 
 
 
Figure 6: Generalised additive model (GAM) plots of the likelihood of a clinical episode occurring in a 
child with a CVL in situ (left), and of the isolated organism being susceptible to the empirical 
antibiotic protocol (right). The x axis is time (days from Jan 1
st
 2001). 
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3.5.4.3 Multivariable analysis of clinical outcomes 
Length of stay (LOS) and time to empirical antibiotics were investigated using 
multivariable linear regression. Both were log transformed in order to meet the 
assumption of linearity between outcome and explanatory variables. Plausible 
explanatory variables (including clinical and biomarker variables) were explored in 
univariable analyses. Scatter plots and GAM plots were inspected, and correlations 
between variables explored. In the time to antibiotics model a piecewise fit for 
platelets was undertaken following inspection of the GAM plot, and found to 
improve the fit of the model (p=0.006, likelihood ratio test). A model including all 
variables individually significant at the 10% level, i.e. variables with a p-<0.1, was 
then adopted as the maximal model, and model simplification was undertaken in a 
backwards stepwise process using the conventional 5% level of significance at each 
stage. 
3.5.5 Ethics approval 
The study retrospectively evaluated anonymised data on clinical episodes. Approval 
for the use of this data was granted by the Research Department of the Alder Hey 
Children’s NHS Foundation Trust. 
 
3.6 Results  
Between 2001 and 2011 692 clinically significant blood cultures were identified in 
children sampled within 48 hours of presentation to the ED. These cultures 
represented 575 clinical episodes in 525 children. Twenty four children died (4.6%). 
3.6.1 Clinical characteristics of children 
The majority of clinical episodes occurred in boys (59%, 95% CI 55-63%). Median 
age at time of presentation was 1.52 years (IQR 0.42-4.27). Figure 7 illustrates the 
age distribution of children presenting with bacteraemia. 
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Figure 7: Age distribution of children presenting to ED with bacteraemia. 
 
The characteristics of the 525 children presenting with bacteraemia are 
summarized in Table 12. Significant comorbidities were present in 151 children 
(29%). The most common comorbidities were gastrointestinal and the majority of 
these (23/25) had indwelling CVLs for the purpose of parenteral nutrition (Table 
13). 
Children with Gram negative isolates were younger, and more likely to have 
significant comorbidities or an indwelling CVL than those with vaccine-preventable 
or typical Gram positive isolates. Mortality in children with ‘other Gram positive’ 
infections was higher (6/37) than in other groups (OR 5.15, 95% CI 1.60-15.8 versus 
vaccine-preventable isolates).  
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Median IQR 
Vaccine-
preventable 
(n=221) 
Typical Gram 
positive 
(n=149) 
Gram 
negative 
(n=118) 
Other Gram 
positive 
(n=37) 
p 
Age/years 1.52 0.42-4.27 
1.80 
(0.83-3.88) 
1.58 
(0.13-6.82) 
0.82 
(0.20-3.08) 
1.64 
(0.69-11.45) 
<0.001* 
LOS/days 6 3-10 6 (4-9) 7 (3-13) 6 (4-10) 7 (2-11) 0.5* 
 
% 95% CI n (%) n (%) n (%) n (%) 
 
CM 28.8 25.1-32.8 36 (16.3) 42 (28.2) 51 (43.2) 22 (59.5) <0.001† 
CVL 9.0 6.80-11.7 3 (1.40) 6 (4.02) 26 (22.0) 12 (32.4) 0.001^ 
PICU 18.9 15.8-22.5 56 (25.3) 23 (15.4) 13 (11.0) 7 (18.9) 0.007† 
Mortality 4.57 3.09-6.71 8 (3.62) 6 (4.02) 4 (3.39) 6 (16.2) 0.005^ 
Table 12: Clinical characteristics of 525 children presenting to the ED with bacteraemia according to type of organism. LOS: Length of hospital stay, CM: Significant 
comorbidity, CVL: Central venous line in situ, PICU: Admission to paediatric intensive care unit. *Kruskal-Wallis †Chi squared.^ Monte Carlo simulation 
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Comorbidity Freq ICD-10 codes 
Gastrointestinal 25 
K36, K51, K90 
Q39, Q42, Q43, D57, Q79 
Neurodevelopment 24 
G40, G71, Q75 G80 
Q02, Q85 
Respiratory 15 
E84 
J45 
Renal 13 
N04, N13, N18 
Q63 
Birth/Prematurity 13 PO7, P27 
Congenital 11 Q87 Q90 
Cardiovascular 11 
I34, I45 
Q20, Q21, Q25 
Haematology/Oncology 10 
C40,C56, C85, C91, C96 
D43, D66 
Skin/Musculoskeletal 10 
L20 
T84 
Q67, Q78 
Endocrine/Metabolic 7 E10, E71, E72, E76 
Immunodeficiency 6 
B20 
D82, D83, D84 
Rheum 4 
M05, M30 
Q82 
ENT 2 
D18 
H66 
Total 151 
 
Table 13: Comorbidities by system, with ICD-10 codes 
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Children with HCA bacteraemia were older than those with CA bacteraemia. LOS in 
HCA bacteraemia was prolonged by 3.9 days versus CA bacteraemia (95% CI 2.3-5.8 
days). Mortality and admission to PICU did not differ between these groups (Table 
14). 
 
 
 
CA (n=444) HCA (n=81) p 
Median age/years (IQR) 1.43 (0.35-3.88) 2.32 (0.96-6.48) 0.001* 
Median LOS/days (IQR) 6 (3-9) 9 (4-18) <0.001* 
PICU/% (95% CI) 19.0 (15.6-22.9) 18.5 (11.6-28.3) 0.15† 
Mortality/% (95% CI) 4.1 (2.6-6.3) 7.4 (3.4-15.2) 0.25^ 
Group 
 Vaccine-preventable 
 Typical Gram positive 
 Gram negative 
 Other Gram positive 
207 
133 
82 
22 
14 
16 
36 
15 
<0.001† 
Median time to antibiotics 
/minutes (IQR) 
181 (59-321) 218 (91-353) 0.15* 
Table 14: Clinical characteristics of Community-acquired (CA, see definitions) and Healthcare-
associated bacteraemia (HCA). *Kruskal-Wallis †Chi Squared ^Monte Carlo simulation 
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3.6.2 Aetiology of bacteraemia in the children’s ED 
Isolated organisms varied with age (Figure 8). In early infancy, the most common 
organisms were Escherichia coli and Group B Streptococcus. There were 47 
presentations of neonatal sepsis, including one of early onset disease (Group B 
Streptococcus). S.pneumoniae was the most commonly isolated organism overall. 
S.pneumoniae and N.meningitidis occurred commonly between the ages of 1 and 5 
years, whilst S.aureus was the most common organism in children older than 5 
years. Most (87/96) meningococcal isolates were Group B, the remainder were 
Groups C (5), W135 (3) and Y (1). Two episodes of Methicillin-resistant S.aureus 
bacteraemia occurred over the 11 year period, one associated with ventriculitis in a 
child with a ventriculo-peritoneal shunt, and one in a previously well child. There 
were 17 polymicrobial infections in 13 children. Twelve had significant 
comorbidities and eight had CVLs in situ. Isolated organisms are summarized in 
Table 15. 
 
Figure 8: Isolated organisms by age group. 
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‘Vaccine-preventable’ n=223 % 
S.pneumoniae  109 19.0 
N.meningitidis  96 16.7 
H.influenzae (type B)  18 3.1 
‘Typical Gram positive’ n=149 
 
S.aureus  89 15.4 
Group B Streptococcus  32 5.6 
Group A Streptococcus  28 5.9 
‘Gram negative’  n=152 
 
Escherichia coli  59 10.3 
Klebsiella sp.  26 4.5 
Acinetobacter sp. 11 1.9 
Enterobacter sp. 10 1.7 
Pseudomonas sp 10 1.7 
Salmonella sp. 9 1.6 
Moraxella catarrhalis 9 1.6 
Other 18 3.2 
‘Other Gram positive’  n=51 
 
Coagulase-negative Staphylococcus 21 3.5 
Enterococcus sp.  19 3.3 
Non pyogenic Streptococcus 6 1.0 
Other 5 0.9 
Table 15: Predominant organisms by group 
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3.6.3 Time series analysis 
The rate of clinically significant bacteraemia presenting to the children’s ED was 
1.42 per 1000 attendances (95%CI 1.31 to 1.53). The cumulative frequency plot 
reveals a declining rate of vaccine-preventable infections including S.pneumoniae, 
and an increasing rate of Gram negative infections (Figure 9). 
 
 
Figure 9: Cumulative frequency plot of bacteraemia presenting to the ED. 
 
Poisson log-linear regression was used to model the observed rate of bacteraemia 
(Figure 10). For the overall rate of bacteraemia neither the trend over time (p=0.18) 
nor the seasonal effect (p=0.17) were statistically significant. Bacteraemia caused 
by vaccine-preventable isolates including S.pneumoniae was highly seasonal 
(p<0.001). From 2001 to 2011 the rate of vaccine-preventable bacteraemia declined 
from 1.32 to 0.37 per 1000 ED attendances at an annual rate of reduction of 10.6% 
(95%CI 6.6 to 14.5%). The pneumococcal conjugate vaccine (PCV) was introduced 
into the UK immunisation schedule in September 2006. When incorporated in the 
regression model, PCV was associated with a 49% reduction in pneumococcal 
bacteraemia (95%CI 32 to 74%) from 0.50 to 0.25 per 1000 attendances. By 
contrast, the rate of Gram negative bacteraemia increased from 0.24 to 0.53 per 
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1000 ED attendances (p=0.007). The fitted seasonal effect in the Gram negative 
model, although not statistically significant (p=0.07), showed a peak in summer, in 
contrast to that of the vaccine-preventable model, which peaked in winter. 
 
 
Figure 10: Fitted rate of paediatric bacteraemia per 1000 attendances to the Alder Hey Children’s 
Hospital ED 2001-2011. The discontinuity in the fit for Streptococcus pneumoniae is due to the 
introduction of the PCV in September 2006. 
 
The number of blood cultures requested from the ED was examined as an 
alternative denominator to that of ED attendance. Only annual data were available. 
The observed decline in the rate of vaccine-preventable bacteraemia (per 1000 ED 
attendances) occurred despite an increase in the use of blood culture. The number 
of blood cultures requested per 1000 ED attendances increased annually by an 
estimated 7.3 (95% CI 6.0 to 8.6) per 1000 attendances between 2001 and 2011 
(Table 16). Following the observation that the number of blood cultures increased 
over time in parallel with that of Gram negative bacteraemia, we demonstrated an 
increased rate of Gram negative identifications per 1000 cultures performed 
(annual increase of 0.17 per 1000 cultures performed, 95% CI 0.02 to 0.32). 
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16Year 
Blood 
cultures 
Annual 
attendance 
Blood 
cultures / 
1000 
attendances 
Number of 
Gram negative 
isolates 
Rate of Gram 
negatives /1000 
blood cultures 
2001 4864 37051 131.3 11 2.26 
2002 4577 35224 129.9 5 1.09 
2003 4824 37178 129.8 13 2.69 
2004 5517 38092 144.8 11 1.99 
2005 5832 38330 152.2 16 2.74 
2006 5910 37957 155.7 24 4.06 
2007 6626 36944 179.4 25 3.77 
2008 6621 37227 177.9 22 3.32 
2009 6904 37426 184.5 29 4.20 
2010 6846 35969 190.3 22 3.21 
2011 6757 35159 192.2 18 2.66 
Table 16: Annual rate of blood culture investigations by ED attendance, and rate of isolation of Gram negative 
bacteraemia 
 
The rate of CA bacteraemia reduced from 1.18 to 0.71 per 1000 ED attendances 
between 2001 and 2011 (p=0.005), while the rate of HCA bacteraemia increased 
from 0.18 to 0.50 per 1000 (p=0.002). The proportion of clinical episodes occurring 
in children with an indwelling CVL increased from 3.2% in 2001 (95% CI 1.47 to 
6.84%) to a peak of 26.5% before declining to 21.8% in 2011 (95% CI 12.9 to 34.3%). 
In parallel, the likelihood that an isolate was susceptible to empirical therapy 
reduced from 96.3% (95% CI 92.1-98.2%) to 82.6% (95% CI 69.8-90.7) between 2001 
and 2011, reaching a nadir of 74.4% in 2008. These trends are illustrated in Figure 
11. Neither LOS, likelihood of PICU admission nor mortality changed over time.  
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Figure 11: Fitted likelihood over time that an isolate was susceptible to empirical therapy (top), and 
that an episode occurred in a child with an indwelling CVL (bottom). Time was fit as a piecewise term 
to incorporate a clinical intervention. Inclusion of the piecewise term improved the fit of the model. 
Dotted red lines are 95% confidence intervals. 
 
 
3.6.4 Routine biomarkers in children with bacteraemia 
Data on routinely measured blood tests (White cell count, Neutrophil count, 
Platelet count, and C-reactive protein) were extracted from the Trust database. The 
range of values in children presenting to the ED with bacteraemia is summarised in 
Table 17. This study was not designed to evaluate diagnostic accuracy, but it is 
notable that only half (51%, 280/546) of White cell count (WCC) measurements 
were outside the range 5-15 x 109 cells/litre considered normal by the NICE 
“Feverish Illness in Children” guideline. Similarly, 41% (227/549) CRP measurements 
<40mg/dl (a commonly used threshold in diagnostic accuracy studies, see Table 5) 
were observed in children with bacteraemia. In isolation, CRP and WCC are 
insufficiently sensitive for the diagnosis of bacteraemia in the ED.  
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Biomarker Minimum Median IQR Maximum n 
CRP 0 57.2 13.8-135.6 690.5 549 
WCC 0.07 11.66 7.49-19.32 63.95 546 
Neutrophils 0.02 7.81 4.29-14.14 49.88 546 
Platelets 1 267 189-377 847 546 
Table 17: Summary of routinely measured biomarkers in the ED. IQR: interquartile range 
 
Biomarker distribution varied according to the type of organism cultured. 
Compared to vaccine-preventable bacteraemia, lower values of CRP, WCC and 
Neutrophil count were observed in typical Gram positive, Gram negative, and other 
Gram positive infections. Gram negative bacteraemia was associated with a lower 
Platelet count when compared with vaccine-preventable bacteraemia (Figure 12). 
 
 
Figure 12: Distribution of biomarkers according to type of isolate. VP: Vaccine-preventable, Typ.GP: 
Typical Gram positive. GN: Gram negative. Oth.GP: Other Gram positive. Significance tests are 
comparisons with the Vaccine-preventable group of isolates. *p<0.001 
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3.6.5 Timeliness and appropriateness of empirical antibiotics 
The empirical antibiotic protocol was documented in 563/575 clinical episodes 
(Table 18). One child died prior to receiving antibiotics, and a further eighteen 
children received no antibiotics. For children with no indwelling CVL, 375/480 
received monotherapy, commonly Cefotaxime (289/375). In combinations, 
Cefotaxime was also invariably used, alongside Gentamicin, Benzylpenicillin or 
Amoxicillin. In children with an indwelling CVL, combination therapy was commonly 
used (46/83), particularly with Teicoplanin and Gentamicin. 
 
No CVL in situ CVL in situ 
Monotherapy Monotherapy 
3rd gen Cephalosporin 295 Cefotaxime  22 
1st/2nd gen Cephalosporin 58 Teicoplanin 6 
Other 22 Other 8 
375 (78%) 36 (43%) 
Combination therapy Combination therapy 
Cefotaxime and Benzylpenicillin 24 Teicoplanin and Gentamicin 27 
Cefotaxime and Gentamicin 20 Teicoplanin and Cefotaxime 5 
Cefotaxime and Metronidazole 11 Other combination 14 
Other combination 32 
 
87(18%) 46 (57%) 
None 18 None 1 
Total 480 83 
Table 18: Empirical antibiotics administered in children with and without CVLs. 
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It was possible to determine empirical susceptibility in 527 of 575 cases. Vaccine-
preventable isolates were almost universally susceptible to empirical therapy 
(217/219), whilst 22% (29/131) of Gram negative isolates were resistant (p<0.001). 
Data on time to antibiotics was available for 78% (444/575) of all episodes. Median 
time to antibiotics was approximately 3 hours, and varied according to the type of 
organism (Table 19). Vaccine-preventable infections received empirical antibiotics 
earlier than other types of infection. 
 
Median 
/minutes 
IQR p 
All 184 62.5-330.5  
Vaccine-
preventable 
130 34.5-297 
<0.001 
Typical Gram 
positive 
256 118-376 
Gram negative 184 95.5-356 
Other gram positive 253.5 147-401 
Table 19: Time to antibiotics (minutes) according to type of organism 
In order to explore this relationship, a multivariable model of time to antibiotics 
was developed (Table 20). Following adjustment for other explanatory variables, 
time to antibiotics was increased by 57 minutes for Gram negative infections 
compared to vaccine-preventable infections. Older children received antibiotics 
later than younger children. Overall, time to antibiotics increased by approximately 
3 minutes per year of the study (p=0.006 for linear trend).  
 
Both Platelet count and CRP were associated with time to antibiotics. In the case of 
Platelets, below a value of approximately 250 (as determined by the breakpoint 
which minimised the residual deviance of the multivariable model), time to 
antibiotics reduced linearly with the platelet count. Paradoxically, time to 
antibiotics increased with CRP count. An increase of 100mg/ml was associated with 
an increased time to antibiotics of 10 minutes.  
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Variable Estimate LCI UCI p-value 
Intercept 3.90 3.20 4.60 <0.001 
Group 
 Vaccine-preventable 
 Typical Gram positive 
 Gram negatives 
 Other Gram positive 
 
REF 
0.75 
0.77 
1.06 
 
 
0.42 
0.44 
0.47 
 
 
1.07 
1.10 
1.66 
 
 
<0.001 
<0.001 
<0.001 
Age 0.047 0.016 0.078 0.003 
Year 0.058 0.017 0.100 0.006 
Platelets (left slope) 0.005 0.002 0.008 0.003 
Platelets (right slope) 0.0002 -0.001 0.002 0.78 
CRP 0.002 0.0008 0.003 0.001 
Table 20: Multivariable model of log (time to antibiotics). LCI: Lower confidence interval. UCI: Upper 
confidence interval. 
3.6.6 Time to antibiotics and ED activity 
Time to antibiotics is one indicator which is used to evaluate ED ‘busyness’. Though 
no real-time measures of ED activity were available in this retrospective analysis, 
we examined whether time to antibiotics were associated with the surrogate 
measures time of day, day of week, month of the year and daily number of ED 
attendances. When included as categorical variables in regression analysis, there 
were no significant associations between time to antibiotics and time of day, day of 
the week or month of the year. These relationships are illustrated in Figure 13. 
Similarly there was no association of time to antibiotics with daily number of ED 
attendances. 
 
   Estimate Std. Error t value  Pr(>|t|) 
(Intercept)  4.8914412 0.3401537 14.38  <2e-16*** 
ED attendance -0.0003521 0.0031947 -0.11  0.912 
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Figure 13: Boxplots of log (Time to antibiotics) against time of day, day of week and month of the 
year.  
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3.7 Discussion 
This study details the changing aetiology of bacteraemia in the busiest children’s ED 
in the UK. It demonstrates a reduction in the rate of vaccine-preventable 
bacteraemia, coincident with an increase in Gram negative bacteraemia. The 
overall rate of bacteraemia is lower than that described in a large study of febrile 
children presenting to the ED in Australia6. This can be explained by the use of a 
different denominator in this study. As significant bacteraemia presented to the ED 
in association with a variety of clinical presentations (including bone and joint 
infections, and abdominal sepsis), the denominator used was all non-trauma 
presentations. The introduction of the PCV7 in 2006 was associated with a halving 
of the rate of pneumococcal bacteraemia. These trends are consistent with data 
from surveillance studies of invasive bacterial infections internationally.12,39,40,287,288 
A seasonal variation was observed in Gram negative bacteraemia with peak in the 
summer. While not statistically significant this is consistent with other published 
data.289,290 
During the course of the study, there was no significant increase in the number of 
children attending the ED, and ED attendance was used as an offset in the 
regression modelling to provide rates of bacteraemia per 1000 attendances. There 
was however a significant increase in the number of blood culture investigations 
performed in children attending the ED. This increase rules out the possibility that 
the observed reduction in vaccine-preventable bacteraemia was a consequence of a 
reduced reliance on blood culture for the diagnosis of bacteraemia. This may have 
occurred, for example, alongside the increased use of specific, highly sensitive PCR 
assays. On the contrary, clinicians appeared more inclined to consider bacteraemia, 
and request blood cultures as time progressed.  
Increased rates of blood culture use thus occurred in parallel with the increase in 
Gram negative bacteraemia identifications. There was a small increase over time in 
the rate of Gram negative identifications per 1000 cultures performed. The 
inference that an increased rate of blood culturing may have contributed 
significantly to the observed increase in the rate of identification of Gram negative 
organisms – that is, that the increase is not real, but rather reflects increased yield 
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from a more sensitive sampling approach – seems clinically implausible. Gram 
negative bacteraemia is a severe infection in children for which prolonged 
intravenous antibiotics would almost always be considered necessary. The 
likelihood that despite clinicians undertaking many thousands of negative tests 
even early in the study period (at which time approximately 1 in 7 of all non-trauma 
related attendances had a blood culture performed), a significant number of Gram 
negative isolates were missed appears remote. While we cannot say with certainty 
that the increased use of blood culture did not contribute to the increase in Gram 
negative bacteraemia identifications, our data demonstrating an increased rate of 
Gram negative bacteraemia presenting to the ED are consistent with national 
laboratory data demonstrating the same40. 
The results illustrate the changing characteristics of children presenting to the ED 
with bacteraemia. Increasingly these are children with underlying comorbidities, 
and indwelling CVLs. HCA bacteraemia is of increasing importance. The proportion 
of episodes involving children with CVLs increased to a peak in 2008 before 
declining towards the end of the study. This occurred in parallel with an initial 
reduction in antibiotic susceptibility which also improved after 2008. This is likely to 
reflect an increased number of children with CVLs receiving total parenteral 
nutrition (TPN) in the community. Unpublished data from Alder Hey identified a 
threefold increase in CVL-associated infection rates with the use of TPN (from 3.3 to 
10.4 per 1000 line days, personal communication from Sara Melville, specialist 
vascular access nurse). At the end of 2007, the hospital increased investment in 
specialist intravenous nurses, with responsibility for training in the management of 
CVLs. This intervention may explain the later reduction in CVL-associated infections 
presenting to the ED.  
The changing aetiology of childhood bacteraemia in the ED was not associated with 
temporal changes in mortality or PICU admission. HCA bacteraemia was associated 
with an increased LOS, irrespective of the responsible organism. Other investigators 
have related increased LOS in adults to HCA bacteraemia291 but this has not been 
described in children before. To date, this category of infection remains poorly 
defined in children. 
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Despite acceptance that time to antibiotics influences outcome in sepsis,292 few 
studies have reported time to antibiotics in the paediatric ED.293,294 The results of 
this study suggest that the changing nature of bacteraemia in the paediatric ED has 
implications for both recognition and management. A median time to antibiotics of 
3 hours is comparable with other published data.42 
Empirical therapy took longer to initiate in children with Gram negative infections 
than in children with vaccine-preventable infections, even with adjustment for 
other explanatory variables. Platelet count and CRP were found to be associated 
with time to antibiotics. It is unlikely that the tests were being used to guide 
treatment, rather that the tests were indicative of a more general clinical condition 
which prompted therapy. The association of a low platelet count with a shortened 
time to antibiotics is intuitive, as thrombocytopenia is a recognised feature of 
severe sepsis. The association between CRP and increasing time to antibiotics is a 
little more difficult to explain however. It is well recognised that CRP is insensitive 
in the early stages of severe infections191, and so a plausible explanation is that 
those most fulminant presentations which prompted early antibiotic administration 
were associated with low CRP. 
Multivariable modelling allowed the estimation of an increase in time to antibiotics 
of 38 minutes over the 11 years of the study, irrespective of changes in aetiology. 
These changes are likely multifactorial, but the implication is that additional 
resources in diagnostics and training are required in order to minimize delays in the 
treatment of these most invasive infections.  
Over 11 years, susceptibility to empirical antibiotic protocols declined. Adults with 
Gram negative HCA bacteraemia experience delays in appropriate antibiotic 
therapy,280 and mortality is increased when initial empirical therapy is 
inadequate.282 Death in children is uncommon even in serious infection, and we 
failed to draw an association between death or likelihood of PICU admission, and 
inappropriate empirical antibiotics. 
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3.7.1 Limitations 
This was a retrospective, single centre study of culture positive bacteraemia in the 
paediatric ED. Blood culture yield is affected by the use of prior antibiotics, more so 
than PCR.295 Collecting data on prior antibiotics was impractical in this retrospective 
analysis. Community antibiotic prescribing for children in the UK decreased 
substantially in the 1990s,296,297 though there is data to suggest an increase through 
the course of this study.298 This would not account for the reduction in 
pneumococcal bacteraemia, for which there was no temporal trend prior to the 
introduction of the PCV. An increase in pre-hospital antibiotics may have impacted 
blood culture yield over time however, particularly if well targeted towards children 
with bacteraemia.  
The analysis failed to account for changes to the population of the hospital 
catchment area which may have impacted the observed rate of bacteraemia. 
Instead, ED attendance was incorporated. Over time, there was no change in 
medical attendances to the ED. 
There is as yet no established definition of ‘healthcare-associated bacteraemia’ in 
children. The study used a pragmatic definition, based upon the published 
literature281. A number of surrogate markers of frequent exposure to healthcare 
environments were identified, but it was not possible to collect robust data 
quantifying how frequently or how recently this exposure may have occurred in 
individual clinical episodes. Understanding this exposure better, thereby 
establishing a valid definition of healthcare-associated bacteraemia would help to 
guide empirical treatment in the ED. The definition was applied consistently across 
the 11 years of the dataset, and so, as defined, the analysis of temporal trends is 
robust.  
Data on time to antibiotics was missing in approximately 20% of clinical cases, and 
the study only considered time to empirical therapy, though others have reported 
time to ‘appropriate’ therapy.280 Explanatory variables that may reflect the severity 
of the clinical presentation (including biomarkers) and that may influence time to 
antibiotics (such as age) were retrieved from the clinical notes in order to better 
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understand the variation observed. Other studies have used validated measures of 
disease severity (such as the Glasgow Meningococcal Septicaemia Prognostic Score) 
and demonstrated an association with time to antibiotics.293 A comparable measure 
of illness severity may help to explain the variation seen, though no such tool is 
currently in use in all acutely unwell children in the ED.  
It has been assumed that the variation in time to antibiotics observed was related 
to clinical recognition. Time to antibiotics is also used as a measure of crowding in 
EDs. Some investigators have identified an association between markers of ED 
crowding and time to antibiotics in young infants,299 though not consistently.300 
Data on ED crowding was not available. There was no overall increase in numbers 
presenting to the Alder Hey Children’s Hospital ED over the course of the study 
however, nor was there an association between time of day, day of the week, or 
time of year – all of which are associated with the volume of ED activity - and time 
to antibiotics.  
 
3.8 Conclusions 
The aetiology of bacteraemia presenting to the Alder Hey children’s ED evolved 
between 2001 and 2011. Increasingly bacteraemia in the children’s ED is 
healthcare-associated. Bacteraemia in the children’s ED is now more likely to be 
resistant to empirical therapy, appears more difficult to recognise and, in the case 
of HCA bacteraemia is associated with a prolonged length of stay. Prompt and 
effective antimicrobial treatment of bacteraemia requires improved diagnostic 
tools alongside continued aetiological surveillance. 
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Chapter 4: 16S ribosomal RNA PCR 
(SepsiTest) with sequencing in the evaluation 
of febrile children presenting to the 
Emergency Department 
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4.1 Overview of the chapter 
The previous chapter illustrated the changing aetiology of bacteraemia presenting 
to the children’s ED, highlighting the need for prompt pathogen identification to 
ensure appropriate antimicrobial therapy. In this chapter, I evaluate the use of a 
broad-range molecular test (SepsiTest) for the diagnosis of bacteraemia in children 
presenting to the ED.  
4.2 Background 
4.2.1 Blood culture in children 
In clinical practice, the diagnosis of bacteraemia in children is largely dependent 
upon blood culture. The identification of a causative organism and the ability to 
evaluate antimicrobial susceptibility ensures that culture methods remain, so far, 
irreplaceable. The sensitivity of blood culture in children is limited, however, by the 
volume of blood which is commonly obtained59,301, and by the use of prior 
antibiotics75. Furthermore, the value of culture is limited by the time taken to 
achieve a result. Whilst detection time has decreased with automation, median 
time to positivity in adults with Streptococcus pneumoniae is still estimated to be 
14h302. Following the initial positive identification, a process of phenotypic testing 
designed to characterise the isolate is undertaken71. This process commonly takes 
days. 
The process of phenotypic identification is being supplemented by alternative 
methods. Matrix assisted laser desorption ionisation-time of flight (MALDI-TOF) is a 
technique which allows the mass spectrum of organic molecules including bacterial 
colonies to be analysed, and compared with known profiles. This is a process that 
can be completed in minutes. Platforms such as MALDI-TOF have established a 
clinical role in hastening pathogen identification. Shortening the time to 
identification allows prompt antimicrobial targeting, and has been found to be 
effective in expediting appropriate antibiotics in the context of an antimicrobial 
stewardship programme303. Such an approach does not address such limitations as 
the poor sensitivity of blood culture. 
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4.2.2 Nucleic acid based detection methods 
Molecular tests based upon the detection of bacterial genes have the potential to 
address these limitations of culture methods. The most relevant of the nucleic acid 
based detection methods is the polymerase chain reaction (PCR). The PCR method 
amplifies target DNA which is complementary to short DNA primers. These primers 
are selected to allow the specific amplification of target DNA, such as the DNA 
sequence specific to an individual pathogen. The method consists of cycles of 
repeated heating and cooling causing separation of double-stranded DNA into 
single strands (denaturation) which then become templates for the amplification 
process. During the cooling step, target DNA present binds the complementary 
primers (annealing) and with the addition of a DNA polymerase, the primers are 
extended along the target sequence. This process is then repeated with the 
resultant DNA now serving as the template, and the quantity of DNA increasing 
exponentially. In this way, even small quantities of DNA can be amplified within a 
period of a few hours304. 
4.2.2.1 Pathogen-specific molecular diagnosis 
One of the most common applications of the PCR method is in the molecular 
diagnosis of specific pathogens. Pathogen-specific PCR assays have improved the 
sensitivity of blood culture for the diagnosis of bacteraemia caused by Neisseria 
meningitidis76 and Streptococcus pneumoniae259, but are limited by the narrow 
range of pathogens identified. Following the introduction of effective conjugate 
vaccines to these important pathogens, their relative contribution to the burden of 
paediatric bacteraemia has declined305. Assays for other important pathogens have 
been developed, including those capable also of detecting genes encoding 
antimicrobial resistance such as the mecA gene of Staphylococcus species306. 
However, the number of potential organisms causing bacteraemia (and other 
invasive infections) has necessitated a shift towards the simultaneous detection of 
a range of pathogens. 
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4.2.2.2 Broad-range molecular tests in the diagnosis of bacteraemia 
A number of broad-range molecular tests for the diagnosis of bacteraemia have 
been developed and evaluated77 (see Section 1.6.1.2). Such tests employ a variety 
of approaches. They may be undertaken on positive blood cultures or be culture 
independent, and use either a multiplex approach, or a ‘universal’ approach 
targeting conserved sequences within the bacterial genome. Following bacterial 
DNA isolation, commonly involving PCR amplification, identification is undertaken 
using methods such as hybridisation, microarray detection, electrospray ionisation 
mass spectrometry (ESI MS) or sequencing. Commercially available broad-range 
assays for the diagnosis of bacteraemia are summarised in Table 21. 
Culture independent methods capable of accurately identifying the range of 
potential bloodstream infections have the potential to both speed accurate 
pathogen identification, and to improve diagnostic accuracy. Importantly, effective 
techniques for the extraction of pathogen DNA are essential for this approach to 
succeed. Bacterial DNA is present in blood in much smaller quantities than host 
DNA, and whole blood is inhibitory to the PCR reaction307. In children from whom 
only small samples are commonly obtained, these challenges are particularly acute. 
Various pre-analysis treatment tools have been developed to improve the isolation 
and selective amplification of pathogen DNA from whole blood81,308. 
 
SeptiFast (Roche) performs multiplex real-time PCR, is capable of identifying 25 
pathogens as well as the mecA gene which encodes Methicillin resistance in 
Staphylococci, and has been found to be highly sensitive and specific in vitro. The 
assay is completed in 6 hours79. One large study of hospitalised children reported 
encouraging performance characteristics (sensitivity and specificity 85% and 93.5% 
respectively) for a composite outcome of bacteraemia defined by SeptiFast, blood 
culture, and clinical impression309. A recent meta-analysis was less encouraging 
however, and highlighted particularly the limited evidence from children80.   
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PLEX-ID (Abbott) is a technique which combines a multiplex PCR step with broad 
primers for groups of pathogens, and for resistance genes, followed by amplicon 
detection with ESI MS. Initially evaluated in positive blood cultures, the technique 
was found to be highly concordant with culture results, and to be substantially 
quicker310. PCR/ESI MS was found to be similarly concordant with MALDI-TOF 
MS311. Practical considerations, including cost, have supported the adoption of the 
MALDI-TOF platform into clinical practice. Promising recent evaluations of ESI MS in 
whole blood make this an attractive technology, however312,313. The assay proved 
to be a valuable adjunct to blood culture, though adequate sensitivity was only 
achieved using 5ml samples of blood. For use in children, this is an important 
limitation. 
4.2.2.3 SepsiTest 16S rRNA PCR with sequencing 
SepsiTest (Molzym, Bremen, Germany) is a semi-automated, culture independent 
diagnostic test based upon PCR amplification of variable regions of the 16S rRNA 
gene followed by sequence analysis. It has been demonstrated to be a sensitive 
method for detecting and identifying a broad range of aetiologies of sepsis and 
infectious endocarditis in adults83,84. To date it remains the only commercially 
approved universal molecular diagnostic for use in whole blood. A pre-analytical 
stage is used to improve the sensitivity of the SepsiTest assay82,308. This ‘MolYsis’ 
protocol entails the selective lysis of host cells, followed by the degradation of host 
DNA by DNAse. Bacterial cells are then lysed and the isolated DNA extracted.  
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Assay 
(Manufacturer) 
Culture  Technique Pathogen 
identification  
Range Reference 
FilmArray BCID 
(BioFire) 
Dependent Multiplex 
PCR 
qPCR by melt 
curve analysis 
19 bacteria, 5 
yeasts, mecA, 
vanA/B, KPC  
Zheng, 2014
314
 
MALDI-TOF MS 
(Bruker, 
Biomérieux) 
Dependent MALDI-TOF MS Universal La Scola, 
2011
315
 
Plex-ID  
(Abbott) 
Dependent Multiplex 
PCR/ ESI  
MS Universal Kaleta, 2011
310
 
Prove-it Sepsis 
(Mobidiag) 
Dependent Multiplex 
PCR 
Hybridisation 
on microarray 
50 organisms, 
mecA 
Tissari, 2010
316
 
Verigene 
GP/GN 
(Nanosphere) 
Dependent Multiplex 
PCR 
Hybridisation 
on microarray 
29 bacteria, 8 
yeasts, mecA, 
van A/B 
Sullivan, 
2013
317
 
Magicplex 
(Seegene) 
Independent Multiplex 
PCR 
qPCR 85 bacteria, 6 
fungi, mecA, 
vanA/B 
Carrara, 
2013
318
 
Plex-ID  
(Abbott) 
Independent Multiplex 
PCR/ ESI 
MS Universal Laffler, 2013
312
 
SepsiTest 
(Molzym) 
Independent Broad-range 
(16S rRNA) 
PCR 
Sequencing Universal Wellinghausen, 
2009
83
 
SeptiFast 
(Roche) 
Independent Multiplex 
PCR 
qPCR by melt 
curve analysis 
25 organisms, 
mecA 
Dark, 2015
80
 
Table 21: Commercially available broad-range molecular detection assays for the diagnosis of 
bacteraemia, including detection of resistance genes mecA, van A/B, KPC 
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4.3 Hypothesis 
SepsiTest is a sensitive and specific tool for the diagnosis of bacteraemia in febrile 
children with clinical evidence of sepsis presenting to the Emergency Department. 
 
4.4 Aims and Objectives 
The study set out to evaluate the use of SepsiTest in febrile children in the Alder 
Hey Children’s Hospital NHS Foundation Trust ED. Specifically, the study objectives 
were to: 
I. Describe the performance characteristics of SepsiTest for the diagnosis of 
bacteraemia in a selected ‘high-risk’ group of children recruited to the SPICED 
study 
II. Evaluate the use of the biomarkers Procalcitonin, NGAL and Resistin in the 
prediction of bacteraemia in this group 
III. Compare the performance characteristics of SepsiTest in groups of children 
according to the pre-test likelihood of bacteraemia defined by a combined 
biomarker risk model 
 
4.5 Methods 
4.5.1 Study design 
The evaluation of SepsiTest was undertaken as part of the SPICED study, a 
prospective diagnostic accuracy study of febrile children attending the Alder Hey 
Children’s Hospital Emergency Department (see Methods, 2.2). 
4.5.2 Participants 
As the risk of bacteraemia in febrile children in the ED is low6, a sample of children 
considered to have an increased pre-test probability of bacteraemia was selected 
for evaluation. This was estimated based upon known clinical indicators of SBI 
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(temperature, heart rate, respiratory rate, CRP)10,185 as well as length of hospital 
stay. Outcome diagnoses at the time of sample selection had not been determined. 
Together these children constituted a ‘high-risk’ group. A comparison group of 26 
children considered to have a low pre-test probability of bacteraemia was selected 
from the same diagnostic accuracy study. Risk was again estimated using the clinical 
criteria alongside CRP. Nearly three quarters of children in the high-risk group met 
two or more paediatric SIRS criteria 86, as did 43% of those in the low-risk group 
(73% v 43%, p=0.007). The characteristics of high-risk (n=120) and low-risk (n=26) 
children are summarised in Table 22. 
 
  High-risk 
(n=120) 
Low-risk 
(n=26) 
p 
Median age / months (IQR) 44 (17-86) 25 (13-47) 0.06 
Male / % (95% CI) 60 (51-69) 54 (34-73) 0.56 
Significant comorbidity / % 
(95% CI) 
34 (26-43) 19 (7-40) 0.14 
Clinical variables/Median (IQR)    
Temperature 38.1  
(37.2-39.1) 
37.7  
37.0-38.6) 
0.20 
Heart rate 144 
(119-170) 
132 
(120-142) 
0.16 
Respiratory rate 30 
(24-38) 
28 
(24-32) 
0.31 
Biomarkers/Median (IQR)    
CRP / mg/dl 93  
(65-137) 
6  
(0-12) 
<0.001 
WCC / x109/l 14.3  
(10.7-18.4) 
8.99 
(6.08-11.2) 
<0.001 
PCT / ng/ml 0.97 
(0.40-4.22) 
0.19 
(0.08-0.34) 
<0.001 
≥2 SIRS criteria / % 73.1 42.9 0.007 
Median LOS / days 3 0 <0.001 
SBI / % (95% CI) 43 (34-53) 0 <0.001 
Table 22: Clinical features of children included in the evaluation of broad-range 16S rRNA with 
sequencing study. IQR: interquartile range; LOS: length of hospital stay. 
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4.5.3 Outcome diagnosis 
Outcome diagnoses for children recruited to the diagnostic accuracy study were 
independently determined by a Paediatric Infectious Disease consultant and a 
Paediatric Infectious Disease registrar using pre-defined composite reference 
standards. In the case of disagreement, a second Paediatric Infectious Disease 
consultant considered the evidence and consensus was reached. This approach 
reflects the lack of a ‘gold’ reference standard for SBIs in children.  
 
Bacteraemia was defined as: 
 the identification of a relevant pathogen by any method (culture, pathogen-
specific PCR or SepsiTest) 
 the identification of a possible pathogen in two blood cultures, or 
corroborated by two different methods 
 the identification of a possible pathogen in culture or SepsiTest, with 
supportive clinical evidence of bacteraemia. Clinical evidence of bacteraemia 
was considered to be signs of sepsis on presentation, alongside elevated 
markers of infection (in this case, WCC and CRP), prolonged administration 
of intravenous antibiotics, and prolonged hospital stay despite negative 
culture results 
 clinical evidence of bacteraemia (as described) with supportive 
microbiological evidence of a relevant pathogen (for example, an acute 
serological response to Streptococcus pneumoniae in a child presenting with 
signs of Streptococcal septicaemia). 
The details of this evaluation are summarised in Table 23.  
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Culture Specific 
PCR 
SepsiTest Clinical 
signs 
Supportive 
microbiology 
Outcome 
Pathogen ± ± ± ± Bacteraemia 
± Pathogen ± ± ± Bacteraemia 
± ± Pathogen ± ± Bacteraemia 
Possible pathogen: 
 
Single isolation 
 
 
Repeated isolation 
 
 
-ve 
-ve 
-ve 
-ve 
 
 
Same organism 
-ve 
-ve 
± 
 
 
± 
+ve 
-ve 
± 
 
 
± 
± 
± 
± 
 
 
Bacteraemia 
Bacteraemia 
No bacteraemia 
Bacteraemia 
Negative 
 
-ve 
 
Possible pathogen 
 
+ve 
-ve 
± 
± 
Bacteraemia 
No bacteraemia 
Negative 
 
 
-ve 
 
 
Negative 
 
 
+ve 
+ve 
-ve 
+ve 
-ve 
± 
Bacteraemia 
No bacteraemia 
No bacteraemia 
Table 23: Outcome diagnosis of bacteraemia according to microbiological and clinical evidence 
 
4.5.4 Conventional microbiology evaluation 
Blood culture bottles (BacT/ALERT PF, bioMeriéux, Marcy-l’Etoile, France) were 
inoculated with 1ml blood collected from a venepuncture and incubated for up to 
five days. Additional tests were undertaken according to routine clinical practice 
and at the discretion of the clinical team. This included the use of pathogen-specific 
PCR assays for Neisseria meningitidis and Streptococcus pneumoniae. Pathogen-
specific PCRs were performed at the Meningococcal Reference Unit in Manchester, 
UK 259. 
4.5.5 SepsiTest molecular analysis 
Blood was drawn into EDTA collection tubes from which 1ml was withdrawn and 
stored at -80°C in UMD-Tubes (Molzym, Germany) until analysis. Frozen samples 
were shipped to Bremen on dry ice, to be analysed in the Molzym laboratory. 
SepsiTest analysis was undertaken blinded to outcome diagnosis. Thawed samples 
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underwent a process of pathogen amplification using a chaotropic buffer containing 
guanidine hydrochloride to selectively lyse host cells. Host DNA was then degraded 
using DNAse, and intact bacterial cells recovered by centrifugation. The procedure 
was continued automatically with the lysis of microorganisms, extraction of the 
sample and isolation of DNA by a magnetic bead-based protocol. The eluate was 
subsequently included in Real-Time PCR targeting conserved sites for the 
amplification of variable regions of the 16S rRNA (V3/V4) and 18S rRNA (V9) genes 
respectively. Amplifications were performed in a DNA Engine Opticon cycler (Bio-
Rad, Hercules, USA) following the recommended programme in the SepsiTest 
SelectNA™ manual. Following a positive reaction, amplicons were sequenced using 
supplied sequencing primers. Editing by visual inspection was directed to the 
correction of single bases if unrecorded because of signalling below the set 
threshold. Strains were identified using SepsiTest-BLAST (http://www.sepsitest-
blast.net). At sequence identities >97 and 99% genus and species names were 
filed, respectively. Mixed sequences (i.e., chromatograms showing overlapping 
sequences of two or more different sequences) were analysed using the RipSeq 
mixed programme (Isentio, Bergen, Norway). This tool uses an algorithm for the 
separation of mixed sequences which are then identified by Blast analysis. Cases 
positive in the 16S PCR assay and with mixed sequences that could not be resolved 
were assigned positive for bacteria.  
4.5.6 Biomarker analysis 
Blood (0.5-1.0ml) taken at the same time as routine clinical tests including blood 
culture, was collected into Lithium Heparin and centrifuged at 13,000 rpm for 5 
minutes. Plasma was removed and stored in Sarstedt 0.5ml microtubes at -80°C. 
Sample freezing occurred within 1 hour. Prior to analysis the samples were thawed, 
vortex mixed and centrifuged again to remove bubbles and particulate matter. 
Procalcitonin (PCT) analysis was undertaken on the B.R.A.H.M.S. Kryptor platform 
(Thermofisher scientific, e Hennigsdorf). Samples were analysed according to 
manufacturer’s instructions, in batches of 50. Quality control samples were 
analysed at the beginning and end of a run. Neutrophil Gelatinase-associated 
Lipocalin (NGAL, R&D systems, Minneapolis) and Resistin (Assaypro, Missouri) were 
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analysed using validated commercial ELISA according to the manufacturer’s 
instructions. Intra and inter-plate variability were monitored. 
 
4.5.7 Statistical methods 
Statistical analysis was undertaken in R, version 3.0.3263. Continuous data were 
described by median and interquartile range, and comparison between groups 
performed using the Mann-Whitney U-test. Categorical variables were expressed as 
percentages with 95% confidence intervals (95% CI). Groups were compared by 
means of a χ2 test. In order to compare the performance characteristics of blood 
culture and SepsiTest, and the proportion of VGS bacteraemia between the two 
groups, a Monte Carlo simulation was used to check the accuracy of the asymptotic 
approximation of the null sampling distribution.  
For the diagnosis of bacteraemia, performance characteristics of the biomarkers 
individually, and in combination, were evaluated using the epiR package in R319. 
Receiver operating characteristic (ROC) curves were plotted in the pROC package320. 
The biomarker models were used to estimate the probability of bacteraemia from 
which multiple risk thresholds were derived. Using these thresholds, we evaluated 
the performance characteristics of SepsiTest in isolation, and SepsiTest in 
combination with blood culture. In this scenario, all children were considered to 
have undergone testing with blood culture, while the use of SepsiTest was limited 
to children above each stated risk threshold. The impact of this testing strategy on 
the whole group was estimated. 
4.5.8 Ethics approval 
Children were recruited to the study following written, informed consent. Ethical 
approval was granted by the Greater Manchester West Research Ethics Committee 
(10/H1014/53) and site approval granted by the Alder Hey Children’s NHS 
Foundation Trust Research and Development department. 
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4.6 Results 
Sixteen children (11%, 95% CI 6 to 17%) were diagnosed with bacteraemia. This was 
confirmed microbiologically (by any method) in thirteen cases. Two had concurrent 
meningitis (both Streptococcus pneumoniae).  
4.6.1 Performance characteristics of blood culture and SepsiTest 
The performance characteristics of both SepsiTest and blood culture are detailed in 
Table 24. Though the sensitivity of two tests was not significantly different, the high 
positivity rate of SepsiTest translated into a significantly less specific test (68% v. 
95%, p=0.02). The addition of SepsiTest to blood culture evaluation improved the 
sensitivity of diagnosis from 63% to 75% at the expense of specificity (95% to 66%). 
16S PCR with 
sequencing 
(SepsiTest) 
Bacteraemia + Bacteraemia - Total 
Test + 9 41 50 
Test - 7 89 96 
Sensitivity (95% CI) 56% (30 to 80%) 
Specificity (95% CI) 68% (60 to 76%) 
PLR 1.78 (1.08 to 2.94) 
NLR 0.64 (0.36 to 1.13) 
Blood culture Bacteraemia + Bacteraemia - Total 
Test + 10 6 16 
Test - 6 124 130 
Sensitivity (95% CI) 63% (35 to 85%) 
Specificity (95% CI) 95% (90 to 98%) 
PLR 13.5 (5.68 to 32.3) 
NLR 0.39 (0.21 to 0.74) 
SepsiTest and 
blood culture 
combined 
Bacteraemia + Bacteraemia - Total 
Test + 12 44 56 
Test - 4 86 90 
Sensitivity (95% CI) 75% (48 to 93%) 
Specificity (95% CI) 66% (57 to 74%) 
PLR 4.82 (1.64 to 14.2) 
NLR 0.82 (0.71 to 0.94) 
Table 24: Performance characteristics of blood culture and SepsiTest 16S rRNA PCR with sequencing 
for the diagnosis of bacteraemia in the children’s Emergency Department. 
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The overall positivity rate of SepsiTest in febrile children in the ED was 50/146 (34%, 
95% CI 27 to 43%). A further five positive tests were discounted as environmental 
contaminants. Sixteen positive blood cultures were obtained (11%, 7 to 17%) of 
which 6 were considered contaminants. Blood culture and SepsiTest results were 
concordant in 8/16 cases of bacteraemia. 
Both methods identified the same 2 of 5 cases of meningococcal septicaemia, the 
remainder of which were confirmed by specific PCR. SepsiTest identified a 
Streptococcus dysgalactiae in the context of a child with chickenpox, and negative 
blood cultures. It further identified a Group A Streptococcus and Klebsiella 
pneumoniae in a mixed central venous line infection which cultured only K. 
pneumoniae, and a Streptococcus mitis in a culture-negative presumed septicaemia. 
There were significantly more positive SepsiTest identifications than positive blood 
cultures. Of particular note, Viridans Group Streptococci (VGS) were identified by 
SepsiTest in 17 children. All of these identifications occurred in the high-risk group 
(17/120 v 0/26, p=0.06). The clinical characteristics of children with VGS 
bacteraemia are described in Table 25. Additional positive identifications of 
bloodstream infections caused by Gemella haemolysans (in a child with 
pneumonia), Moraxella osloensis (pneumonia) and Enterococcus spp. (orbital 
cellulitis) were made by SepsiTest.  
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Age / 
months 
Sex Clinical 
diagnosis 
CRP LOS Identification of VGS Additional microbiology 
(source) 
58 M URTI 67.1 0 Streptococcus salivarius Group A Streptococcus 
(throat swab) 
16 F URTI 56.6 4 Streptococcus sanguinis  
19 M URTI 125.2 3 Streptococcus mitis 
group 
 
59 M URTI 91.5 0 Streptococcus salivarius  
125 F Bacteraemia 172.2 3 Streptococcus mitis 
group 
 
12 M URTI 52.5 1 Streptococcus mitis 
group 
 
73 M Peri-orbital 
cellulitis 
61.9 2 Streptococcus mitis 
group 
 
66 M Dental 
abscess 
265.5 2 Streptococcus mitis 
group 
 
85 M Lymphadenitis 153 0 Streptococcus 
thermophilus 
 
40 M LRTI 134.6 1 Streptococcus mitis 
group 
 
1 M LRTI 71 3 Streptococcus cristatus  
6 M LRTI 67.4 11 Streptococcus peroris Respiratory syncytial virus 
(nasopharyngeal aspirate) 
15 M LRTI 73.2 1 Streptococcus salivarius  
21 F Meningococca
l sepsis 
364.5 7 Streptococcus salivarius Neisseria meningitidis 
(blood) 
31 M Cellulitis 85.8 2 Streptococcus peroris  
64 M Gastroenteriti
s 
63.4 1 Streptococcus 
parasanguinis 
 
87 F Pyelonephritis 263.1 5 Streptococcus 
thermophilus 
Escherichia Coli (urine) 
Table 25: Clinical characteristics of febrile children with VGS bacteraemia. URTI: upper respiratory 
tract infection; LRTI: lower respiratory tract infection. 
 
4.6.2 Risk stratification using the biomarkers PCT, NGAL and Resistin 
The biomarkers PCT, NGAL and Resistin all demonstrated reasonable discrimination 
between children with bacteraemia and those without (Area under the ROC curve 
0.80, 0.81, and 0.71 respectively, Figure 14). 
The combination of the three biomarkers improved the fit of the model to the data 
(p<0.001), though this did not translate into an improvement in the AUC (0.80, and 
0.79 respectively, p=0.8; Figure 15). Performance characteristics for the combined 
biomarker model at various risk thresholds are recorded in Table 26. At a risk 
threshold of 10%, the positive likelihood ratio indicated a significantly increased 
likelihood of bacteraemia (PLR 3.32, 95%CI 1.75 to 6.30).  
 125 
 
 
 
Figure 14: ROC curves for PCT, NGAL and Resistin in the diagnosis of bacteraemia 
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Figure 15: ROC curves for PCT alone, and in combination with NGAL and Resistin (RTN) for the 
diagnosis of bacteraemia 
 
4.6.3 Use of SepsiTest in risk groups defined by the combined biomarker 
model 
The biomarker model was used to define risk groups in which to estimate the 
performance of SepsiTest. Table 27 details the performance characteristics of 
SepsiTest in those children above each listed risk threshold, for the diagnosis of 
bacteraemia. Limiting the use of SepsiTest to groups at increasing risk of 
bacteraemia reduced the number of false positive identifications but was 
insufficiently sensitive to confidently rule out bacteraemia in this selected group of 
children. 
  
1
2
7
 
Risk Sensitivity  
(95% CI) 
Specificity  
(95% CI) 
PPV  
(95% CI) 
NPV  
(95% CI) 
PLR  
(95% CI) 
NLR  
(95% CI) 
5% 1 (0.71 - 1.00) 0.09 (0.04 - 0.15) 0.12 (0.07 - 0.19) 1 (0.62 - 1) 1.10(1.04 - 1.16) NaN (NaN) 
10% 0.5 (0.25 -0.75) 0.85(0.77 - 0.91) 0.3 (0.14 - 0.50) 0.93 (0.87 - 0.97) 3.32(1.75 - 6.30) 0.59 (0.36 - 0.97) 
20% 0.38 (0.15 -0.65) 0.95(0.90 - 0.98) 0.5 (0.21 - 0.79) 0.92 (0.86 - 0.96) 7.88(2.88 - 21.5) 0.66 (0.45 - 0.96) 
30% 0.31 (0.11 -0.59) 0.99(0.96 - 1.00) 0.83 (0.36 - 1.00) 0.92 (0.86 - 0.96) 39.40(4.90 - 316) 0.69 (0.50 - 0.96) 
Table 26: Performance characteristics of the combined biomarker model for the diagnosis of bacteraemia at various risk thresholds 
 
Risk n Bacteraemia 
(%) 
SepsiTest Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PLR (95% CI) NLR (95% CI) 
TP FP FN TN 
All 146 16 (11) 9 41 7 89 56 (30 to 80) 68 (60 to 76) 1.78 
(1.08 to 2.94) 
0.64 
(0.36 to 1.13) 
5% 131 16 (12) 9 35 7 80 56 (30 to 80) 70 (60 to 78) 1.85 
(1.11 to 3.09) 
0.63 
(0.36 to 1.11) 
10% 27 8 (30) 5 5 3 14 63 (24 to 91) 74 (49 to 91) 2.38  
(0.94 to 5.98) 
0.51 
(0.20 to 1.30) 
20% 12 6 (50) 4 2 2 4 67 (22 to 96) 67 (22 to 96) 2.00  
(0.56 to 7.09) 
0.50 
(0.14 to 1.77) 
30% 6 5 (83) 4 0 1 1 80 (28 to 99) 100 (1 to 100) Inf 
(-Inf to Inf) 
0.20  
(0.03 to 1.15) 
Table 27: Performance characteristics of SepsiTest for the diagnosis of bacteraemia applied to children above the listed risk thresholds, defined by the biomarker 
model. TP: True positive, FP: False positive, FN, False negative, TN: True negative. 
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Risk 
/% 
SepsiTest Combined SepsiTest and Blood culture (n=146) 
n Bacteraemia 
(%) 
TP FP FN TN TP FP FN TN Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
 
PLR  
(95% CI) 
NLR  
(95% CI) 
All 146 16 (11) 9 41 7 89 12 44 4 86 75 (48 to 93) 66  
(57 to 74) 
2.22 
(1.53 to 3.21) 
0.38 
(0.16 to 0.89) 
>5 131 16 (12) 9 35 7 80 12 39 4 91 75 (48 to 93) 70  
(61 to 78) 
2.50 
(1.70 to 3.68) 
0.36 
(0.15 to 0.84) 
>10 27 8 (30) 5 5 3 14 11 11 5 119 69 (41 to 89) 92  
(85 to 96) 
8.13 
(4.22 to 15.6) 
0.34 
(0.16 to 0.71) 
>20 12 6 (50) 4 2 2 4 11 8 5 122 69 (41 to 89) 94  
(88 to 97) 
11.2 
(5.29 to 23.6) 
0.33 
(0.16 to 0.69) 
>30 6 5 (83) 4 0 1 1 11 6 5 124 69 (41 to 89) 95  
(90 to 98) 
14.9 
(6.38 to 34.8) 
0.33 
(0.16 to 0.68) 
Table 28: Performance characteristics of a combination of SepsiTest used in children above the listed thresholds defined by the biomarker model, along with 
blood culture in all children. TP: True positive, FP: False positive, FN, False negative, TN: True negative. 
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Of more interest is how the application of SepsiTest at various risk thresholds 
impacted the diagnosis of bacteraemia in the whole group (Table 28). This assumes 
that SepsiTest is performed only in children above each listed threshold, but 
supplemented by blood culture in all. Limiting the use of SepsiTest only to the most 
high-risk children reduces the number of false positive identifications, and results in 
improvements in specificity and PLRs when compared with the use of SepsiTest in 
all children.  
As an illustration, when SepsiTest is applied to the whole group, 146 additional 
tests are performed. For this diagnostic investment, two additional cases of 
bacteraemia are identified in addition to those identified by culture. Thirty-eight 
additional false positives result. By restricting SepsiTest to children with a 
biomarker-predicted risk >10%, 27 additional SepsiTest investigations are 
performed, identifying a single case of bacteraemia in addition to those identified 
by blood culture. In this case, there are only two additional false positives to 
consider. The PLR of this diagnostic approach is 8.13 (95% CI 4.22 to 15.6).  
 
4.7 Discussion 
In febrile children in the ED with a significant pre-test probability of sepsis, 
SepsiTest broad-range 16S-rRNA PCR with sequencing augmented the use of blood 
culture in the diagnosis of bacteraemia. In this first evaluation of SepsiTest in 
children using samples of approximately 1ml of blood, the performance 
characteristics of SepsiTest and blood culture were broadly comparable. The use of 
the two tests in combination yielded better sensitivity than either test in isolation.  
Both blood culture and broad-range PCR failed to identify significant pathogens. Of 
five cases of meningococcal septicaemia, SepsiTest and blood culture both 
identified the same two cases, but failed to identify a further three confirmed by 
meningococcal-specific PCR. It is possible that the concentration of pathogen DNA 
in these cases was below the limit of detection 83,84. Alternatively, while pathogen-
specific PCR detects DNA from both viable and killed organisms, the SepsiTest pre-
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analytical stage degrades free DNA from killed and lysed organisms which may 
explain the negative results321. For diagnostic purposes, this is an important 
limitation.  
The use of pathogen-specific PCR is well established for the purpose of improving 
yield in the diagnosis of MCD. Highly sensitive PCR assays for MCD have 
demonstrated superior performance characteristics to blood culture295 and are 
widely used in paediatric practice in the UK. The molecular diagnosis of invasive 
pneumococcal disease (IPD) using PCR has proven more challenging, but recent PCR 
assays targeting the autolysin gene of S.pneumoniae have been demonstrated to be 
more sensitive than blood culture in both adults and children, and in contrast to 
those targeting the pneumolysin gene, highly specific322-324. The limitations of 
pathogen-specific diagnostics are, of course, that while the test may be highly 
sensitive for a suspected pathogen, its sensitivity for the diagnosis of bacteraemia 
overall is poor – a negative test only rules out a single pathogen. Broad-range 
methods, such as 16S rRNA PCR, offer the potential of identifying all possible 
causative organisms, but to date remain insufficiently sensitive to reliably rule out 
bacteraemia83. 
The yield from the use of SepsiTest in all children in our pre-selected sample is 
relatively small. The test is insufficiently sensitive for a negative test to rule out 
bacteraemia. The test benefits can be summarised as the identification of two 
additional cases of bacteraemia and the potential of reduced time to identification 
in other concordant cases. Such benefits need to be measured against the costs 
involved. Furthermore, the frequent positive identification of organisms of 
uncertain significance may have unintended consequences including unnecessary 
antimicrobial therapy and prolonged hospital admission. The use of risk 
stratification may have a role in optimising the use of the test, providing 
supplementary diagnostic information to blood culture in those most likely to have 
bacteraemia in a shortened time frame, while limiting the number of false positive 
identifications. 
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There is no gold standard for the diagnosis of bacteraemia, which makes diagnostic 
accuracy studies difficult to interpret. The performance characteristics of the 
SepsiTest have been estimated against a pre-defined outcome composite reference 
diagnosis of bacteraemia. The approach risks incorporation bias however, as the 
identification of a ‘true pathogen’ on SepsiTest was incorporated into the definition 
of bacteraemia. By contrast plausible organisms not commonly associated with the 
diagnosis of bacteraemia were only considered ‘true’ if associated with 
corroborative findings as interpreted by the investigators. This is an accepted 
approach to the problem of imperfect reference standards64, and more appropriate 
than a direct comparison with blood culture. 
Alternative approaches (discussed in Section 1.5.2) might include, for example, 
latent class analysis where the results of the SepsiTest assay were considered as 
one of a number of predictor variables for the true unknown ‘latent’ state. Such an 
approach may yield more accurate estimates of diagnostic performance, but the 
clinical benefit would be unclear. SepsiTest, for example, identified a number of 
plausible pathogens in children who received an outcome diagnosis other than 
bacteraemia. Gemella haemolysans and Moraxella osloensis were both identified by 
SepsiTest in the bloodstream of children with significant respiratory infections. 
Though typically opportunistic, both have been described in children with invasive 
infections 325,326. It is possible that these children, alongside a child with post-septal 
cellulitis in which SepsiTest identified Enterococcus were wrongly considered not to 
have bacteraemia. In order to demonstrate the value of these SepsiTest 
identifications, it would be necessary to demonstrate that the disease state defined 
by the latent class model was of clinical interest. That is, are these children of 
similar severity to those with blood culture-positive bacteraemia, do they require 
the same treatment, and are their outcomes the same?  
The finding of VGS bacteraemia in this selected high-risk group of febrile children is 
interesting. The fact that no VGS bacteraemia was identified in a low-risk 
comparison group of febrile children sampled in the same way argues against this 
being a problem relating to sample contamination. VGS are abundant oral 
commensals. By the age of one year, Streptococcus mitis, S. parasanguinis and S. 
 132 
 
oralis predominate in the oral flora327. Whilst typically benign organisms of the 
upper respiratory tract, invasive infections of the immunocompromised host are 
well recognised 328,329. VGS are also a common cause of infective endocarditis in 
immunocompetent children and adults330, and one of the most commonly 
identified bloodstream infections in the UK331. In one study of community-acquired 
bacteraemia in the UK, 12% of all paediatric cultures were VGS (13/106, of which 7 
were of ‘probable’ clinical significance) although this is at odds with our 
retrospective analysis of bacteraemia in the ED (6/575, 1%; Chapter 3). Most of 
these children presented with acute respiratory infections, as in our study332. This 
association has also been made in children with fever and neutropenia333. It is 
unclear why we identified VGS bacteraemia with such frequency in culture negative 
samples. Conceivably, intracellular VGS are released into the blood sample during 
the pre-analytical lysis of host cells. This finding deserves further exploration. 
The mechanisms by which VGS cause invasive infection is of increasing interest334. 
Streptococcus mitis binds platelets via phage proteins PbIA and PbIB, and the loss of 
expression of these proteins results in decreased virulence in animal models of 
endocarditis335. Similarly, it is hypothesised that S. parasanguinis is implicated in 
endocarditis by its ability to bind platelets336. Streptococcus mitis shares significant 
homology with the highly pathogenic S. pneumoniae, and the recently completed 
genome of S. mitis337 and S. oralis338 isolates have highlighted the presence of genes 
analogous to virulence genes present in S. pneumoniae.  
Whether VGS in the bloodstream of this group of acutely unwell children contribute 
to the clinical picture, mediating the inflammatory response and conferring 
morbidity is unclear. The finding may indeed be a response to a profound 
inflammatory illness during which alterations to mucosal immunity allow the 
invasion of oropharyngeal organisms into the bloodstream. VGS have the potential 
to cause significant invasive infection and the possibility that a significant 
proportion of immunocompetent children with acute febrile illnesses experience a 
VGS bacteraemia deserves greater examination. VGS bloodstream isolates are 
commonly resistant to antibiotics331, and have the potential to transfer 
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chromosomal DNA to S. pneumoniae resulting in high-level resistance339. This is a 
clinical scenario with significant implications. 
 
4.7.1 Comparison with other studies 
A number of broad-range molecular approaches to the diagnosis of bacteraemia 
have been developed and evaluated, mostly in adults 77,340. Fewer studies have 
been undertaken in children. A large study of the use of a multiplex PCR (SeptiFast, 
Roche, Germany) in children supported its use as an adjunct to blood culture, and 
suggested a shortened time to pathogen identification 309. A number of small 
studies have investigated the use of 16S rRNA PCR in neonates 341-343, with variable 
results. This is the first study of this approach in the children’s ED. 
The value of SepsiTest in the children’s ED is in expediting pathogen identification in 
those at risk, that is, in ruling in bacteraemia and guiding appropriate treatment. In 
our high-risk sample, the use of SepsiTest in 120 children yielded additional 
information to blood culture in only two children. This may be considered clinically 
worthwhile, particularly if these and other concordant results are available to 
clinicians more quickly than culture, but further stratifying risk in this setting may 
be appropriate. This approach was taken in a study of adults in ED, though in this 
setting, SepsiTest performed poorly in comparison to blood culture 344. In our study, 
applying a risk threshold of 10% to a biomarker based model limited the use of the 
test to 31 children, in whom 7 had bacteraemia, five of which were identified by 
SepsiTest. One Streptococcus dysgalactiae bacteraemia was not identified by either 
culture, or pathogen-specific PCR. The test would be insufficiently sensitive in this 
group to rule out bacteraemia and stop treatment, but may have value in guiding 
appropriate antimicrobial therapy if the results are available to clinicians prior to 
blood culture. At a time when the aetiology of bacteraemia in the children’s ED is 
evolving, this is important 305. 
The broad-range identification of pathogens in small volumes of blood requires a 
process of host DNA removal and pathogen amplification. The pre-analytical 
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MolYsis protocol has been demonstrated to reduce host DNA, but at the expense of 
reduced bacterial load345. Concern has been expressed that the protocol may 
particularly affect Gram negative organisms with a relatively more fragile cell wall, 
and that this approach would not be successful for the diagnosis of Gram negative 
organisms346. We have demonstrated the successful diagnosis of Gram negative 
septicaemia in small samples obtained from children, though the lack of sensitivity 
for N.meningitidis is of concern. 
 
4.7.2 Limitations 
For pragmatic reasons, our analysis was undertaken in a sample of children 
considered to have an increased pre-test probability of bacteraemia. Given that the 
likelihood of bacteraemia in febrile children in ED is estimated to be 1 in 2506, the 
yield of the test in all children in this setting would have made the study 
impractical. This pragmatic approach to study recruitment yielded in effect a ‘case-
control’ design in which the performance of SepsiTest was compared in children considered 
likely to have the target condition (bacteraemia) versus those considered unlikely. Inclusion 
in the study was non-consecutive. Both are characteristics of diagnostic studies which are 
recognised to overstate diagnostic accuracy. The most striking example of this occurs in 
studies which recruit severe cases and healthy controls. Studies of this kind have been 
shown to yield Diagnostic Odds Ratios for index tests of approximately 5 times that of more 
appropriately designed studies56,347. We avoided this particular bias by studying febrile 
children in the ED, but recognise the bias in the selection strategy. 
Further stratification of the sample using a biomarker based risk model suggests 
that it may be possible to target the use of the test in the highest risk children. 
However, other than asserting that this was a selected ‘high-risk’ group of children, 
it is not possible to generalise to which children the test may be of value. We 
advocate for future studies to evaluate the use of the test in high-risk children 
stratified by externally validated risk prediction models appropriate to the 
children’s ED6,96. 
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Molecular analysis was not undertaken in real time, so we are unable to comment 
on the logistics of the method. One attraction of the molecular approach to 
diagnosis is in reducing time to pathogen identification, and expediting appropriate 
antimicrobial therapy. The SepsiTest method evaluated is a semi-automated 
method, which undertakes the pre-analytical phase and PCR within 4h, requiring 75 
minutes hands on laboratory time. Sequencing is estimated to require a further 4h 
and requires the skills to interpret and possibly edit the sequence output. Whilst 
the treatment of bacteraemia in the ED would remain largely empirical, and based 
upon local epidemiology, SepsiTest and other broad-range molecular platforms may 
have a role in optimising rational and effective antimicrobial therapy by expediting 
pathogen identification. 
As the aetiology of invasive infections in children evolves, it is increasingly 
important to make a rapid aetiological diagnosis which current methods fail to 
achieve. In order for clinical improvements to be realised, broad-range molecular 
tests such as SepsiTest will need to be incorporated into models of care integrating 
laboratory services with appropriate clinical expertise. Improvements in 
antimicrobial stewardship have been achieved by combining new diagnostic 
technologies (such as MALDI-TOF MS303 and Verigene BC-GP348) with clear 
multidisciplinary strategies for reporting timely results, and communicating clinical 
decisions. It is in this context that it is possible to suggest the use of SepsiTest in 
high-risk children as an adjunct to established methods.  
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4.8 Conclusions 
SepsiTest broad-range PCR and sequencing augmented the use of culture in the 
diagnosis of bacteraemia in children in the ED. It is insufficiently sensitive to rule 
out bacteraemia, but in expediting pathogen identification, it may have a role in 
optimising and rationalising empirical antimicrobial therapy in high-risk children. 
SepsiTest is possible in small volume paediatric samples. Further, it identified 
bloodstream infections caused by organisms with the potential to confer significant 
morbidity including VGS. Risk stratification using a combination of biomarkers may 
identify high-risk children in whom the test has the greatest value. This is a tool 
with potential value to support the culture-based diagnosis of bacteraemia in 
febrile children. 
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Chapter 5: The derivation and validation of a 
multivariable risk prediction model for the 
diagnosis of Serious Bacterial Infection in the 
children’s Emergency Department 
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5.1. Overview of the chapter 
In this chapter, the focus will shift from bacteraemia, an important but uncommon 
SBI in the children’s ED, to the diagnosis of all SBI in the ED. I will present the results 
of a large prospective diagnostic accuracy study of febrile children presenting to the 
ED (the SPICED study) with a particular focus on the derivation and internal 
validation of a multivariable clinical risk prediction model for the diagnosis of 
‘pneumonia’ and ‘other SBIs’. 
 
5.2. Background 
5.2.1. Serious bacterial infections in the children’s Emergency 
Department 
Acute infections make up a large proportion of all attendances to the children’s ED3. 
Differentiating SBI from self-limiting infection in this setting is challenging. The 
likelihood of SBI in febrile children under 5 years presenting to the ED is 
approximately 7%, the majority of which are lower respiratory or urinary tract 
infections6. 
Prompt recognition of SBI in children is essential for effective management. 
Children with meningococcal disease are frequently missed at initial presentation45, 
and delays in the recognition and management of severe sepsis increase 
mortality15,16. Though rates of invasive infections attributable to Neisseria 
meningitidis, Haemophilus influenzae and Streptococcus pneumoniae have declined 
in recent decades following the introduction of conjugate vaccines12,20,287,349, SBI 
continues to account for a substantial proportion of childhood morbidity and 
mortality37. 
The challenge of differentiating SBI from self-limiting infection is not limited to a 
failure of recognition of serious infection. Difficulty in ruling out SBI also has serious 
implications. Despite declining rates of invasive infections presenting to the ED, the 
likelihood of a child being admitted to hospital has increased over the last decade49. 
The greatest increase is in young children with uncomplicated short stay admissions 
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for acute infections, in whom the rate of admission approximately doubled 
between 1999 and 201022. Many of these admissions are for ‘primary-care 
sensitive’ conditions, that is, conditions which are considered appropriate to treat 
in the community.  
Failure to rule out SBI also limits rational antimicrobial use. Antimicrobial 
consumption is associated with an increasing rate of antimicrobial resistance 
(AMR)350, and global efforts to mitigate the impact of AMR include a focus on 
antimicrobial stewardship351. Improving the ability of clinicians to confidently rule 
out SBI in the ED could make a valuable contribution to improving rational decision-
making regarding both admission to hospital, and antimicrobial use.  
5.2.2. The diagnosis of SBI in the children’s ED 
The assessment of the febrile child includes the evaluation of multiple clinical 
variables alongside the use of adjunctive tests. Numerous studies have reported the 
performance characteristics of these clinical10 and laboratory185 variables in the 
diagnosis of paediatric SBI in the ED. Presently in the UK, the approach to the febrile 
child is guided by the NICE “Feverish illness in children” guideline184. This is a 
consensus guideline designed for use in children under 5 years, and makes use of a 
‘traffic light’ system to categorise risk. Recently, the guideline has undergone 
evaluation and been found to have limited capacity to discriminate between serious 
and self-limiting infections249,250,352. 
Recognising the limited ability of individual clinical signs, or biomarker tests to 
differentiate between SBI and self-limiting infections, numerous authors have 
sought to combine clinical and biomarker variables in clinical prediction rules or 
models. Two large prospective studies derived and internally validated risk 
prediction models comprising clinical variables6,9, and another demonstrated the 
value of the addition of the biomarker C-Reactive Protein (CRP) to a clinical 
model96. An alternative approach has been to build a ‘Lab score’ made up of CRP, 
Procalcitonin (PCT) and urinalysis7,253. A previous study from the University of 
Liverpool, investigated Malawian children with pneumonia and meningitis, and 
demonstrated that a combination of the biomarkers PCT, Resistin, and Neutrophil 
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Gelatinase-associated Lipocalin (NGAL) improved diagnostic accuracy over any one 
individual marker221. 
Despite the demonstration of robust discrimination, studies of diagnostic tests in 
childhood SBI have so far failed to significantly impact clinical practice. A recent 
Health Technology Assessment review highlighted methodological weaknesses 
limiting the external validity of the findings of diagnostic accuracy studies. One 
recommendation was to avoid restrictive inclusion criteria, such as age, 
temperature, or clinical syndrome in order that study findings might be more 
appropriately generalised to other populations64. 
 
5.3. The SPICED study 
The SPICED study was a prospective diagnostic accuracy study undertaken in febrile 
children (up to 16 years of age) presenting to the ED.  
 
5.4. Hypothesis 
The combination of clinical and biomarker variables in a risk prediction model 
discriminates between SBI and no SBI, and between pneumonia, ‘other SBIs’ and no 
SBI. 
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5.5. Aims and objectives 
 
The study sought to evaluate the use of clinical and biomarker variables for the 
diagnosis of SBI in febrile children of all ages presenting to the ED. 
Specifically, the study objectives were: 
I. To derive and validate a multivariable model including established 
clinical and biomarker variables alongside the biomarkers PCT, NGAL 
and Resistin for the diagnosis of SBI in this population of children. 
II. To derive and validate a multivariable risk prediction model to 
discriminate between pneumonia, ‘other SBIs’ and no SBI. 
III. To determine the value of salivary PCT as a marker of SBI in this 
population of children 
 
5.6. Methods 
This was a prospective study of the diagnostic accuracy of clinical and biomarker 
variables for the diagnosis of SBI in children presenting to the Alder Hey Children’s 
Hospital ED. The study methods are detailed in chapter 2. The study is reported in 
line with the published Standards for Reporting of Diagnostic accuracy studies 
(STARD)353. 
5.6.1. Ethics approval 
Ethics approval for the study was granted by the Greater Manchester West 
Research Ethics Committee (10/H1014/53), and site approval granted by the Alder 
Hey Children’s NHS Foundation Trust Research and Development department. 
5.6.2. Saliva as a non-invasive sample for the detection of PCT 
There is no validated assay for the measurement of PCT in saliva. Measurement of 
salivary PCT was thus undertaken using a commercial ELISA validated for use in 
serum, plasma and cell culture supernatants (Abcam, Cambridge) as well as the 
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automated assay used in the hospital laboratory (B.R.A.H.M.S Kryptor, 
Thermofisher Scientific, Hennigsdorf). A spike and recovery experiment was 
performed on saliva samples using the commercial ELISA. 
5.6.2.1. Reagent and sample preparation 
Saliva samples were obtained and stored as detailed in Methods (Section 2.5.1.3). A 
solution of PCT standard (55ng/ml) was prepared according to the manufacturer’s 
instructions, and a serial dilution performed. Standard concentrations ranged from 
27pg/ml to 20ng/ml. The supplied wash buffer, calibrator diluents, and substrate 
solutions were prepared according to the instructions provided. 
5.6.2.2. ELISA procedure 
The ELISA assay was performed on a supplied pre-coated 96-well PCT microplate. 
100µl of prepared standard or sample was added to each well. Samples were 
assayed in duplicate. Standards and samples were incubated for 2.5 hours at room 
temperature before washing with the supplied wash buffer using an autowasher. 
100µl of biotinylated PCT antibody was then added to each well and incubated for a 
further 1 hour. Following a further wash cycle, 100µl of HRP-Streptavidin conjugate 
was then added to each well, and incubated for a further 45 minutes. After 
washing, 100µl of TMB One-Stop Substrate Reagent was added and incubated for 
30 minutes in a dark room, tapping the microplate to ensure mixing. 50µl Stop 
solution was then added to each well, and the optical density read by the ELx800 
absorbance reader (Biotek instruments, Winooski) set to 450nm. As before, a 4 
parameter logistic curve was constructed with each assay run, using the KC junior 
software package produced by Biotek. 
5.6.2.3. Spike and recovery experiment 
Following sample preparation, three randomly selected clinical saliva samples were 
serially diluted (neat, 1:2, 1:4) using the assay diluent provided. Each dilution was 
split into two 245 microlitre aliquots. One of each aliquot was spiked with a 
concentration of 400pg/ml PCT standard. Spiked and unspiked samples at each 
dilution were assayed in duplicate (Table 29). 
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Sample Recovered 
spiked 
concentration 
(pg/ml) 
Mean Unspiked 
concentration  
(pg/ml) 
Mean Recovery 
(%) 
A 223.91 253.72 238.82 9.88 54.76 32.32 53.21 
A 1:2 461.59 497.54 479.57 158.04 150.41 154.22 83.83 
A 1:4 443.41 434.96 439.19 136.71 73.09 104.90 86.13 
B 107.72 114.14 110.93 <9 <9 0.00 28.58 
B 1:2 395.05 379.11 387.08 285.66 192.79 239.23 38.10 
B 1:4 554.65 478.25 516.45 196.33 237.30 216.81 77.20 
C 282.51 321.16 301.84 183.86 218.82 201.34 25.89 
C 1:2 485.16 578.83 532.00 340.76 358.59 349.67 46.98 
C 1:4 490.67 397.93 444.30 252.10 269.83 260.96 47.24 
Buffer 449.02 387.82 418.42 30.31 <9 15.16 97.03 
Table 29: PCT concentrations measured in spiked and unspiked saliva samples at three dilutions. 
 
Recovery of spiked PCT was poor in neat samples, and improved with dilution. 
Mean recovery of the 3 samples at 1:4 dilution was 70.2%. On the basis of this 
experiment, clinical saliva samples were diluted 1:4 for use in the assay. 
 
5.6.3. Statistical methods 
Statistical analysis was undertaken using R, version 3.1.3. 
5.6.3.1. Univariate analysis 
Univariate analysis of all clinical and biomarker variables was undertaken using 
logistic regression, where the outcome was SBI, and using multinomial regression, 
where the outcome was one of ‘pneumonia’, ‘other SBI’ or ‘no SBI’. 
5.6.3.2. Checking the assumptions of logistic regression 
Explanatory variables were plotted against each other to look for evidence of co-
linearity. Scatter plots and generalised additive model (GAM) plots286 of continuous 
explanatory variables, fitted using the gam() function in the mgcv R package, were 
examined for evidence of non-linearity on the log-odds scale. Where the 
assumption of linearity appeared not to hold, we examined candidate variables 
using piecewise and polynomial transformations. Inspection of the GAM plot 
suggested a piecewise transformation of CRP should be used (Figure 16). 
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Figure 16: GAM plot of CRP versus SBI suggesting a non-linear relationship between CRP and SBI 
 
5.6.3.3. Imputation of missing data 
In order to provide valid inferences from incompletely recorded data, imputation of 
missing data was undertaken. Data was assumed to be “missing at random”. 
Missing values were imputed ten times by fully conditional specification. This was 
performed with the ‘multivariate imputation using chained equations’ (MICE) 
package in R269. In this method, missing values are replaced by plausible values 
drawn from a conditional distribution specific to each individual predictor variable 
and defined by its own imputation model. Figure 17 illustrates the relationship 
between observed and imputed values of temperature in relation to heart rate for 
10 imputations. 
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Figure 17: Observed (blue) and imputed (purple) values of temperature in relation to heart rate 
(‘Pulserate’) for 10 imputation cycles 
 
5.6.3.4. Multivariable model for the diagnosis of SBI 
The dataset was randomised into a split sample “derivation set”, and “validation 
set”. Following the initial univariate analysis, an estimate of the number of true null 
hypotheses was made using a plot of (1-p)-values354 (Figure 18). Using this 
technique, the slope of the plot estimates the number of true null hypotheses to be 
rejected. We thus determined the significant explanatory variables to include in a 
forward stepwise model building process. 
In the model building process, each of the significant explanatory variables was 
regressed against the outcome SBI. Improvement of the models from the null was 
tested by measuring the change in deviance between the null model and each 
univariate model. The variable associated with the most highly significant 
improvement in model deviance was then included in the model. The process was 
repeated, adding each remaining variable to this univariate model, and testing the 
significance of the change in deviance between each two variable model and that of 
the univariate model. This stepwise cycle of adding each remaining variable 
individually to the model established by the previous cycle was continued until the 
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addition of further explanatory variables produced no significant improvement in 
the residual deviance. 
 
 
Figure 18: Plot of the sorted (1-p) values obtained from univariate logistic regression analysis of all 
variables for the outcome of SBI. The slope of the straight line section estimates the number of true 
null hypotheses
354
. 
 
Having identified a parsimonious model for the identification of SBI, these variables 
were then included in a multinomial logistic regression model using the categorical 
outcomes “pneumonia”, “other SBI”, and “no SBI”. Multinomial regression was 
undertaken using the multinom () function in the ‘nnet’ package in R.  
5.6.3.5. Model evaluation 
Discrimination of the regression models was measured using the c statistic, and 
illustrated using Receiver Operating Characteristic (ROC) curves (roc() function of 
the ‘pROC’ package in R320). For the multinomial regression model, the c statistic 
estimated discrimination between pairs of patients – either a patient with 
pneumonia and a patient with no SBI, or patient with “other SBI” and a patient with 
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no SBI. Confidence intervals (95%) for the area under the ROC curve were 
estimated by means of a bootstrapping process using 2000 bootstrap replicates. 
Goodness-of-fit was tested using the Hosmer-Lemeshow test355, and illustrated by 
calibration plots. The Hosmer-Lemeshow test sorts the study sample into deciles 
based upon predicted probabilities, and tests the significance of the difference 
between observed and expected frequencies using the chi-square distribution274. 
Influence plots were used to evaluate any excess contribution of individual study 
subjects to the fitted model. Performance characteristics of the models were 
calculated at various risk thresholds. Sensitivity, specificity, positive and negative 
likelihood ratios were estimated using the epiR package in R. 
 
5.7. Results 
Between 1st November 2010 and 3rd April 2012, 7949 children presented to the 
Alder Hey children’s ED with fever, or history of fever as part of their presenting 
complaint. Of these 1872 had routine blood investigations carried out and were 
thus eligible for inclusion in the study. 1101 children were recruited to the study 
(see flowchart, Figure 19). 
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Figure 19: Study flow chart of children recruited to the SPICED study 
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5.7.1. Patient characteristics 
The median age of children in the study was 2.4 years (IQR 0.9-5.7 years), 55% were 
boys. Approximately one third of children had significant comorbidities, requiring 
the ongoing care of a paediatric specialist. The characteristics of recruited children 
are described in Table 30. 
A total of 264 children (24.0%) were diagnosed with SBI, 108 with pneumonia and 
156 with other SBIs. Outcome diagnoses are illustrated in Figure 20. Nineteen 
children were admitted to PICU. Of these, nine had bacteraemia (seven MCD, one 
iGAS, and one S.pneumoniae), two of whom had concurrent meningitis (one MCD, 
and one S.pneumoniae). Five children were admitted to PICU with pneumonia 
including one child with empyema and Varicella Zoster Virus (chickenpox) infection. 
A single child with significant comorbidities was admitted to PICU with a 
Pseudomonas UTI. Four children were admitted with viral diagnoses, and in 3 of 
these cases PICU admission was for management of prolonged seizures. One young 
infant required ventilation for bronchiolitis (virus not identified) for a period of 6 
days. A 10 month old previously healthy girl with S.pneumoniae meningitis and 
septicaemia was the only fatality observed during the course of the study. 
Children with pneumonia were older than those with no SBI (3.5 years v 2.2 years, 
p<0.001), and more likely to have significant comorbidities (47% v 30%, p<0.001). 
Children with pneumonia and other SBIs had a higher median temperature and 
heart rate, than those with no SBI (p<0.05), and children with pneumonia had 
higher respiratory rates than those with no SBI (median 38 v 28, p<0.01).  
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Overall 
n=1101 
Pneumonia 
n=108 
Other SBI 
n=156 
No SBI 
n=837 
Demographics Median IQR Median IQR Median IQR Median IQR 
Age 2.39 0.88-5.73 3.51† 1.60-6.29 2.28 0.43-7.54 2.21 0.92-5.35 
 
Proportion 95%CI Proportion 95%CI Median IQR Proportion 95%CI 
Male sex 0.55 0.52-0.58 0.48 0.39-0.57 0.59 0.51-0.66 0.56 0.52-0.59 
PMH 0.31 0.28-0.34 0.47† 0.38-0.57 0.26 0.19-0.33 0.30 0.27-0.33 
Clinical variables Median IQR Median IQR Median IQR Median IQR 
Temperature 37.8 37.0-38.6 37.9* 37.1-38.9 38.0* 37.2-38.8 37.7 36.9-38.6 
Heart Rate 140 121-166 147* 132-170 148* 122-175 139 120-163 
Respiratory Rate 30 24-38 38† 28-48 30 24-38 28 24-36 
Biomarkers Median IQR Median IQR Median IQR Median IQR 
CRP 19.6 5.8-54.0 49.0† 21.1-119 68.3† 28.9-137 14.3 4.0-36.5 
WCC 11.5 7.9-15.8 11.8* 8.4-18.5 15.0† 10.9-20.5 10.8 7.7-14.7 
NC 6.9 3.8-10.8 8.0† 4.8-13.4 10.0† 5.9-14.8 6.2 3.4-9.7 
NGAL 77.1 52.5-121 92.1† 65.9-162 120† 74.4-170 69.7 49.5-103 
PCT 0.23 0.10-0.83 0.49† 0.12-2.85 1.10† 0.15-5.85 0.18 0.09-0.53 
Resistin 40.3 21.1-73.4 67.3† 31.4-107 60.6† 29.7-113 35.7 19.8-64.3 
Outcomes Median IQR Median IQR Median IQR Median IQR 
Length of stay 2 0-3 3† 2-6 4.5† 2-7 1 0-2 
 
n (%) 95%CI n (%) 95%CI n (%) 95%CI n (%) 95%CI 
PICU 19 (1.73) 1.11-2.68 5* (4.63) 2.00-10.4 10*(6.41) 3.52-11.4 4 (0.48) 0.19-1.22 
Mortality 1 (0.09) 0.01-0.51 0 0-3.40 1 (0.65) 0.12-3.55 0 0-0.46 
Table 30: Characteristics of study subjects. Statistical comparisons are between Pneumonia or Other SBI and No SBI. Continuous data were 
compared by means of the Kruskal Wallis test, proportions were compared by means of the Pearson’s Chi squared statistic. Rare events such as 
admission to PICU or death were compared by means of a Monte Carlo simulation. †p<0.001 *p<0.05.  
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Figure 20: Outcome diagnoses in children recruited to the SPICED study by organ system
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5.7.2. Salivary PCT in children 
Saliva samples were obtained in 1006 children. The first 50 samples were batched 
and analysed using the B.R.A.H.M.S Kryptor system, validated for use in plasma. Of 
these, 6 samples were insufficient for analysis, and of the remaining 44 all but two 
failed to detect PCT (lower limit of assay detection 20 pg/ml). The two samples with 
detectable PCT were quantified at 60 pg/ml, and 210 pg/ml. The range of PCT in the 
corresponding plasma samples (collected contemporaneously) was up to 17.6 
ng/ml. All but three had plasma levels of PCT >60 pg/ml. 
Following the demonstration of measurable quantities of PCT in spiked samples 
using a commercial ELISA (Abcam, Cambridge), a further 48 clinical samples were 
tested in duplicate. Of these, a single sample yielded a result of 540 pg/ml, while 
the remainder were undetectable (<160 pg/ml). We concluded that using two 
independent methods of detection, we were unable to detect significant levels of 
PCT in saliva. 
 
5.7.3. Univariate analysis 
Initial univariate analysis was undertaken in the entire dataset (n=1101). Consistent 
with other studies, increased work of breathing (odds ratio (OR) 10.41, 95% 
confidence interval 6.69 to 16.2), hypoxia (9.29, 5.35 to 16.1), and other features of 
an abnormal respiratory examination were significantly associated with the 
presence of pneumonia. These features reduced the likelihood of other SBIs. Neck 
stiffness (20.6, 2.1 to 199), a bulging fontanelle (3.37, 1.35 to 8.40), irritability (3.23, 
1.54 to 6.78) and dysuria (3.34 , 1.28 to 8.68) were all associated with other SBIs. 
Prolonged capillary refill time was associated with other SBIs (1.43, 1.05 to 1.97) 
but not pneumonia. Neither an ill appearance nor parental concern predicted 
pneumonia nor other SBIs. (See Table 32 and Figure 21). 
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The likelihood of pneumonia and other SBIs increased linearly with heart rate, 
respiratory rate and temperature. The biomarkers CRP, Procalcitonin, NGAL and 
Resistin were all associated with likelihood of SBI. Lactate and blood glucose were 
not, though were measured in fewer children (Table 31). 
 
Biomarkers n 
Pneumonia Other SBI 
OR LCI UCI OR LCI UCI 
Procalcitonin 1034 1.22 1.15 1.29 1.23 1.16 1.30 
Neutrophils 1059 1.09 1.06 1.13 1.12 1.09 1.15 
WCC 1059 1.05 1.02 1.08 1.08 1.06 1.11 
CRP 1072 1.02 1.01 1.02 1.02 1.02 1.02 
Resistin 1045 1.01 1.00 1.01 1.01 1.01 1.01 
NGAL 1046 1.00 1.00 1.01 1.01 1.00 1.01 
Blood glucose 123 0.78 0.54 1.12 1.03 0.89 1.20 
Lactate 167 0.67 0.42 1.09 1.12 0.84 1.50 
Table 31: Odds ratios of biomarker variables in univariate multinomial regression for the diagnoses 
of pneumonia and other SBIs. ‘n‘: number of subjects in which the variable was recorded. OR: Odds 
ratio, LCI: lower 95% confidence interval, UCI: upper 95% confidence interval 
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Variable n 
Pneumonia Other SBI 
OR LCI UCI OR LCI UCI 
Neck stiffness 652 0 0 3x1023 20.6 2.13 199 
Normal air entry 1069 0.09 0.06 0.14 9.60 2.34 39.4 
Chest clear 1069 0.09 0.06 0.14 5.79 2.33 14.4 
Bulging fontanelle 246 0.16 0.04 0.62 3.37 1.35 8.40 
Rash 1009 0.30 0.17 0.50 0.50 0.33 0.77 
Abdominal pain 306 0.42 0.19 0.93 1.83 0.93 3.59 
Parental concern 159 0.72 0.18 2.84 0.47 0.15 1.49 
History of myalgia 151 0.73 0.22 2.41 0.73 0.18 2.85 
Irritability 256 0.84 0.32 2.22 3.23 1.54 6.78 
Abnormal ENT signs 921 0.84 0.54 1.31 0.45 0.30 0.68 
Heart rate 1058 1.01 1.00 1.02 1.01 1.00 1.01 
History of diarrhoea 899 1.03 0.62 1.72 0.55 0.33 0.92 
Respiratory rate 907 1.05 1.04 1.07 1.00 0.99 1.02 
Duration of fever (day) 1101 1.09 1.05 1.13 0.89 0.83 0.96 
Temperature 1092 1.23 1.03 1.47 1.22 1.05 1.42 
Prolonged Capillary Refill 
(>2s) 
909 1.37 0.63 3.02 2.08 1.15 3.75 
History of dysuria 270 1.53 0.32 7.32 3.34 1.28 8.68 
Dehydration 480 1.84 0.91 3.73 2.06 1.12 3.78 
Pallor 469 1.90 1.03 3.51 2.67 1.53 4.66 
Comorbidity 1101 2.12 1.42 3.19 0.82 0.56 1.21 
History of drowsiness 295 2.30 0.90 5.92 2.25 0.93 5.42 
Prior antibiotics 1097 2.55 1.66 3.93 1.19 0.78 1.82 
Wheeze 1074 3.21 1.84 5.60 0.20 0.05 0.83 
Ill appearance 108 3.56 0.71 17.7 2.22 0.41 12.09 
History of chest pain 118 7.75 2.06 29.1 0.01 2x10-32 1x1026 
Chest crackles 1071 8.16 5.30 12.57 0.20 0.07 0.56 
History of cough 847 9.00 3.88 20.9 0.22 0.14 0.35 
Hypoxia (Sats <92%) 963 9.29 5.35 16.10 0 0 1x1018 
Decreased Breath Sounds 1068 10.00 6.25 16.00 0.10 0.01 0.73 
Increased Work of 
Breathing 
1071 10.41 6.69 16.20 0.64 0.36 1.13 
Table 32: Odds ratios of clinical variables in univariate multinomial regression analysis for the 
outcomes of pneumonia and other SBIs. ‘n‘: number of subjects in which the variable was recorded. 
ENT: ear, nose, throat. OR: Odds ratio, LCI: lower 95% confidence interval, UCI: upper 95% 
confidence interval Variables associated with an increased risk are highlighted red, and those 
associated with a reduced risk are highlighted green. 
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Figure 21: Plot of odds ratios (with 95% confidence intervals given by horizontal bars) of clinical variables in univariate multinomial regression analysis for the 
outcomes of pneumonia and other SBIs. 
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The presence of a rash reduced the likelihood of both pneumonia and other SBIs. 
The presence of a petechial rash was associated with a reduced risk of both 
pneumonia and other SBI (Table 33). 
 
Rash (n=937) n 
Pneumonia Other SBI 
OR LCI UCI OR LCI UCI 
None 570 Ref Ref 
Maculopapular 112 0.57 0.28 1.15 0.58 0.30 1.15 
Petechial 209 0.17 0.07 0.39 0.33 0.18 0.61 
Purpuric 10 0 0 Inf 1.21 0.25 5.82 
Vesicular 18 0.87 0.19 3.97 1.60 0.51 5.14 
Other 18 0 0 Inf 0.65 0.65 2.89 
Table 33: OR for the presence of rash in univariate multinomial regression 
 
5.7.4. Multivariable risk prediction model for the diagnosis of SBI 
Using a forward stepwise model building approach, a multivariable logistic 
regression model was fitted to the derivation group (n=532) for the outcome of SBI. 
The model derived was: 
 
 
The coefficients of the derived multivariable model for the diagnosis of SBI are 
reported in Table 34. 
 
Variable beta SE z value p-value OR LCI UCI 
(Intercept) -1.676 0.490 -3.417 0.001 0.187 0.070 0.485 
CRP (<30mg/l) 0.035 0.013 2.662 0.008 1.036 1.010 1.063 
CRP (>30mg/l) 0.012 0.003 3.425 0.001 1.012 1.005 1.019 
Respiratory rate 0.031 0.011 2.828 0.005 1.031 1.010 1.054 
PCT 0.164 0.049 3.383 0.001 1.179 1.082 1.311 
Normal air entry -1.311 0.284 -4.617 0.000 0.270 0.154 0.470 
Resistin 0.004 0.002 2.128 0.033 1.004 1.000 1.007 
Table 34: Coefficients of the multivariable model for the diagnosis of SBI in the derivation group. 
 
 
logit (SBI) = -1.676027 + 0.034923 (CRP.low) + 0.011681 (CRP.high) + 0.030766 (resp.rate)  
 + 0.164464 (PCT) + (-1.311112)*(Normal.air.entry) + 0.003741 (Resistin) 
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In the derivation group, discrimination measured by the c statistic was 0.77 (95% CI 
0.72-0.82). Calibration appeared acceptable (HL test, p=0.79), though the model 
predicted a higher rate of SBI than was observed in low-risk children (Figure 22). 
 
 
Figure 22: ROC curve (left) and calibration plot (right) for the multivariable model for SBI in the derivation 
group. ROC curves are plotted using the linear predictor generated by each of the 10 imputed datasets, and the 
mean is shown in red. The blue shaded area represents the 95% CI of the ROC curve obtained by 2000 
bootstrap replicates 
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5.7.5. Internal validation of the SBI prediction model 
Discrimination of the model remained acceptable when applied to the validation 
group (C statistic 0.79 (95% CI 0.75-0.84). Calibration of the model was good (Figure 
23). 
 
Figure 23: ROC curve (left) and calibration plot (right) for the multivariable model for SBI in the 
validation group. ROC curves are plotted using the linear predictor generated by each of the 10 
imputed datasets, and the mean is shown in red. The blue shaded area represents the 95% CI of the 
ROC curve obtained by 2000 bootstrap replicates. 
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5.7.6. Derivation of multinomial risk prediction model 
Having established a parsimonious model for the diagnosis of SBI, these variables 
were fitted to a multinomial logistic regression model for the categorical diagnosis 
of pneumonia, other SBI or no SBI.  
The coefficients of the multivariable model for the diagnosis of pneumonia and 
other SBIs are documented in Table 35. The model discriminated well between 
pneumonia and no SBI, with a C statistic of 0.89 (95% CI 0.84-0.93) and between 
other SBIs and no SBI (C statistic 0.79, 95% CI 0.73-0.86). Calibration of the model 
for pneumonia was good, though the model appeared to predict fewer cases of 
other SBI than were observed (Figure 24). 
 
 
Pneumonia Other SBI 
Est OR LCI UCI Est OR LCI UCI 
(Intercept) -2.516 0.081 0.025 0.260 -2.779 0.062 0.016 0.239 
CRP (<30) 0.025 1.025 0.990 1.060 0.045 1.046 1.011 1.081 
CRP (>30) 0.010 1.010 1.003 1.018 0.012 1.012 1.005 1.019 
Respiratory rate 0.047 1.048 1.021 1.076 0.009 1.009 0.980 1.039 
PCT 0.173 1.189 1.079 1.310 0.168 1.183 1.074 1.303 
Normal air entry -2.387 0.092 0.046 0.182 0.240 1.271 0.514 3.142 
Resistin 0.003 1.003 0.999 1.008 0.004 1.004 1.000 1.007 
Table 35: Coefficients of the multivariable model using multinomial regression for the diagnosis of 
pneumonia, other SBIs and no SBI. 
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Figure 24: ROC curves (left) and calibration plots (right) for the multivariable risk prediction models 
for pneumonia (top) and other SBIs (bottom) in the derivation group. 
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5.7.7. Internal validation of multinomial risk prediction model 
The derived multinomial model was then applied to an internal validation group 
(n=569). For the diagnosis of both pneumonia, and other SBI, discrimination of the 
model was good (AUC 0.84, 95%CI 0.78 to 0.90 and 0.77, 95%CI 0.71 to 0.83 
respectively. Calibration plots revealed that the model overestimated the risk of 
pneumonia and underestimated the risk of other SBI in the validation group (Figure 
25). 
 
Figure 25: ROC curves (left) and calibration plots (right) for the multivariable risk prediction models for 
pneumonia (top) and other SBIs (bottom), applied to the validation group. 
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Performance characteristics for the multinomial model were calculated at various 
risk thresholds (Table 36). At a low-risk threshold of 5%, the model performed well 
in ruling out pneumonia (NLR 0.10, 95% CI 0.03 to 0.31), though was less good at 
ruling out other SBIs (NLR 0.28, 0.15 to 0.51). At a high-risk threshold, the models 
appeared better able to rule in other SBIs than pneumonia. A risk threshold of 20% 
achieved a PLR of 5.14 (3.81 to 6.94) for the diagnosis of other SBIs, and of 3.82 
(2.80 to 5.22) for the diagnosis of pneumonia. 
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Pneumonia 
 
Sensitivity 95% CI Specificity 95% CI PPV 95% CI NPV 95% CI PLR 95% CI NLR 95% CI 
2.5% 1 (0.88 - 1) 0.37 (0.32 - 0.41) 0.14 (0.10 - 0.18) 1 (0.97 -1) 1.58 (1.47 - 1.70) 0 NA 
5% 0.93 (0.82 - 0.99) 0.64 (0.59 - 0.69) 0.21 (0.16 - 0.27) 0.99 (0.97 - 1) 2.59 (2.24 - 3.00) 0.10 (0.03 - 0.31) 
10% 0.80 (0.65 - 0.90) 0.76 (0.72 - 0.80) 0.26 (0.19 - 0.34) 0.97 (0.95 - 0.99) 3.38 (2.71 - 4.23) 0.26 (0.15 - 0.47) 
20% 0.62 (0.47 - 0.76) 0.84 (0.80 - 0.87) 0.28 (0.20 - 0.38) 0.96 (0.93 - 0.97) 3.82 (2.80 - 5.22) 0.45 (0.31 - 0.66) 
30% 0.47 (0.32 - 0.62) 0.89 (0.86 - 0.92) 0.30 (0.20 - 0.43) 0.94 (0.91 - 0.96) 4.23 (2.81 - 6.39) 0.60 (0.46 - 0.79) 
Other SBI 
 
Sensitivity 95% CI Specificity 95% CI PPV 95% CI NPV 95% CI PLR 95% CI NLR 95% CI 
2.5% 1 (0.94 - 1) 0.00 (0 - 0.02) 0.16 (0.14 - 0.20) 1 (0.28 - 1) 1.00 (1.00 - 1.02) 0 NA 
5% 0.89 (0.80 - 0.94) 0.41 (0.36 - 0.45) 0.23 (0.19 - 0.28) 0.95 (0.90 - 0.97) 1.49 (1.34 - 1.66) 0.28 (0.15 - 0.51) 
10% 0.77 (0.67 - 0.86) 0.66 (0.61 - 0.70) 0.31 (0.25 - 0.38) 0.94 (0.90 - 0.96) 2.28 (1.91 - 2.71) 0.34 (0.23 - 0.51) 
20% 0.63 (0.52 - 0.73) 0.88 (0.84 - 0.91) 0.51 (0.41 - 0.61) 0.92 (0.89 - 0.94) 5.14 (3.81 - 6.94) 0.43 (0.33 - 0.56) 
30% 0.47 (0.36 - 0.58) 0.94 (0.91 - 0.96) 0.60 (0.48 - 0.72) 0.90 (0.87 - 0.92) 7.52 (4.90 - 11.6) 0.57 (0.47 - 0.69) 
Table 36: Performance characteristics of the multinomial model for the prediction of pneumonia (top) and other SBIs (bottom) in the validation set.
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5.8. Discussion 
5.8.1. Main findings 
This chapter details the findings of a large, prospective study of children up to 16 
years of age presenting to the Emergency Department with febrile illness. In this 
heterogeneous group, risk prediction for SBIs is possible. 
5.8.1.1. Univariate analysis 
Initial univariate analysis of our large sample reveals associations broadly in line 
with other published data6,10,96. Our finding that clinical variables such as hypoxia, 
abnormal respiratory findings, irritability and dehydration increase the likelihood of 
SBI is consistent with studies from similar settings10,96,97. We failed to demonstrate 
the value of more subjective assessments, such as an ‘ill appearance’, and ‘parental 
concern’. Recent studies which have quantified the value of an ‘ill appearance’ in 
the febrile child in ED have concluded that it is of limited value96,97, though in the 
largest recent study of clinical features of SBI in febrile children, it was of greater 
value in predicting the most serious outcome of bacteraemia6. In the low-risk 
setting of primary care, parental concern that the current illness is different to 
previous illnesses is strongly associated with the presence of serious infection, as is 
the clinician assessment that ‘something is wrong’356. This ‘gut feeling’ of the 
clinician that something is wrong, particularly when at odds with a reassuring 
clinical assessment may have diagnostic value in this setting357. Whilst we may have 
failed to consistently apply these variables, because our study made use of 
numerous clinicians with their own understanding of these assessments, we believe 
this to be a ‘real-life’ – and thus plausible – illustration of their true value. There 
was, however, also a significant problem of missing data for some of these more 
subjective assessments, and it is possible that we failed to accurately quantify their 
value.  
A ‘non-blanching’ rash in the context of the febrile child has long been considered a 
‘red flag’ sign, and remains so in the latest NICE guidelines for the management of 
fever in children under 5 years184. Of interest is the finding that, in univariate 
analysis, a petechial rash (non-blanching spots less than 2mm in diameter) is 
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associated with a reduced risk of both pneumonia and other SBIs (see Table 33). 
This requires some explanation. Firstly, the number of children included in the 
study with a petechial rash was high - moreso than, for example, a maculopapular 
rash. This is a consequence of a specific departmental protocol advocating blood 
testing in all children with fever and a petechial rash. As a result, many clinically 
well children were tested, and became eligible for the study. Upon adjustment for 
other indicators of clinical wellbeing in the multivariable model, this association 
disappears.  
The particular concern of the clinician with regard to a non-blanching rash in a 
febrile child is the possibility of septicaemia, and particularly (though not 
exclusively) meningococcal septicaemia. The high number of respiratory and urinary 
tract infections in our sample may have masked the association of a petechial rash 
with less common outcome diagnoses including bacteraemia. Multivariable 
modelling for bacteraemia was not robust as a result of its relative infrequency 
(n=35). Univariate analysis however suggests that the presence of a petechial rash 
was associated with a small increase in the likelihood of bacteraemia (OR 2.58, 95% 
CI 1.1 to 5.99). This translates into a PLR of 1.52 (95%CI 0.92 to 2.50) increasing the 
probability of bacteraemia from a pre-test probability in our sample of 3.2% to a 
post-test probability of 5.3%. Of 12 children in the study with a final diagnosis of 
MCD, 10 had a rash, of which 5 had petechiae, 3 purpura and 2 a maculopapular 
rash. 
A recent large prospective study of febrile children in ED with a low-risk of SBI failed 
to demonstrate an association between ‘rash’ and bacteraemia6. In a small recent 
study of febrile children presenting to the ED with petechial rash, a viral infection 
was identified in 39/58 children, most commonly the herpesviruses (EBV, CMV), 
enteroviruses, rhinovirus and other respiratory viruses (including RSV), and 
adenovirus. No cases of bacteraemia were identified, though 5 children had 
‘presumed sepsis’358. Even in the high-risk setting of unwell children with presumed 
meningococcal disease, a substantial proportion are found to have alternative 
diagnoses359. Non-blanching rashes, including petechial rashes may of course 
indicate serious illness, including SBI. As with other predictive clinical signs, the 
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presence of petechial spots should prompt a thorough clinical assessment, which 
may include a period of observation, and further investigation. Specifically in well 
appearing children in the era of conjugate vaccines, the value of this sign may be 
overstated however.  
5.8.1.2. Multivariable risk modelling 
A stepwise model building approach yielded a parsimonious model for the diagnosis 
of SBI which performed well in the validation group. The model made use of 
commonly collected clinical signs alongside a combination of biomarkers. Using 
these same variables we derived and validated a multinomial model which 
discriminated well between pneumonia, other SBIs and no SBI. In the validation 
group, the models predicted a higher rate of SBI - in particular, a higher rate of 
pneumonia - than was observed. This was reflected in the relative lack of specificity 
for the pneumonia model, even at high-risk thresholds (specificity 89% at a risk 
threshold of 30%, PLR 4.2).  
5.8.2. Strengths 
This is a large prospective study designed to derive and internally validate a 
prediction model comprising clinical and biomarker variables for the diagnosis of 
SBI in the children’s ED. We have measured multiple biomarkers of SBI in more than 
1000 children. We have evaluated children from birth to 16 years of age, 
irrespective of past medical history or clinical syndrome at presentation, and 
obtained comparable discrimination to other studies. In common with other recent 
data 6,96, we have demonstrated the value of a diagnostic prediction model 
combining clinical and biomarker variables. 
5.8.3. Limitations 
The study is a single centre study, and whilst we have performed internal validation 
of our derived model, external validity requires the demonstration of its value in an 
alternative setting. Our approach of using a split sample for internal validation may 
underestimate the true value of the diagnostic model, though is a robust and well 
established methodology360. 
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Diagnostic studies of this kind with imperfect reference standards require a 
pragmatic approach in order to determine outcomes. Diagnostic tests were 
requested at the discretion of the clinical team, and not all tests were performed in 
all children. This is a well-recognised limitation of studies in this context. In 
particular, an aetiological diagnosis of lower respiratory tract infections is 
challenging. We recorded only 63 positive samples for respiratory pathogens. In 
view of the fact that approximately 500 children received an outcome diagnosis of 
either an upper or lower respiratory infection, a universal application of respiratory 
pathogen detection assays may have yielded additional evidence upon which to 
base our classification. Our use of a radiological diagnosis of ‘pneumonia’, despite 
its limitations, is commonly used in this setting9,251, though some have required two 
independent radiological opinions. Despite these limitations, we believe that our 
approach, using a pre-defined composite reference standard is robust. By 
establishing clear criteria for each outcome diagnosis in advance we hope to 
minimise verification bias.  
As with other similar studies, we have only studied children already considered at 
risk of SBI, in whom the clinical team have initiated further investigation. Inevitably 
then, the overall risk of SBI in the study sample (24%) is substantially higher than 
that of all febrile children attending the ED. It remains necessary to undertake 
diagnostics research in low-risk populations (that of all children attending the ED, or 
in primary care)8. With the increasing acceptance of near patient testing, evaluating 
clinical prediction and decision tools using biomarkers in these groups is possible, 
and may have an important role in improving rational decision-making. The 
difficulty of undertaking such evaluations is not insubstantial however. Appropriate 
outcomes of interest need to be identified as the lack of extensive investigation 
precludes the use of robust outcome diagnoses, whilst the reliable collection of 
clinical data in the low-risk, high turnover setting is challenging. A large recent study 
of almost 10000 febrile children in primary care concluded that current CPRs 
derived in the ED failed to reliably predict the need for referral to hospital. Many of 
the clinical variables included in the CPRs were not routinely documented in the 
primary care setting361. 
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The process of model building was undertaken in a forward stepwise manner, testing the 
improvement in model fit at each stage (by measuring the change in residual deviance). 
With this approach a simple, parsimonious model was achieved which included three 
biomarkers and two clinical variables. This process of stepwise model building is well-
established in the context of clinical risk prediction models, but has been criticised for 
failing to identify important predictor variables from candidate variables, particularly where 
there is significant collinearity. Furthermore, stepwise variable selection may lead to biased 
regression coefficients, and overestimate precision, leading to falsely narrow confidence 
intervals362. The derived model, while simple to implement, may in addition lack the 
necessary face validity to be considered of clinical value. Clinicians may question the 
omission of clinical variables recognised to have an important association with the 
presence of serious infection. A theoretically satisfying response to each of these concerns 
is achieved with the inclusion of all variables determined to be important based upon 
clinical expertise. 
5.8.4. Next steps 
These results support a growing body of research to suggest that clinical prediction 
models can improve the prediction of risk of SBI in febrile children of all ages 
presenting to the ED. The derived models presented here require external 
validation in alternative populations before undergoing impact analysis to 
determine their value in improving decision-making in the clinical setting363. 
Our model building approach driven by associations in the data yielded a simple 
model making use of only two clinical variables alongside a combination of 
biomarkers. This is a plausible model which performs well in the validation set. The 
inclusion of two clinical signs relating to the respiratory system likely reflects the 
preponderance of respiratory infections in this setting. This process of model 
selection is open to criticism, particularly in the context of multinomial 
regression362. Our internal validation provides some reassurance of the 
appropriateness of the model, but as already stated, external validation is now 
necessary. An alternative to this approach would be to include a larger set of 
clinically relevant variables based upon the published literature irrespective of their 
apparent statistical contribution to the model. 
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Two recent diagnostic accuracy studies published the results of the use of 
multivariable CPRs in febrile children presenting to the ED9,96. A further study 
proposed the use of a combination of biomarker tests (CRP, PCT and urinalysis in 
the ‘Lab score’) and has performed well on external validation7,253,364. This dataset 
provides the opportunity to validate these rules in an external population, and also 
to examine the additional value of the multiple biomarkers measured in our 
population. This shall be the focus of the next chapter. 
 
5.9. Conclusions 
A diagnostic model combining clinical and biomarker variables discriminated well 
between pneumonia, other SBIs and no SBI in febrile children presenting to the ED. 
Improving the ability of clinicians to discriminate between SBI and self-limiting 
infections has the potential to improve rational decision-making by initiating 
prompt therapy in those with SBI, and safely discharging those without. For this 
potential to be realised, risk prediction rules such as this need to be externally 
validated before impact analysis is undertaken of decision rules designed to 
incorporate this improved risk prediction.  
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Chapter 6: External validation of risk 
prediction models and comparison using net 
reclassification improvement 
 172 
 
  
 173 
 
6.1. Overview of the chapter 
In the previous chapter, a multivariable clinical prediction model discriminated well 
between pneumonia, other SBI and no SBI, and performed well on internal 
validation. In order to realise the clinical value of improved clinical risk prediction, 
such models are required to undergo a process of external validation. In this 
chapter, I will use the dataset obtained during the SPICED study to externally 
validate three previously published clinical prediction models (by Brent9, Galetto-
Lacour7 and Nijman96). Using Net Reclassification Improvement, I will also estimate 
improvements in classification between models. 
6.2. Background 
6.2.1. The current approach to the febrile child in the ED 
Numerous studies have estimated the diagnostic accuracy of individual clinical 
signs10 and laboratory tests185 in the diagnosis of SBI in children. Recognising the 
limitations of such signs in isolation, the NICE ‘feverish illness in children’ 
guideline184, sought to combine clinical signs to improve the ability of clinicians to 
recognise serious infections. Though widely implemented in the UK, recent 
evaluations of the NICE guideline have highlighted its own limitations. In a study of 
more than 15000 febrile children under 5 years, the presence of any intermediate 
(“yellow”) or high-risk (“red”) signs resulted in a sensitivity of 86%, with a specificity 
of 28% for the diagnosis of SBI. The overall c statistic, measuring discrimination 
between SBI and no SBI was 0.64250. A subsequent analysis applying the NICE 
guideline to a further 6000 children recruited prospectively to seven studies in 
‘ambulatory care’ settings (primary care or ED), found that few of the individual 
signs had value in ruling in serious infection in more than one dataset, and in no 
dataset was the guideline able to rule out serious infection352.  
In the UK, the most commonly used tests to support the diagnosis of SBI in children 
are the White Cell Count (WCC), and CRP. A large recent evaluation of the WCC 
highlighted its limited value in this context, with a c statistic of 0.65 for the 
diagnosis of SBI. At a threshold of 15x109/l, the test achieved a positive LR of 1.93 
(95% CI 1.75 to 2.13), and a negative LR of 0.70 (0.65 to 0.75)186. CRP has been 
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evaluated more favourably. A meta-analysis which included nearly 1400 children in 
5 studies estimated a pooled positive LR of 3.15 (95% CI 2.67 to 3.71) and pooled 
negative LR of 0.33 (0.22 to 0.49)185. CRP is advocated by the NICE clinical guideline 
for use in children identified as being at risk of SBI by the ‘traffic light’ evaluation184. 
I have previously described the markers PCT, Resistin, and NGAL and their potential 
value as diagnostic biomarkers of SBI in the children’s ED (Chapter 1.6.6). Compared 
to CRP, PCT has favourable performance in the diagnosis of SBI in children, 
particularly in the early stages of infection101,189,190. In combination PCT, Resistin 
and NGAL improved the diagnosis of pneumonia in Malawian children with 
pneumonia or meningitis215. In Chapter 5, both PCT and Resistin (along with CRP) 
were demonstrated to improve the fit of a multivariable risk prediction model for 
the diagnosis of pneumonia, and other SBIs.  
6.2.2. Risk prediction of SBI in the children’s ED 
The approach taken by the NICE guideline in combining variables known to be 
associated with SBI can be formalised in the development of a CPR. Here the 
explanatory variables exert a greater or lesser influence over the risk prediction 
depending on the strength of their association with the outcome, and with each 
other. 
Though CPRs are not widely established in clinical practice in the setting of the 
febrile child, research in this area dates back more than 30 years. The earliest 
prediction rules were developed in infants less than 3 months of age. In this group, 
the conventional approach had been to admit and treat all, on the basis that in this 
high-risk group, a missed diagnosis of SBI may have serious consequences. 
Investigators therefore sought to identify those within this group at the lowest risk 
who could be safely observed or discharged. This approach led to the development 
of clinical scores such as those from Rochester187 and Philadelphia237 with the 
ability to identify low-risk infants, and thus rule out SBI. 
The previous chapter illustrated the potential value of the use of multivariable risk 
prediction for the diagnosis of SBI in children in the ED. A simple and parsimonious 
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model reliably discriminated between SBI and self-limiting illness by combining a 
small number of clinical variables with a combination of biomarkers. In the internal 
validation, the model appeared to overestimate the risk of pneumonia, and 
underestimate the risk of other SBI. In order to estimate the true value of such a 
model, a process of external validation should now be undertaken363. 
6.2.3. Translating risk prediction into clinical decision-making 
Studies of diagnostic accuracy in childhood SBI have so far failed to significantly 
impact clinical practice. Establishing a prediction rule to support decision-making in 
clinical practice is a multi-step process363. This process was well described by Reilly 
et al and is summarised in Table 37.  
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Level of Evidence Definitions and Standards 
of Evaluation 
Implications for Clinicians 
Level 1: Derivation of 
prediction rule 
Identification of predictors 
using multivariable model; 
blinded assessment of 
outcomes 
Needs validation and 
further evaluation before 
using clinically in patient 
care 
Level 2: Narrow 
validation of prediction 
rule 
Verification of predictors 
when tested prospectively 
in 1 setting; blinded 
assessment of outcomes 
Needs validation in 
various settings; may use 
predictions cautiously in 
patients similar to sample 
studied 
Level 3: Broad validation 
of prediction rule 
Verification of predictive 
model in varied settings 
with wide spectrum of 
patients and physicians 
Needs impact analysis; 
may use predictions with 
confidence in their 
accuracy 
Level 4: Narrow impact 
analysis of prediction 
rule used as a decision 
rule 
Prospective 
demonstration in 1 setting 
that use of prediction rule 
improves physician 
decisions (quality or cost-
effectiveness of patient 
care) 
May use cautiously to 
inform decisions in 
settings similar to that 
studied 
Level 5: Broad impact 
analysis of prediction 
rule used as decision rule 
Prospective 
demonstration in varied 
settings that use of 
prediction rule improves 
physician decisions for 
wide spectrum of patients 
May use in varied settings 
with confidence that its 
use will benefit patient 
care quality of 
effectiveness 
Table 37: Standards of evidence for developing and evaluating prediction rules. Taken from Reilly et al363. 
 
The SPICED study offered the opportunity to externally validate previously 
published CPRs, which may provide supportive evidence for their potential impact 
in future impact studies. We set out to externally validate CPRs published by Brent, 
Galetto-Lacour and Nijman7,9,96. 
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6.2.4. External validation of published clinical prediction rules 
6.2.4.1. Brent et al 
This study prospectively recruited 1951 children under 15 years to a diagnostic 
accuracy study over two winter periods between 2000 and 20029. The rate of SBI 
was low (3.8%). A simple risk score comprising clinical variables was derived in 1600 
children and internally validated in the remainder. The composition of the score is 
presented in Table 38.  
Clinical variable  Score 
Developmental delay No delay 
Delay 
0 
4 
Risk factor for infection None 
Present 
0 
2 
State variation Eyes open 
Eyes close briefly 
Falls asleep 
0 
1 
2 
Temperature <37.5°C 
37.5-38.4°C 
≥38.5°C 
0 
1 
2 
Capillary refill time (s) <2 
≥2 
0 
1 
Hydration status Well hydrated 
Dry mucous membranes 
Reduced skin turgor 
0 
2 
4 
Respiratory rate Not tachypnoeic 
Tachypnoeic 
0 
1 
Hypoxia Not hypoxic (SaO2 ≥95%) 
Mild hypoxia (SaO2 90% - 95%) 
Severe hypoxia (SaO2 <90%) 
0 
1 
2 
Table 38: Risk prediction score for the diagnosis of SBI derived by Brent et al
9 
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The risk score discriminated well between SBI and no SBI (c statistic 0.77). At a risk 
threshold of 5 points, the score achieved a NLR of 0.37 (95% CI 0.31 to 0.45) with a 
sensitivity of 75% and specificity of 68%.  
In order to validate the score in the SPICED dataset, the following clinical variables 
were modified: 
 State variation, categorised according to the AVPU scale in our dataset was 
re-categorised. The category ‘Awake’(A) was considered equivalent to the ‘Eyes 
open’ category reported by Brent, and ‘Unresponsive’ (U) was considered 
equivalent to the ‘Falls asleep’ category. The categories ‘Responds to voice’ (V) and 
‘Responds to pain’ (P), were combined and assigned to the intermediate ‘Falls 
asleep briefly’ category. The proportions of the new category were similar to those 
reported in the Brent paper.  
 Hydration status, categorised as ‘none’, ‘mild’, ‘moderate’ and ‘severe’ in 
the SPICED dataset were re-categorised as three categories (‘none’, ‘mild’, ‘severe’), 
and equated to the 3 categories of the variable in the Brent score (‘Well hydrated’, 
‘Dry mucous membranes’, ‘Reduced skin turgor’).  
The frequency of the re-categorised variables, along with their univariable odds 
ratios for the diagnosis of SBI are shown in Table 41.  
6.2.4.2. Galetto-Lacour et al 
The authors derived, and have since externally validated a simple score in children 
under 3 years based upon three laboratory tests (CRP, PCT and urinalysis, the ‘Lab 
score’, Table 39)7. The original study (rate of SBI 27%) estimated a sensitivity of 
94%, specificity of 78% at a risk score of 3 for the diagnosis of SBI.  
 
  
 179 
 
Predictor  Points 
PCT (ng/ml) <0.5 
≥0.5 
≥2 
0 
2 
4 
CRP (mg/l) <40 
40-99 
≥100 
0 
2 
4 
Urinalysis Negative 
Positive* 
0 
1 
Table 39: Variables included in the Lab score
7
, with weighting based upon OR in 
univariable analysis. *Positive urinalysis is test positive for either leucocyte 
esterase, or urinary nitrite. 
 
6.2.4.3. Nijman et al 
This study combined two large, prospectively collected datasets from the 
Netherlands in which to derive risk prediction models for the diagnosis of 
pneumonia, ‘other SBIs’ and ‘no SBI’ in children up to 15 years old96. The authors 
identified candidate predictor variables for the diagnosis of SBI from the published 
literature, and derived a multivariable model inclusive of each irrespective of their 
statistical contribution (Table 40). The derived model was then validated in a 
separate population recruited in the UK. 
Variable 
Age 
Sex 
Duration of fever 
Temperature 
Tachypnoea 
Tachycardia 
Hypoxia (<94%) 
Cap refill (>3s) 
Chest wall retractions 
Ill appearance 
lnCRP 
Table 40: Variables included in the clinical prediction model by Nijman
96 
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6.2.5. Comparing risk prediction models 
The identification of numerous risk prediction models poses the question, which is 
best? Traditional measures of evaluation of risk prediction models focus on 
discrimination and calibration. Thus improvement in discrimination as measured by 
the increase in the c statistic (or the AUC) of two models is a traditional measure. 
This has been quantified by DeLong365, though has been demonstrated to have 
limited power to detect differences between nested models, and to detect 
improvements over already discriminatory baseline models366. 
New measures have been developed in order to quantify improvements in model 
performance and aid comparison. One such measure estimates improvements in 
classification. This approach defines risk thresholds of clinical importance, and 
quantifies how often cases are re-classified appropriately into higher risk 
categories, and non-cases into lower risk categories. This movement can be 
quantified as a summary ‘net reclassification improvement’ (NRI)277. The NRI has 
become a popular way to estimate the incremental improvement of additional 
markers applied to prediction models, and has particular attraction when 
associated with clinical scenarios in which risk thresholds are well defined, and 
associated with clear clinical decisions. Where such thresholds fail to exist, the 
relevance of reclassification across arbitrary thresholds is less clear. In this case, 
justification of the risk thresholds chosen ought to be made based upon related 
clinical situations, or upon the event rate. As an alternative, the category-free NRI 
considers all changes in predicted risk irrespective of risk thresholds, quantifying 
the net percentage of subjects with or without events who are correctly assigned a 
different predicted risk. Thus it requires no assumptions to be made about the 
clinical relevance of risk thresholds. It is of limited value however in quantifying 
overall model performance, and fails to indicate the potential impact of decision-
making based upon the two models367. 
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6.3. Hypothesis 
Improvements in the classification of febrile children presenting to the ED can be 
achieved by the addition of the biomarkers PCT and Resistin to a previously 
validated clinical risk prediction models by Nijman96. 
6.4. Aims and objectives 
I. To externally validate published risk prediction models for the diagnosis 
of SBI in febrile children presenting to the ED7,9,96 
II. To re-fit the externally validated models in multinomial regression 
models for the categorical outcome of ‘pneumonia’, ‘other SBI’, and ‘no 
SBI’. 
III. To estimate the improvement in classification of a multivariable model 
derived in the SPICED study (the ‘SPICED’ model) to that achieved by the 
use of CRP as recommended by the NICE guideline “Feverish illness in 
children”184. 
IV. To estimate the improvement in classification achieved by the addition 
of the biomarkers PCT and Resistin to CRP alone. 
V. To estimate the improvement in classification achieved by the addition 
of the biomarkers PCT and Resistin to the validated multivariable model 
by Nijman (the ‘Nijman’ model)96. 
 
6.5. Methods 
The SPICED study has been explained in detail in Chapter 5.  
6.5.1. Performance characteristics of CRP 
The diagnostic accuracy of CRP alone was estimated by developing first a logistic 
regression model for the diagnosis of SBI, followed by multinomial regression 
models for the diagnosis of pneumonia, other SBI, and no SBI. As previously 
described, CRP was fit as a piecewise linear term with a breakpoint at 30 mg/l. 
Missing data was imputed 10 times using the MICE algorithm described in Section 
5.6.3.3, and regression analysis undertaken on the pooled dataset. Discrimination 
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of the model was measured by c statistic, and calibration of the models estimated 
by the Hosmer-Lemeshow test, and illustrated using calibration plots of predicted 
risk versus observed frequency of events. 
6.5.2. External validation of previously published models 
External validation of the three published clinical prediction rules was undertaken 
in the multiply imputed SPICED dataset. Proxy variables (whereby clinical variables 
recorded in each dataset were comparable, but not identical) were identified and 
categorised appropriately. Initial validation of the Brent score and the Lab score 
was undertaken maintaining the categorical nature of the data (Table 38 and Table 
39), and discrimination of the score evaluated using the c statistic. Subsequently, 
logistic regression and multinomial regression models were fitted to the multiply 
imputed dataset incorporating the variables of the two scores, and discrimination 
and calibration once more evaluated.  
External validation of the Nijman model was performed using the published 
coefficients of the multinomial regression analysis, and using the transformations 
described. This model was then re-fitted to the multiply imputed SPICED dataset 
and discrimination and calibration measured.  
6.5.3. Net reclassification improvement  
Classification of subjects was compared using Net Reclassification Improvement 
(NRI). Three category NRI was performed using the ‘rap’ function in R368, with 
weighted reclassification of more than one risk category367. Presently, no risk 
thresholds are established in clinical practice to guide decision-making in febrile 
children in the ED. We report the use of NRI with the following risk categories: low 
(<=5%), intermediate (5-20%), and high (>20%). These thresholds equate roughly to 
half, and double the event rate for both pneumonia (10%) and other SBI (14%). This 
approach has more clinical utility than the continuous NRI, and is analogous to the 
‘traffic light’ approach taken by the NICE guidance. 
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6.6. Results 
6.6.1. Performance characteristics of CRP 
The diagnostic accuracy of CRP was assessed by fitting regression models for the 
diagnosis of SBI, and subsequently the categorical diagnosis of pneumonia, other 
SBI, or no SBI to the multiply imputed dataset.  
Discrimination of the CRP model for the diagnosis of SBI was limited (c statistic 0.75, 
95% CI 0.71 to 0.78). Calibration was good, although the model failed to predict 
children at low risk of SBI (Figure 26). In multinomial regression model for the 
categorical diagnosis of pneumonia, other SBI and no SBI, discrimination of both 
models was limited (c statistic 0.72 and 0.75 for the diagnosis of pneumonia and 
other SBIs respectively, Figure 27). 
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Figure 26: ROC curve (top) and calibration plot (bottom) for the CRP model for the diagnosis of SBI in the 
multiply imputed dataset. ROC curves are plotted using the linear predictor generated by each of the 10 
imputed datasets, and the mean is shown in red. The blue shaded area represents the 95% CI of the ROC curve 
obtained by 2000 bootstrap replicates. 
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Figure 27: ROC curves (left) and calibration plots (right) of the CRP model for the diagnosis of pneumonia (top) 
and other SBI (bottom) in the multiply imputed dataset. ROC curves are plotted using the linear predictor 
generated by each of the 10 imputed datasets, and the mean is shown in red. The blue shaded area represents 
the 95% CI of the ROC curve obtained by 2000 bootstrap replicates 
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6.6.2. External validation of previously published risk prediction models 
6.6.2.1. Brent clinical risk score 
The clinical risk score as described in Table 38 was validated in the multiply imputed 
SPICED dataset for the binary diagnosis of SBI. The score discriminated poorly 
between SBI and no SBI with a c statistic of 0.65 (95% CI 0.61 to 0.68, Figure 28).  
The variables in the Brent score were the re-fitted to the dataset in a multivariable 
logistic regression model. Table 41 records the frequency of the categorical 
variables included in the risk model, and the odds ratios of each variable for the 
diagnosis of SBI. Discrimination of the model remained poor (c statistic 0.65, 95%CI 
0.61 to 0.69). Calibration of the model was good, though the calibration plot 
highlighted that the model was unable to predict children at low risk of SBI (Figure 
29). 
 
Figure 28: ROC curve for the external validation of the Brent clinical score in the multiply imputed dataset 
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Variable Category n SBI % OR LCI UCI 
Risk factor for infection No  1054 244 23.15    
 
Yes 43 20 46.51 2.362 1.180 4.727 
Developmental delay No  1043 243 23.30    
 
Yes 56 21 37.50 1.335 0.691 2.579 
State variation Awake 1077 257 23.86    
 
Briefly asleep 14 3 21.43 0.949 0.251 3.592 
 
Asleep 5 0 0.00 0.004 0.000 >1x10
6 
Temp <37.5 451 95 21.06    
 
37.5-38.5 313 75 23.96 1.179 0.812 1.713 
 
>38.5 337 94 27.89 1.324 0.910 1.927 
Tachypnoea No  654 117 17.89    
 
Yes 447 147 32.89 1.804 1.298 2.506 
Cap refill <2s 978 225 23.01    
 
>=2s 123 39 31.71 1.186 0.767 1.834 
Hypoxia None (>95%) 904 188 20.80    
 
Mild (90-95%) 162 57 35.19 1.572 1.025 2.412 
 
Severe (<90%) 35 19 54.29 2.162 1.138 4.110 
Hydration status None 355 67 18.87    
 
Mild 86 28 32.56 1.336 0.801 2.230 
 
Severe 16 4 25.00 1.226 0.459 3.271 
Table 41: Frequency of categorical variables included in the risk score derived by Brent et al
9
, and their odds 
ratios (OR, with 95% upper and lower confidence intervals) when fit to a multivariable model for the prediction 
of SBI. 
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Figure 29: ROC curve (top) and calibration plot (bottom) of the Brent score fitted to the SPICED dataset for the 
diagnosis of SBI 
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A multinomial regression model with the categorical outcome ‘pneumonia’, ‘other 
SBI’, and ‘no SBI’ was then fitted to the data. This approach yielded improved 
discrimination between pneumonia and no SBI (c statistic 0.82), but poor 
discrimination between other SBIs and no SBI (c statistic 0.64,Figure 30). Calibration 
of both models was good. 
 
 
Figure 30: ROC curves (left) and calibration plots (right) for the risk prediction model for pneumonia 
(top) and other SBI (bottom) based upon the Brent clinical risk score. 
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6.6.2.2. Galetto-Lacour ‘Lab score’ 
External validation of the Lab score published by Galetto-Lacour et al7 was 
performed. The published clinical score (as described in Table 39) demonstrated 
reasonable discrimination between SBI and no SBI (c statistic 0.79,Figure 31).  
 
Figure 31: ROC curve of the Lab score performed on the multiply imputed dataset for the diagnosis of SBI. 
 
The variables in the Lab score were fitted to a logistic regression model for the 
diagnosis of SBI. The c statistic estimated by the mean of the linear predictors 
generated by the multiple imputations was 0.84 (Figure 32). It is notable that the 
ROC curve generated by the mean of the linear predictors differed significantly 
from that of the individual imputations, which largely fell outside of the confidence 
intervals. A complete case analysis was performed in this case (n=223). In this 
group, the model discriminated well (c statistic 0.82, 95% CI 0.74 – 0.90, Figure 33). 
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Figure 32: ROC curve of the re-fitted Lab score for the diagnosis of SBI in the multiply imputed dataset. 
 
Figure 33: ROC curve of the Lab score for the diagnosis of SBI. Complete case analysis (n=223). 
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The variables of the Lab score were then fitted to a multinomial regression model, 
for the categorical diagnosis of pneumonia, other SBI and no SBI (Figure 34).The 
models discriminated reasonably well, and were well calibrated. For the diagnosis 
of ‘other SBIs’, the overall c statistic estimated by the mean of the linear predictors 
was again higher than that of the individual imputed datasets. 
 
Figure 34: ROC curves (top) and calibration plots (right) for the fitted Lab score model for the diagnosis of 
pneumonia (top) and other SBIs (bottom) 
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6.6.2.3. Nijman clinical prediction model 
The Nijman model96 was validated using the published model coefficients. The 
model discriminated well between pneumonia and no SBI, though performed less 
well for the diagnosis of other SBIs. The calibration plots suggested an 
underestimation of the risk of pneumonia, and an overestimation of the risk of 
other SBIs (Figure 35). 
 
Figure 35: ROC curves (left) and calibration plots (right) of the published multinomial model of Nijman et al for 
the diagnosis of pneumonia (top) and other SBIs (bottom). 
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The variables in the Nijman model were then re-fitted to the dataset. Model 
discrimination and calibration was good (Figure 36). The performance 
characteristics of this re-fitted model at different risk thresholds are recorded in 
Table 42. 
 
Figure 36: ROC curves (left) and calibration plots (right) of the re-fitted model of Nijman et al for the 
diagnosis of pneumonia (top) and other SBIs (bottom). 
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Table 42: Performance characteristics of the Nijman variables fitted to the multiply imputed SPICED dataset. PPV: positive predictive value, NPV: negative predictive value, PLR: positive 
likelihood ratio, NLR: negative likelihood ratio. 
  
Pneumonia 
 Sensitivity 95% CI Specificity 95% CI PPV 95% CI NPV 95% CI PLR 95% CI NLR 95% CI 
2.5% 0.93 (0.86 - 0.97) 0.51 (0.47 - 0.55) 0.20 (0.16 - 0.24) 0.98 (0.96 - 0.99) 1.91 (1.75 - 2.08) 0.14 (0.07 - 0.28) 
5% 0.89 (0.81 - 0.94) 0.70 (0.67 - 0.73) 0.28 (0.23 - 0.33) 0.98 (0.97 - 0.99) 2.98 (2.63 - 3.37) 0.16 (0.09 - 0.27) 
10% 0.81 (0.79 - 0.88) 0.82 (0.79 - 0.84) 0.36 (0.30 - 0.43) 0.97 (0.95 - 0.98) 4.41 (3.72 - 5.23) 0.24 (0.16 - 0.35) 
20% 0.69 (0.60 - 0.78) 0.89 (0.87 - 0.91) 0.45 (0.38 - 0.53) 0.96 (0.94 - 0.97) 6.46 (5.12 - 8.14) 0.34 (0.26 - 0.46) 
30% 0.60 (0.92 - 0.96) 0.94 (0.92 - 0.96) 0.58 (0.48 - 0.67) 0.95 (0.93 - 0.96) 10.5 (7.66 - 14.4) 0.42 (0.33 - 0.53) 
Other SBI 
 Sensitivity 95% CI Specificity 95% CI PPV 95% CI NPV 95% CI PLR 95% CI NLR 95% CI 
2.5% 0.99 (0.96 - 1.0) 0.09 (0.07 - 0.11) 0.17 (0.15 - 0.19) 0.99 (0.93 - 1.00) 1.09 (1.06 - 1.12) 0.07 (0.01 - 0.50) 
5% 0.97 (0.93 - 0.99) 0.24 (0.21 - 0.27) 0.19 (0.17 - 0.22) 0.98 (0.95 - 0.99) 1.28 (1.22 - 1.34) 0.13 (0.06 - 0.31) 
10% 0.83 (0.77 - 0.89) 0.58 (0.55 - 0.62) 0.27 (0.23 - 0.31) 0.95 (0.93 - 0.97) 1.99 (1.79 - 2.21) 0.29 (0.20 - 0.41) 
20% 0.56 (0.48 - 0.64) 0.89 (0.87 - 0.91) 0.49 (0.41 - 0.56) 0.92 (0.90 - 0.93) 5.13 (4.04 - 6.50) 0.49 (0.41 - 0.59) 
30% 0.4 (0.32 - 0.48) 0.95 (0.94 - 0.97) 0.61 (0.51 - 0.70) 0.89 (0.87 - 0.91) 8.31 (5.80 - 11.9) 0.63 (0.56 - 0.72) 
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6.6.3. Net reclassification improvement 
6.6.3.1. Comparison of CRP alone with the multivariable SPICED 
model 
Diagnostic accuracy achieved by the use of CRP alone was compared to that 
achieved by the multivariable SPICED model (Chapter 5). This comparison was 
undertaken in the validation group. In this group, CRP demonstrated limited 
discrimination. Discrimination using the c statistic was 0.72 (95% CI 0.63 to 0.80) for 
the diagnosis of pneumonia and 0.75 (0.68 to 0.81) for the diagnosis of other SBIs. 
Discrimination achieved by the SPICED model was 0.84 (0.78 to 0.90, p=0.004 for 
the difference) for pneumonia, and 0.77 (0.71 to 0.83, p=0.38) for other SBIs. 
Reclassification of subjects by the two models is presented in Table 43. There was a 
substantial improvement in the classification of non-events of 58.9% (50.4 to 
67.5%), and 40.4% (33.9 to 46.8%) for pneumonia and other SBI respectively. 
Though there was no significant change in the classification of pneumonia events, 
there was a significant reduction in appropriate classification of other SBI events. Of 
88 other SBIs in this validation group, 38 were inappropriately classified as low-risk 
(<5%) by the SPICED model. As the CRP model failed to classify any children as low-
risk, this resulted in a NRI of -60.2% (-77.7 to -42.8%). This is consistent with the 
calibration plots which revealed a higher observed rate of other SBIs than that 
predicted by the SPICED model (NLR at a threshold of 5% 0.28, 95%CI 0.15 to 0.51, 
Chapter 5, Table 36). 
6.6.3.2. Comparison of CRP with CRP, PCT and Resistin 
Diagnostic accuracy achieved by the use of CRP alone was compared to that 
achieved by the combination of CRP, PCT and Resistin. Discrimination of the 
multiple biomarker model using the c statistic was 0.75 (95% CI 0.70 to 0.80) and 
0.78 (95% CI 0.73 to 0.83) for the diagnosis of pneumonia and other SBIs 
respectively. This compares with values of 0.72 and 0.75 for the CRP model (p-value 
for the difference 0.04 and 0.06 respectively). 
The models were compared using 3 category NRI. Reclassification according to 
outcome is summarised in Table 44. For the diagnosis of pneumonia, NRI for events 
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was 3.7% (95% CI -3.1 to 10.5%) and for non-events, NRI was 7.8% (5.6% to 9.9%), 
and overall NRI 0.11 (0.04 to 0.18). For the diagnosis of other SBIs, there was a 9.6% 
improvement in classification of events (4.4% to 14.8%), though no difference in the 
classification of non-events (NRI 0%, -1.5% to 1.5%), and overall NRI 0.10 (0.05 to 
0.15). Notably, neither of these models was able to classify children into a low 
(<5%) risk group.  
6.6.3.3. Addition of PCT and Resistin to the Nijman model 
The externally validated Nijman model, with variables fitted to the SPICED dataset 
was compared with an extended model including PCT and Resistin. Discrimination 
and calibration of the original model (as shown previously in Figure 36) was good. 
Extension of the model by the addition of PCT and Resistin resulted in an 
improvement in AUC for the diagnosis of pneumonia from 0.88 to 0.90 (p=0.03) and 
for the diagnosis of other SBIs from 0.82 to 0.84 (p=0.03) 
The performance characteristics of the extended model at various risk thresholds is 
summarised in  
Table 45. At a low-risk threshold of 5%, the extended model had a sensitivity of 91% 
(95%CI 84 to 95%) for the diagnosis of pneumonia with a negative likelihood ratio 
(NLR) of 0.13 (0.07 to 0.24). For other SBIs, the model sensitivity was 97% (93 to 
99%), with a NLR 0.12 (0.05 to 0.28). At the high-risk threshold (>20%), the model 
specificity was 91% (95%CI 88 to 92%) for the diagnosis of pneumonia, with a 
positive likelihood ratio (PLR) of 7.55 (5.93 to 9.62), and was 91% (88 to 92%) for 
the diagnosis of other SBI, with a PLR of 6.52 (5.11 to 8.32).  
Three category NRI revealed moderate improvements with the extended model 
(Table 46). For events the NRI achieved by the addition of PCT and Resistin was 
2.8% (95% CI -0.4% to 5.9%) and 4.5% (-0.6 to 9.6%) for pneumonia and other SBI 
respectively. For non-events, this was 1.1% (-0.5 to 2.7%) and 5.3% (3.0 to 7.5%). 
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Pneumonia=1 Derived multivariable model NRI 
CRP <5% 5-20% >20% Total Event SE Z LCI UCI 
<5% 0 0 0 0 0.000 0.104 0.000 -0.204 0.204 
5-20% 6 11 12 29 
>20% 1 4 11 16 
Total 7 15 23 45 
Pneumonia=0 Derived multivariable model NRI 
CRP <5% 5-20% >20% Total Non event SE Z LCI UCI 
<5% 0 0 0 0 0.610 0.043 14.059 0.525 0.695 
5-20% 294 69 46 409 
>20% 3 12 12 27 Summary NRI 0.61 (0.41 to 0.84) 
Total 297 81 58 436 
Other SBI=1 Derived multivariable model NRI 
CRP <5% 5-20% >20% Total Event SE Z LCI UCI 
<5% 0 0 0 0 -0.602 0.089 -6.786 -0.776 -0.428 
5-20% 35 4 7 46 
>20% 3 19 20 42 
Total 38 23 27 88 
Other SBI=0 Derived multivariable model NRI 
CRP <5% 5-20% >20% Total Non event SE Z LCI UCI 
<5% 0 0 0 0 0.851 0.044 19.158 0.764 0.938 
5-20% 333 57 2 392 
>20% 9 22 13 44 Summary NRI 0.25 (0.11 to 0.39) 
Total 342 79 15 436 
Table 43: Reclassification of subjects from CRP model to the SPICED model for the prediction of pneumonia (top) and other SBI (bottom) in 
the validation group 
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Pneumonia=1 CRP, PCT, Resistin NRI 
CRP <5% 5-20% >20% Total Event SE Z LCI UCI 
<5% 0 0 0 0 0.037 0.035 1.069 -0.031 0.105 
5-20% 3 64 9 76 
>20% 0 2 30 32 
Total 3 66 39 108 
Pneumonia=0 CRP, PCT, Resistin NRI 
CRP <5% 5-20% >20% Total Non event SE Z LCI UCI 
<5% 0 0 0 0 0.078 0.011 7.135 0.056 0.099 
5-20% 69 714 9 792 
>20% 0 5 40 45 Summary NRI 0.107 (95% CI 0.038 to 0.176) 
Total 69 719 49 837 
Other SBI=1 CRP, PCT, Resistin NRI 
CRP <5% 5-20% >20% Total Event SE Z LCI UCI 
<5% 0 0 0 0 0.096 0.026 3.638 0.044 0.148 
5-20% 0 66 16 82 
>20% 0 1 73 74 
Total 0 67 89 156 
Other SBI=0 CRP, PCT, Resistin NRI 
CRP <5% 5-20% >20% Total Non event SE Z LCI UCI 
<5% 0 0 0 0 0 0.008 0.000 -0.015 0.015 
5-20% 0 737 21 758 
>20% 0 21 58 79 Summary NRI 0.096 (95% CI 0.045 to 0.148) 
Total 0 758 79 837 
Table 44: Reclassification of subjects from CRP model to multiple biomarkers model for the prediction of pneumonia (top) and other SBI 
(bottom) in the validation group 
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Table 45: Performance characteristics of the Nijman model extended by the inclusion of the biomarkers Procalcitonin and Resistin. PPV: positive predictive value, NPV: 
negative predictive value, PLR: positive likelihood ratio, NLR: negative likelihood ratio. 
  
Pneumonia 
 Sensitivity 95% CI Specificity 95% CI PPV 95% CI NPV 95% CI PLR 95% CI NLR 95% CI 
2.5% 0.94 (0.88 - 0.98) 0.52 (0.48 - 0.55) 0.20 (0.17 - 0.24) 0.99 (0.97 - 0.99) 1.96 (1.80 - 2.13) 0.11 (0.05 - 0.23) 
5% 0.91 (0.84 - 0.95) 0.7 (0.67 - 0.73) 0.28 (0.23 - 0.33) 0.98 (0.97 - 0.99) 3.04 (2.69 - 3.43) 0.13 (0.07 - 0.24) 
10% 0.83 (0.75 - 0.90) 0.83 (0.80 - 0.85) 0.38 (0.32 - 0.45) 0.97 (0.96 - 0.98) 4.78 (4.03 - 5.66) 0.20 (0.13 - 0.31) 
20% 0.71 (0.62 - 0.80) 0.91 (0.88 - 0.92) 0.49 (0.41 - 0.57) 0.96 (0.94 - 0.97) 7.55 (5.93 - 9.62) 0.32 (0.24 - 0.43) 
30% 0.60 (0.50 - 0.69) 0.94 (0.92 - 0.96) 0.57 (0.47 - 0.66) 0.95 (0.93 - 0.96) 10.3 (7.53 - 14.0) 0.42 (0.34 - 0.53) 
Other SBI 
 Sensitivity 95% CI Specificity 95% CI PPV 95% CI NPV 95% CI PLR 95% CI NLR 95% CI 
2.5% 0.99 (0.95 - 1.00) 0.09 (0.07 - 0.11) 0.17 (0.14 - 0.19) 0.97 (0.91 - 1.00) 1.08 (1.05 - 1.11) 0.15 (0.04 - 0.60) 
5% 0.97 (0.93 - 0.99) 0.27 (0.24 - 0.31) 0.20 (0.17 - 0.23) 0.98 (0.95 - 0.99) 1.33 (1.27 - 1.40) 0.12 (0.05 - 0.28) 
10% 0.83 (0.77 - 0.89) 0.67 (0.63 - 0.70) 0.32 (0.27 - 0.36) 0.96 (0.94 - 0.97) 2.49 (2.21 - 2.80) 0.25 (0.18 - 0.36) 
20% 0.62 (0.53 - 0.69) 0.91 (0.88 - 0.92) 0.55 (0.47 - 0.62) 0.93 (0.91 - 0.94) 6.52 (5.11 - 8.32) 0.42 (0.35 - 0.52) 
30% 0.50 (0.42 - 0.58) 0.95 (0.93 - 0.96) 0.63 (0.54 - 0.72) 0.91 (0.89 - 0.93) 9.30 (6.72 - 12.9) 0.53 (0.45 - 0.62) 
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Pneumonia=1 Extended Nijman (+ PCT,RTN) NRI 
Nijman <=5% 5-20% >20% Total Event SE Z LCI UCI 
<=5% 10 2 0 12 0.028 0.016 1.732 -0.004 0.059 
5-20% 0 19 1 20 
>20% 0 0 76 76 
Total 10 21 77 108 
Pneumonia=0 Extended Nijman (+ PCT,RTN) NRI 
Nijman <=5% 5-20% >20% Total Non event SE Z LCI UCI 
<=5% 573 14 1 588 0.010 0.008 1.131 -0.007 0.026 
5-20% 14 142 5 161 
>20% 0 15 73 88 Summary NRI 0.039 (95% CI 0.004 to 0.074) 
Total 587 171 79 837 
Other SBI=1 Extended Nijman (+ PCT,RTN) Modified NRI 
Nijman <5% 5-20% >20% Total Event SE Z LCI UCI 
<5% 4 1 0 5 0.045 0.026 1.750 -0.005 0.095 
5-20% 1 50 11 62 
>20% 0 4 85 89 
Total 5 55 96 156 
Other SBI=0 Extended Nijman (+ PCT,RTN) Modified NRI 
Nijman <5% 5-20% >20% Total Non event SE Z LCI UCI 
<5% 190 11 0 201 0.053 0.010 5.014 0.032 0.073 
5-20% 39 491 11 541 
>20% 0 27 68 95 Summary NRI 0.097 (0.041 to 0.154) 
Total 229 529 79 837 
Table 46: Reclassification of subjects from the Nijman model to a model extended by the inclusion of PCT and Resistin. (Top) pneumonia. 
(Bottom) Other SBI. 
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6.7. Discussion 
6.7.1. Main results 
6.7.1.1. External validation 
The SPICED study presented the opportunity to externally validate previously 
published clinical prediction rules. This external validation is a necessary stage in 
the process of estimating the true value of a diagnostic test. 
Consistent with other evaluations, CRP demonstrated reasonable discrimination 
between subjects with and without SBI (c statistic 0.75), but was unable to identify 
children at low risk of SBI.  
The Brent score failed to discriminate well between subjects with and without SBI (c 
statistic 0.65), nor between other SBI and no SBI (c statistic 0.64). The score 
discriminated better between cases of pneumonia and no SBI (c statistic 0.82). This 
is the first external validation of this risk score. The difference in model 
performance from that achieved in the derivation study may relate to the 
significant difference in the rate of SBI (24% v 3.8%).  
The Lab score demonstrated reasonable discrimination between SBI and no SBI (c 
statistic 0.79). When the model was re-fitted using CRP and PCT as continuous 
variables, a discrepancy was evident between the ROC curves plotted by the linear 
predictors of the individual imputations, and that of the pooled linear predictors. 
This is likely a result of the high proportion of urinalysis observations missing (80%). 
A complete case analysis (n=223) estimated a c statistic of 0.82 (95% CI 0.74 to 
0.90). Using multinomial regression analysis, the model appeared to discriminate 
better between other SBI and no SBI, than pneumonia and no SBI (c statistic 0.87 
and 0.78 respectively). Model calibration was acceptable. 
External validation of the Nijman model revealed encouraging discrimination (c 
statistic 0.85 and 0.76 for the diagnosis of pneumonia and other SBI respectively). 
Calibration of the models was good, though the models underestimated the risk of 
pneumonia and overestimated the risk of other SBIs.  
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6.7.1.2. Comparison using net reclassification improvement  
Comparison of CRP alone with a combination of CRP, PCT and Resistin revealed 
improvements in classification for both pneumonia and other SBI (overall NRI 0.11 
and 0.10 respectively). The addition of the biomarkers PCT and Resistin particularly 
improved the classification of other SBI events (NRI 9.6%, 95% CI 4.4 to 14.8%), and 
pneumonia non-events (NRI 7.8%, 5.6% to 9.9%). 
There was a substantial improvement in classification when comparing the SPICED 
model to CRP. Overall NRI was 0.61 (0.41 to 0.84) for pneumonia, and 0.25 (0.11 to 
0.39) for other SBIs. In particular this was a reclassification improvement of non-
events for both pneumonia (61%, 41 to 84%) and other SBI (85%, 76 to 94%). This 
reflects the failure of the CRP model to identify children at low risk (<5%). With the 
SPICED model, however, there was a 60% (43 to 78%) inappropriate net 
reclassification of other SBIs to lower risk categories. The baseline CRP model has a 
sensitivity of 100% at this low-risk threshold, as it fails to classify any subject below 
this level. By contrast at a 5% risk threshold the SPICED model only achieves a 
sensitivity of 58% and a NLR of 0.54 (see Table 36, Chapter 5). The SPICED model is 
not sufficiently sensitive to rule out other SBIs. For the diagnosis of pneumonia, at a 
risk threshold of 5%, the SPICED model achieves a NLR of 0.14, and a sensitivity of 
91%. 
The addition of the biomarkers PCT and Resistin to the published Nijman model 
achieved a small improvement in discrimination for both the pneumonia and other 
SBI models (c statistic increased from 0.89 to 0.90, and from 0.82 to 0.84 
respectively; p=0.03 for the difference), and in classification. Overall NRI was 0.04 
and 0.10 for pneumonia and other SBI models respectively. Significantly, there was 
a 5.3% (3.2 to 7.3%) improvement in the classification of non-events achieved by 
the extended other SBI model. This incremental improvement was achieved despite 
a good baseline model. 
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6.7.2. Strengths 
This external validation presents further evidence of the value of multivariable risk 
prediction in our large, prospectively recruited sample. In particular the 
performance characteristics of the Nijman model are encouraging. The application 
of multiple risk thresholds has the potential to support rational decision-making in 
the ED. A low-risk threshold (<5%), with a NLR of 0.16 (pneumonia) or 0.13 (other 
SBIs) may support a decision to discharge, and to withhold antibiotic treatment. 
Conversely a high-risk threshold (>20%) with PLRs of 6.46 and 5.13 for pneumonia 
and other SBIs respectively, may expedite prompt recognition and treatment. This 
approach results in a substantial improvement in classification when compared to 
the current NICE recommendation of the use of CRP in children considered at risk of 
SBI. In particular, the risk model allows the reclassification of children into a low-
risk category (<5%) which has the potential to support the clinician to rule out SBI. 
The reliable classification of children into risk categories could be incorporated into 
decision rules to guide clinicians regarding further investigation, treatment and 
disposition (admit or discharge). 
We have estimated the benefit of the addition of PCT and Resistin to the Nijman 
model. Using net reclassification improvement, we suggest that this approach may 
have a role in improving rational decision-making, particularly in the process of 
ruling out SBI. In the context of a recent increase in hospital admissions for short-
stay uncomplicated admissions for young children22,49, and also with regard to 
rational antibiotic use at a time of increasing antimicrobial resistance, this deserves 
further exploration.  
We propose the use of 3 category NRI utilising risk thresholds of 5% and 20% to 
define low, intermediate and high-risk children. This categorisation is not yet 
established in the context of predicting SBI in the children’s ED, but is based upon 
the event rate in this setting, and is analogous to the approach advocated by the 
current NICE consensus guideline. Our analysis provides clinically useful indications 
of the relative value of risk models in this setting, and could form the basis of 
decision rules upon which to perform impact analysis.  
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6.7.3. Limitations 
The SPICED study was a large, prospective study which collected data on multiple 
clinical and laboratory variables. Despite significant investment from both research 
and clinical teams, data recording was not complete. In the busy children’s ED, this 
is not unusual, and substantial efforts were made to mitigate the problem of 
incomplete data. We have undertaken a process of missing data imputation based 
on the assumption of the data being missing at random, and have demonstrated 
plausible missing data imputations. Importantly, assessments of the discrimination 
of the individual imputed datasets largely fell within the confidence interval of the 
pooled analysis. In the external validation of the Lab score, however, this appears 
not to be the case. Given the simple structure of the Lab score, which is based upon 
only three variables, and the proportion of missing data of one of these variables in 
our dataset (urinalysis was only recorded in approximately 20% of the SPICED 
dataset), this is perhaps unsurprising. Our complete case analysis should be 
interpreted with caution, as the performance of urinalysis is associated with the 
outcome. That is, the test was performed in those in whom it is most likely of value. 
We have undertaken a comparison of a multivariable model with that of CRP alone, 
on the basis that CRP is advocated in febrile children considered at risk of SBI. We 
acknowledge that clinicians do not use CRP in isolation, but believe that the study 
population constitutes the same group identified as being at risk in the NICE 
guidance, and our assertion is that evaluating risk in an integrated way in this group 
is preferable to interpreting a blood test performed in addition to the clinical 
assessment.  
 
6.7.4. Next steps 
The demonstration of a discriminatory risk prediction model (the Nijman model) on 
external validation prompts further research to evaluate the impact of decision-
making based upon such a model. This process of impact analysis is important and 
often overlooked in diagnostic research363, and particularly so in children234. 
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The evaluation of impact requires that discriminatory risk prediction rules or 
models are developed into practical clinical decision rules (CDRs). CDRs help 
clinicians to make specific decisions based upon discriminatory and accessible 
diagnostic variables which are evidence-based369. This impact analysis of CDRs falls 
within the remit of implementation science. Implementation science evaluates the 
methods which support sustained uptake of research findings into clinical practice. 
The demonstration of adequate risk prediction may not be sufficient to convince 
clinicians of the value of this risk based decision-making.  
Recent impact studies in the area illustrate this challenge. The Lab score was 
evaluated in a randomised controlled trial of antibiotic prescribing in 271 children 
under 3 years with fever without source. Though the Lab score performed well in 
predicting SBI (AUC 0.91), and recommended 30% fewer antibiotic treatments than 
the control, no reduction of antibiotic prescribing was demonstrated due to lack of 
adherence to the decision algorithm370. Similarly, a CDR based upon the Nijman risk 
prediction model also failed to demonstrate impact in a recent randomised 
controlled trial of 439 children up to 16 years371. In this case, risk predictions 
remained reliable, and compliance with the CDR was high, but no impact upon 
outcomes such as length of hospital (or ED) stay, or likelihood of hospital admission 
were observed. 
Such findings highlight the need to understand barriers to the implementation of 
evidence-based CDRs. The involvement of clinicians and families in discussions 
about how to translate estimates of risk into sound clinical decision-making is 
necessary. The agreement of appropriate risk thresholds for example will require 
consensus agreement if they are to underpin decision rules. Whilst there may be a 
general acceptance that too many febrile children receive unnecessary treatment, 
any recalibration of risk which increases the possibility of missed SBI will require 
careful consideration. 
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6.8. Conclusions 
Multivariable risk prediction in febrile children of all ages presenting to the ED is 
possible. In particular this approach has the potential to safely rule out SBI, and 
improve decision-making regarding admission to hospital and rational antimicrobial 
prescribing. Well-designed implementation studies are required to identify barriers 
to the introduction of CDRs based upon robust and discriminatory risk prediction 
models.  
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7.1. Major findings 
The work presented in this thesis illustrates the ongoing challenge of the 
recognition of SBI in febrile children presenting to the ED. We detail how the 
aetiology of bacteraemia has evolved over the last decade and the implications of 
this in terms of recognition and appropriate antimicrobial therapy. We demonstrate 
the use of 16S rRNA PCR with sequencing (SepsiTest) in whole blood for the first 
time in this setting, and conclude that at present this approach remains only an 
adjunct to blood culture in high-risk children. Finally we present further evidence of 
the ability of multivariable risk prediction to discriminate between children with SBI 
and those without. 
7.1.1. Bacteraemia in the children’s ED is increasingly healthcare-
associated 
Our data describe changes in the aetiology of bacteraemia between 2001 and 2011 
in children presenting to the ED. Recent national studies in the UK have highlighted 
a reduction in the incidence of vaccine-preventable bacteraemia, and an increase in 
Gram negative bacteraemia in children12,40. This work illustrates that these trends 
are true of children presenting to the ED. We estimate that the introduction of the 
PCV was associated with a reduction in pneumococcal bacteraemia of 
approximately one half. Infections previously considered ‘community-acquired’ are 
increasingly ‘healthcare-associated’ (HCA), with implications for both recognition 
and prompt, effective antimicrobial therapy. An increasing proportion of children 
with serious infections have significant comorbidities372. These HCA infections 
required a longer inpatient stay which is an important, if not unexpected, 
observation. 
Though time to empirical antibiotics was not clearly shown to increase in HCA 
bacteraemia, time to antibiotics was significantly longer in Gram negative infections 
(and indeed all other groups) than in vaccine-preventable infections. These 
infections are increasing in frequency, and make up a greater proportion of 
bacteraemia in the ED than they previously did. Even accounting for changes in the 
aetiology, time to antibiotics increased from 2001 to 2011. 
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The increasing frequency of HCA bacteraemia in the children’s ED (from 0.17 to 
0.43 per 1000 presentations) emphasises the importance of developing appropriate 
empirical antimicrobial protocols. Over the course of the years studied, the 
likelihood that an isolated organism was susceptible to the empirical antibiotic 
choice declined. Though we did not demonstrate adverse outcomes (such as death, 
or admission to PICU) associated with ineffective empirical therapy, adult studies of 
bacteraemia have identified an increase in mortality associated with inadequate 
empirical antibiotics282,283. As these outcomes are relatively rare in children, it may 
be that our cohort was simply too small to detect a difference. 
7.1.2. Broad-range molecular identification (SepsiTest) in whole blood is 
possible in children presenting to the ED, and augments the use of blood 
culture 
Difficulty in recognising bacteraemia coupled with changes in the likely aetiology, 
and a growing likelihood of non-susceptibility to empirical therapy all highlight the 
need for improved diagnostics for bacteraemia. To date, despite the limitations of 
blood culture, no culture independent method of identification has been shown to 
significantly improve the diagnosis of bacteraemia in children. 
Our evaluation of SepsiTest, 16S rRNA PCR with sequencing is the first to be 
undertaken in febrile children presenting to the ED. Using clinical samples of 1ml of 
whole blood we have demonstrated that this approach is possible. The sensitivity of 
SepsiTest is comparable to that of blood culture, though the higher rate of 
identification by SepsiTest of organisms of questionable significance resulted in a 
reduced specificity. Both failed to identify important pathogens including 3 cases of 
meningococcal septicaemia diagnosed by a N.meningitidis specific PCR. Their 
combined use may improve the sensitivity of the diagnosis of bacteraemia in the 
children’s ED. 
The moderate improvement in yield, and the potential of more rapid pathogen 
identification offered by SepsiTest needs to be weighed against the added costs of 
the approach. Not only would the use of SepsiTest incur its own cost (estimated at 
approximately £140 per sample in a 2009 paper83), but the implications of a high 
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rate of identification of possible bacteraemia include prolonged length of stay and 
antimicrobial use. In our sample, we identified 41 false positive results (in 
comparison with 6 blood culture isolates which were considered ‘contaminants’). 
Some of these – and we highlight the common finding of Viridans Group 
Streptococcus – may reflect true, possibly transient, bacteraemia, but it is not clear 
that their identification would have improved the clinical management of these 
children. Most were admitted to hospital for significantly shorter than might be 
expected of a child with proven bacteraemia, and many received only a short 
course of antibiotics, including some who received no intravenous antibiotics at all.  
Stratifying risk using biomarkers, or clinical risk prediction models, may help to 
identify children in whom the use of SepsiTest is most of value. This approach could 
balance the benefits of identifying culture negative infections, as well as potentially 
expediting the diagnosis, against that of the increased false positive rate. A Health 
Technology Assessment-funded cost-effectiveness analysis of SepsiTest alongside 
SeptiFast and Iridica (the most recent iteration of the PLEX-ID MS ESI platform, see 
Section 4.1.2.2) is currently ongoing 
(http://www.crd.york.ac.uk/PROSPEROFILES/16724_PROTOCOL_20150112.pdf).  
7.1.3. Multivariable risk prediction discriminates between children with 
SBI and those with self-limiting infections 
This large, prospective sample of febrile children of all ages attending the ED 
allowed us to derive multivariable risk prediction models for the diagnosis of 
pneumonia, ‘other SBI’ and no SBI. On internal validation, a parsimonious 
multivariable risk prediction model combining clinical features (respiratory rate, 
and ‘normal air entry’) and the biomarkers CRP, PCT and Resistin discriminated well 
between pneumonia and no SBI (c statistic 0.84, 95% CI 0.78 to 0.90) and between 
‘other SBI’ and no SBI (c statistic 0.77, 95% CI 0.71 to 0.83). Importantly, we also 
performed external validation of a previously published model (Nijman et 
al96)which confirmed the value of this model in our new sample (c statistic 0.85, 
95% CI 0.81 to 0.90 for pneumonia, and 0.76, 95% CI 0.71 to 0.80 for ‘other SBI’). 
Two further external validations of published CPRs (by Brent, and Galetto-Lacour) 
were undertaken. The Brent score discriminated poorly between SBI and no SBI (c 
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statistics 0.65), while the Galetto-Lacour ‘Lab score’ performed better (c statistic 
0.79 for the diagnosis of SBI). The evaluation of the Lab score was however limited 
by the use of urinalysis (one of three variables in the Lab score) in only 20% of the 
SPICED dataset. 
The use of risk prediction models allowed the estimation of performance 
characteristics at various risk thresholds. On the basis of this evidence, risk 
thresholds may be established upon which to propose clinical decisions. For 
example, using the derived multivariable model, at a risk threshold of 20%, the 
specificity of the model for the diagnosis of pneumonia was 84% (sensitivity 62%), 
with a PLR of 3.82 (95% CI 2.8 to 5.2). For ‘other SBI’, the equivalent values were 
88% (sensitivity 63%), with a PLR 5.14 (95% CI 3.8 to 6.9). These values would 
support a ‘rule in’ decision and guide appropriate treatment. 
The performance characteristics of the externally validated ‘Nijman’ model were 
encouraging. At the 20% risk threshold suggested above, the specificity of the 
model for the diagnosis of pneumonia was 89% (sensitivity 69%), with a PLR of 6.5 
(95% CI 5.1 to 8.1). For ‘other SBI’ the values were 89% (sensitivity 56%) with a PLR 
of 5.1 (95% CI 4.0 to 6.5). At a low-risk threshold of 5%, the pneumonia model 
achieved a sensitivity was 89% (specificity 70%) with a NLR of 0.16 (95% CI 0.09 to 
0.27), while the ‘other SBI’ model achieved equivalent values of 97% (specificity 
24%) with a NLR of 0.13 (95% CI 0.06 to 0.31). The application of these risk 
thresholds to guide treatment decisions would appear to reliably predict a low-risk 
group in whom SBI can be ruled out, and a high-risk group in whom treatment 
ought to be initiated. There remains an intermediate group for whom further 
observation or investigation would be necessary, and importantly there remains 
residual misclassification. This may be particularly important in the context of ruling 
out SBI, and emphasises the ongoing importance of safety netting48. 
Comparison of the performance of the risk prediction models was made by 
estimating improvements in classification. The first comparison was with a model 
based upon CRP, as CRP is currently recommended by the NICE ‘feverish illness in 
children’ guideline to be used in children considered at risk of SBI. Using 3-category 
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Net reclassification improvement (NRI) to compare the derived multivariable model 
with CRP alone, the derived model improved the classification of non-events (by 
61% for pneumonia, and 85% for ‘other SBI’), but this was achieved at a cost of 
wrongly reclassifying 60% of ‘other SBI’ events into a lower risk category than that 
determined by the CRP model. NRI was also used to estimate the improvement in 
classification obtained by the addition of the biomarkers PCT and Resistin (which 
were found to be of value in the derived multivariable model) to the published 
model by Nijman et al. This comparison yielded modest improvements in 
classification, in particular a 5.3% (95% CI 3.2 to 7.3%) improvement in 
reclassification of ‘other SBI’ non-events. 
 
7.2. Comparison with other studies 
Our findings are consistent with national data in describing a decline in vaccine-
preventable bacteraemia, and an increase in Gram negative bacteraemia12,40. Our 
estimate of a 49% reduction in pneumococcal bacteraemia attributable to the 
introduction of the PCV is comparable with other similar estimates of reductions in 
invasive pneumococcal disease20,287,288. The rate of bacteraemia observed (1.4 per 
1000 attendances) is lower than that of a study of 15781 febrile children attending 
ED in Australia (4.1 per 1000)6. The starting point of our study was the identification 
of all positive blood cultures in children who presented via the ED. This is inclusive 
of all children, irrespective of presentation, and so includes children who presented 
with features other than fever, and to non-medical specialities (such as general, 
orthopaedic and ENT surgeons). The denominator used then was all non-trauma 
presentations, rather than acute febrile illnesses which helps to explain this 
variation. 
We observed an increase in the rate of HCA bacteraemia, as defined in the study, 
from 0.18 to 0.50 per 1000 ED attendances (p=0.002), and a reduction in CA 
bacteraemia (from 1.18 to 0.71 per 1000 ED attendances, p=0.005). The proportion 
of bacteraemia that was HCA increased from 13% to 41%. HCA bacteraemia was 
associated with an increased LOS. This has previously been observed in adults291, 
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though not children. We based the definition of HCA bacteraemia upon markers of 
frequent exposure to the healthcare environment and with reference to a recent 
published systematic review of the subject281. This review summarised the criteria 
used to distinguish CA, HCA and hospital-acquired bacteraemia, as well as the 
relative proportions of each. It identified little evidence upon which to estimate the 
proportion of bacteraemia isolates considered CA, HCA and hospital-acquired in 
children. When neonates were excluded, the mean proportion of episodes which 
were CA was 58% (95% CI 55-61%), and in the one study to report all 3 categories of 
infection, HCA was estimated to account for 26% of bacteraemia episodes373. There 
were no data exclusively from the paediatric ED. It concluded that to date 
inconsistent criteria had been applied to studies of bacteraemia in children and that 
population-based studies which incorporate clinical as well as microbiological data 
should be undertaken in order to define clear evidence-based criteria for each 
category of infection. Such an approach, it was argued, may support the clinician to 
determine the likeliest organism and most appropriate empirical therapy.  
The use of SepsiTest has not previously been described in children. To date, 
evaluations of 16S rRNA PCR as a broad-range molecular test for bacteraemia have 
been limited to the NICU, and the results have been variable. One study reported a 
100% sensitivity for the diagnosis of 15 cases of ‘sepsis and meningitis’ (of 190 
neonates sampled) when compared with culture alone342, though a second study of 
295 neonates reported a sensitivity of only 42% when compared with blood 
culture341. In a recent ED evaluation of SepsiTest and Magicplex (a multiplex real-
time PCR) in 125 adults, SepsiTest was reported to have a sensitivity of only 11% 
(3/27) compared with blood culture344. Consistent with this, studies of alternative 
platforms have produced conflicting results. This is evidenced most clearly by the 
recent meta-analysis of SeptiFast which estimated summary sensitivity and 
specificity (compared with blood culture) as 68% (95% CI 63 to 73%) and 86% (95% 
CI 84 to 89%) respectively. It concluded however that methodological weaknesses 
in the studies rendered the analysis unreliable80.  
We identified a number of clinical signs of SBI broadly consistent with other 
published studies10. Features of an abnormal respiratory examination (increased 
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work of breathing, abnormal auscultation, and hypoxia) all significantly increased 
the likelihood of pneumonia in multinomial analysis, while neck stiffness, a bulging 
fontanelle and irritability were associated with the presence of ‘other SBIs’. We 
failed to demonstrate an association with other general features of the clinical 
assessment such as an ‘ill appearance’, or parental concern. In each of these cases, 
we had a significant problem of missing data. Our data suggest that a petechial rash 
(commonly observed in the study owing to the NICE guidance which advocates 
laboratory testing in all febrile children with a petechial rash) only moderately 
increased the likelihood of bacteraemia (PLR 1.52, 95% CI 0.92 to 2.50). Whilst a 
number of studies have supported its use as a ‘red flag’ sign of serious infection10, 
the majority of these were undertaken specifically in children suspected of 
meningitis91,98, or MCD, in which the proportion of children with proven MCD was 
between 10 and 15%94,95. Such estimates of the risk of MCD or meningitis are 
unrepresentative of the risk in febrile children presenting to the ED. A more recent 
evaluation of petechial spots in the context of the NICE guideline provided less 
compelling evidence of its value as a ‘red flag’. Of four datasets which included data 
on ‘non-blanching rash’, two estimated PLRs >598,374, though one of these selected 
children on the basis of fever and meningeal signs98. Two further studies of 
unselected febrile children (under 5 years) estimated PLRs of 1.7 (95% CI 0.9 to 
3.4)249 and 0.4 (95% CI 0.1 to 2.8)375 respectively. We draw a distinction between 
petechial rash and purpura, which occurred rarely in our study (n=10), and which is 
likely to be of more clinical significance. While petechial rashes may indicate serious 
illness, including invasive infection, we question its continued inclusion as a ‘red 
flag’ feature in the NICE guidance. 
Recent diagnostic accuracy studies have demonstrated the value of multivariable 
risk prediction in the diagnosis of SBI in children in the ED. Whilst we approached 
the derivation of a risk prediction model using a stepwise model building approach, 
both Nijman et al96 and Craig et al6 pre-determined the variables to be included in 
their risk models. This was done on the basis of a substantive understanding of the 
importance of these variables in clinical practice. Model selection based upon 
stepwise methods is commonly used, but has been criticised for underestimating 
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the confidence intervals of the parameter estimates, and of ignoring the effects of 
variables with small, but potentially interesting effects362. In order to mitigate this, 
we included a validation sample, in which the derived model performed reasonably 
well.  
The external validity of studies such as this depends upon the population selected. 
We included children up to 16 years (that is, the great majority of children 
presenting to the ED), and did not select on the basis of clinical presentation (other 
than ‘history of fever’). We included children with comorbidities, with the exception 
of immunodeficiency, and children who had received prior antibiotics as we 
considered that these children represented an important risk group for SBI. As the 
primary outcome of the original study was based upon an evaluation of PCT, 
recruitment was limited to those children who were undergoing blood tests. As 
such, the proportion of children with an SBI diagnosis (24%) is higher than that of 
the population of all febrile children attending the ED, estimated (in children under 
5) to be 7%6. This has been a common limitation of diagnostic accuracy studies of 
SBI in children, particularly those in which the focus has been on biomarker 
evaluations185. A recent external validation of published clinical prediction rules in 
nearly 10000 presentations of febrile children to primary care reported 
disappointing performance characteristics for most of the rules. In particular the 
rules demonstrated a limited ability to rule out serious illness361. There were 
particular challenges associated with undertaking the study, including the reliable 
collection of multiple clinical variables, and the appropriate attribution of 
outcomes. In this setting, where the determination of an outcome diagnosis was 
impractical, a proxy of ‘referral to ED’ was applied. This should be considered an 
important and appropriate proxy of serious outcome in febrile children, but it is 
unsurprising that prediction models derived to identify serious infection fail to 
explain additional variation in primary care referral practices. There remains a need 
to undertake high quality diagnostic accuracy studies in lower risk populations in 
both ED and in primary care. Such studies ought to identify the most parsimonious 
models, and identify ways – such as the use of electronic devices – to mitigate 
problems of missing data by automatically documenting clinically relevant variables. 
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Acknowledging the particular characteristics of our sample, the external validation 
of the Nijman et al prediction model provides support for its generalisability. 
Discrimination and calibration of the models for the diagnosis of pneumonia and 
other SBIs was good, and at risk thresholds of 20% the PLRs (6.5 and 5.1 for the 
diagnosis of pneumonia and other SBI respectively) supported a rule in decision, 
and at 5%, the NLRs (0.16 and 0.13 respectively) supported a rule out decision. This 
is the first such validation of the model that we are aware of. The Lab score has 
been externally validated now on two occasions253,364. The most recent validation 
reported a c statistic of 0.79 for the diagnosis of SBI and at a threshold score of 3 (as 
identified in the original study) sensitivity, specificity, PLR and NLR were 60%, 86%, 
4.32 and 0.46 respectively. That is, a score of ≥3 provided some support to rule in 
SBI. Interestingly, as part of the external validation, the authors investigated the 
additional value of PCT or urinalysis over and above CRP (instead of the three 
together as proposed in the Lab score), and concluded that in children with either 
very low or very high CRP, the post-test probability was not substantially altered by 
the addition of these tests. In children with intermediate CRP values (between 20 
and 100), the addition of a PCT result had the potential to significantly alter the 
likelihood of SBI364. The Brent score performed poorly in our sample and we are not 
aware of another external validation of this. 
While the external validation provides reassurance of the reliability of the clinical 
predictions, the important consideration is the potential impact of these 
predictions upon clinical decision-making. This kind of impact analysis is the final 
stage of the process of translating diagnostic accuracy research into clinical 
practice, and is rarely achieved, particularly in children234,363. It is a branch of the 
emerging field of implementation science which seeks to understand how such 
evidence-based tools are adopted and sustained. Disappointingly, a decision model 
based upon the Nijman prediction model was recently evaluated in a randomised 
controlled trial of 439 febrile children (1 month to 16 years) in ED. While the model 
discrimination remained good, and compliance with the decisions was high, no 
significant improvement in outcomes (in terms of correct diagnoses, and also 
improvements in length of stay or hospital admission) were observed371. A small 
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trial of the Lab score similarly failed to demonstrate an impact on antibiotic 
prescribing in young children (less than 3 years)370. 
It is important to understand why these interventions, supported by robust 
evidence to demonstrate the reliability of their predictions, failed to impact clinical 
care. In the case of the Lab score, the authors explain the lack of impact as a 
consequence of a lack of adherence, and suggest that had adherence been higher, 
an estimated 26% reduction in antibiotic prescribing might have been observed370. 
In the case of the Nijman model, adherence to the protocol was good. The authors 
speculate that the lack of demonstrable impact from the decision rule intervention 
may be explained by a high level of diagnostic discrimination in the control group as 
a consequence of the setting in a specialist paediatric ED371. 
In both cases, the introduction of the diagnostic intervention relies upon more than 
simply the evidence demonstrating diagnostic accuracy. Translating this evidence 
from diagnostic accuracy studies into an effective clinical tool requires an 
understanding of the barriers preventing implementation. Such barriers may be 
logistical, behavioural, or economic and should be evaluated as part of studies 
which attempt to quantify impact. Understanding clinician behaviour regarding 
interventions to rationalise imaging in the ED369, as well as to rationalise antibiotic 
prescribing has been important in achieving significant clinical improvements376,377. 
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7.3. Clinical implications 
Bacteraemia is a clinically important SBI associated with substantial morbidity and 
mortality. It occurred in 1.4 per 1000 non-trauma attendances to the ED in our 
dataset, and has been estimated to occur at a rate of 4 per 1000 in febrile children 
in this setting. It remains difficult to predict its presence or absence, still less 
identify a causative organism and its associated antimicrobial susceptibilities. 
Understanding the changing aetiology of children’s bacteraemia in the ED has 
important implications for the establishment of appropriate empirical antibiotic 
regimens. 
The increasing proportion of infections which are HCA means that empirical 
antibiotic regimens will need to take account of a broader range of potential 
pathogens, and appropriately cover possible resistant organisms. Identifying those 
children most likely to require broad antimicrobial cover will be necessary in order 
to make rational use of antibiotics. Evidence-based criteria for the definition of HCA 
bacteraemia would allow the targeting of those children most at risk. 
The use of adjunctive diagnostic tests with the potential to expedite pathogen 
identification would support this objective of rational antibiotic use. Alongside a 
designated antimicrobial stewardship intervention, the use of MALDI-TOF MS 
(which applies mass spectrometry to positive culture isolates, Section 4.2.1) has 
been associated with a shortened time to effective antibiotics in adults with 
bacteraemia303. Our data do not support a role for SepsiTest at this time. SepsiTest 
is able to diagnose bacteraemia in small volumes of whole blood taken from febrile 
children in the ED. Its value in addition to blood culture is moderate, however, and 
we have not evaluated its ability to report positive results more quickly, and 
thereby influence clinical decision relating to antimicrobial use. It is likely that tests 
such as SepsiTest should be used in a targeted fashion in children considered most 
at risk of bacteraemia, and in whom empirical antibiotics have already been started. 
The ongoing cost-effectiveness review of SepsiTest alongside Septifast and Iridica 
(see Section 7.1.2) may be informative in this regard. 
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In the UK, the current approach to the febrile child presenting to the ED is 
supported by the clinical guideline “Feverish illness in children”, published by NICE. 
This consensus guideline has been demonstrated to have limited capacity to 
discriminate between self-limiting and serious infections352, and improved methods 
of risk assessment should be introduced as a priority.  
Our data support a growing body of research to suggest that clinical prediction 
models can improve the prediction of risk of SBI in febrile children of all ages 
presenting to the ED. Combining predictive clinical signs with biomarkers such as 
CRP can accurately predict the presence of SBI. The addition of other biomarkers 
such as PCT and Resistin may further improve risk classification, but our evidence to 
support this is limited.  
 
7.4. Research implications 
The absence of a validated, evidence-based definition of HCA bacteraemia in 
children should be addressed through population-based studies which combine 
clinical and microbiological data. Such a definition would support clinicians to 
identify those children in the ED most likely to need broad empirical antibiotics. 
Further evaluations of adjunctive tests to identify bacteraemia, such as SepsiTest, 
should be undertaken in well-defined populations of children. The potential impact 
of the introduction of such diagnostics is both in increasing the sensitivity of 
diagnosis beyond that of blood culture, and in identifying a clinically relevant 
reduction in time to pathogen identification which significantly impacts clinical care. 
In order to address these questions, studies should be undertaken in real-time, and 
should include a cost-effectiveness evaluation. Identifying suitable methods to 
define an appropriate reference standard (either by using a consensus diagnosis378, 
or statistical methods to ‘correct’ the imperfect reference standard64) would allow a 
better understanding of the true value of these tests. 
The risk classification improvement achieved by updating the model of Nijman et al 
requires validation in an external population. Though relatively modest, the 
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addition of the biomarkers PCT and Resistin to the Nijman model may be 
considered worthwhile if demonstrated to improve outcomes by improving time to 
antibiotics in those with SBI, and by reducing unnecessary hospital admission and 
antimicrobial use in those without. Recognising the challenges of determining 
outcome diagnoses in studies of SBI in children, appropriate outcomes for 
diagnostic accuracy studies should include practical, clinical end-points such as the 
need for hospital admission or antimicrobial use. 
There is a significant need to evaluate the clinical impact of demonstrably accurate, 
validated risk models when incorporated into decision-making. Intervention studies 
of decision tools in this setting have so far been disappointing371,374. Evaluation of 
this clinical impact requires an understanding of the behaviour of clinicians, parents 
and children in using and interpreting such a proposed tool. Important 
considerations would include the determination of appropriate risk thresholds 
around which to base decisions, and what these decisions should be – admit, treat, 
observe, investigate, discharge? Recognising the residual risk inherent in the 
diagnostic process, another important area of research includes the most 
appropriate approach to safety netting – providing adequate support for children 
and families who are being discharged from the ED48. 
The role of biomarkers in published risk stratification models for the diagnosis of 
SBI in children is relatively modest. The model published by Nijman incorporated 
the use of CRP, while the Lab score combines CRP and PCT, alongside a urinalysis 
test. While CRP and PCT assays are both available as near-patient tests, in order to 
realise the potential of these biomarkers in the context of multivariable risk 
prediction, the development of multiplex bedside assays should be pursued. There 
is currently no near-patient test for Resistin. 
The potential impact of improved risk prediction upon clinical decision-making may 
be substantial, though such an outcome has yet to be demonstrated. The increasing 
number of short stay, uncomplicated hospital admission in children with self-
limiting acute infections illustrates the difficulty faced by clinicians in the ED. 
Disappointing recent evaluations of established consensus guidelines, such as the 
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NICE guideline, should prompt a move towards evidence-based rules to support 
decision-making in the ED. In light of the recent evidence from RCTs of the Lab 
score and Nijman model validated here, future studies of diagnostic interventions 
of this type require a multidisciplinary approach in order to understand the most 
effective methods of implementation. Only in the context of such implementation 
studies will it be possible to evaluate the impact of these diagnostic approaches. 
 
7.5. Conclusions 
This thesis details the persistent challenges relating to the diagnosis of SBI in the 
children’s ED. We have described the evolving nature of paediatric bacteraemia, 
and the implications for both prompt recognition and effective empirical 
antimicrobial therapy. Our evaluation of the SepsiTest broad-range molecular 
diagnostic provides evidence of its potential use in whole blood samples from 
children in the ED, but highlights too its limitations in this setting. We have derived 
risk prediction models incorporating recognised clinical variables alongside the 
biomarkers CRP, PCT and Resistin, and externally validated previously published risk 
prediction models of SBI in the children’s ED, estimating the additional value of the 
biomarkers PCT and Resistin to a model incorporating CRP alone. This work should 
provide further impetus for the evaluation of the impact of decision rules based 
upon such risk models upon important clinical outcomes such as admission to 
hospital, and rational antimicrobial use. 
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Appendix 1: Information leaflet detailing the SPICED study provided to eligible older children
 
Do I have to take part? 
No.  
 
 Can I change my mind? 
Yes.  If you change your mind, just tell your parent/guardian or the 
doctor or nurse. 
Who is doing this research? 
Doctors at your hospital and scientists at the University of 
Liverpool. 
 Who do I ask about this? 
Your parents will have been given lots of information.  If they are 
not sure, the doctor or nurse who gave you this information leaflet 
can tell you more.  
 
 
 
 
 
 
   
 
SPICED Study 
Salivary Procalcitonin for the Detection of 
Bacterial Infection in Children admitted to the 
Emergency Department 
   
 
Oldest Participants Information Leaflet 
(13 -16 years) 
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How do the doctors know if the germs are 
making you sick? 
By looking at samples of blood and other fluids under a microscope 
or sending these samples to a laboratory for more tests, doctors 
can sometimes tell if you have a bacterial infection. This is not 
always possible and the tests we currently use may sometimes fail 
to pick up people with a serious infection. 
 
What is the study about? 
 
In this study we will be looking at all children and young people 
who come to A+E with a fever. We are a looking at a test to see if it 
can tell us if you have bacterial germs in your body. We will 
measure this test in your saliva (spit) as well as in your blood. 
 
Why is the study being done? 
If we can show that this new test is reliable at predicting bacterial 
infection in saliva as well as in blood then it can be used to help 
decide whether people need antibiotics or not, without the need 
for  a blood test.  
What will happen? 
 
We will collect the saliva by putting a swab (cotton wool roll) in 
your mouth for a few minutes and then taking it out. It does not 
hurt at all. There will be no extra needle pricks as part of the study. 
We will do the tests on the blood sample that is already being taken 
from your arm or hand. The doctors or nurses will ask if you wish to 
have local anaesthetic cream on before they take the sample. 
 
What will happen to the blood sample? 
Your samples for will be tested in accredited laboratories at 
Alder Hey and at the Health Protection Agency.  They will be 
kept safe in locked freezers and will only be identified by a 
code, for increased security.  Once this study has been 
completed the sample will made anonymous, so it cannot be 
traced back to you.   
 
Are there any risks or benefits to taking part? 
There are no risks for you.  We are hoping the information 
collected will help children/young people in the future. 
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Appendix 2: SPICED study form for recording parental consent 
 
  
 
 
Alder Hey Children's NHS Foundation Trust  
Liverpool 
L12 2AP 
Telephone: 0151 228 4811       Attach patient ID sticker here 
 
Study Number: 
Participation Identification Number for this study: 
 
CONSENT FORM FOR RESEARCH 
For parent/person with parental responsibility 
 
Title of project: Salivary Procalcitonin In Children attending the Emergency Department (SPICED) 
 
 
Name of researcher: Job Title: 
 
 Please 
initial box 
1. I confirm that I have read and understood the information sheet 
dated 10/08/10 (version 2.0) for the above study.  I have had the 
opportunity to consider the information, ask questions and have had 
these answered satisfactorily 
 
 
2. I understand that my child’s participation is voluntary and that I am 
free to withdraw my child at any time, without giving any reason.  If I do 
withdraw, his/her medical care and legal rights will not be affected in 
any way. 
 
 
3. I understand that relevant sections of my child’s medical notes and 
data collected during the study may be looked at by individuals from 
regulatory authorities or from the NHS Trust, where it is relevant to my 
child taking part in this research. I give permission for these individuals 
to have access to my child’s records 
 
 
  
4. I agree for my child to take part in the above study.  
 
5. I agree to my child’s samples being stored for future studies.    
 
 
Name of patient ________________________________________ 
 
 
-------------------------- 
Name of parent and 
Guardian 
---------------------------- 
Date 
-------------------------------- 
Signature 
Name of person taking 
consent 
(if different from researcher) 
---------------------------- 
Date 
-------------------------------- 
Signature 
Researcher ---------------------------- 
Date 
-------------------------------- 
Signature 
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Appendix 3: SPICED study Case Report Form 
 
 
  
Patient ID: 
 
PROCEDURE CHECKLIST (Tick if done) 
 
Signed consent   [  ]   
(white copy to parents, yellow with CRF, pink in notes) 
 
Salivary PCT     [  ] 
 
Blood FBC      [  ]  
Glucose     [  ]   
Blood culture     [  ]  
Blood PCR (0.5ml EDTA/red)  [  ]  
Blood PCT/NGAL (1ml U+E sample)  [  ]  
 
CXR       [  ] 
 
Urine  Urinalysis    [  ]  
Microscopy, Culture    [  ] 
 
 
 
Date of admission  ___/___/___   
 
Date of discharge:  ___/___/___  
 
Discharge diagnosis:  
 
 
 
  
 
Recruitment: 
 
Nurse Doctor 
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Name:        DOB: 
 
Unit No:       Sex:  M / F 
 
Postcode 
 
 
Date of admission  ___/___/___  Time of booking 
       (24 hour clock) 
 
 
Route of Admission  Direct to A+E / GP / other hospital 
 
 
Sought medical care in previous 24 hrs   Y N 
If yes, from GP/walk-in/ NHS direct/A+E 
 
Sought medical care in previous 48 hrs   Y N 
If yes, from GP/walk-in/ NHS direct/A+E 
 
Any antibiotic given prior to admission to A+E Y N 
 
 
 
 
 
Past Medical History: 
 
Preceding Illness Y / N   
ICD 10 code: 
   
Chronic Illness  Y / N  
ICD 10 code:  Primary 
Secondary 
 
Antibiotic Dose Frequency Start date 
dd/mm/yy 
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Feeding:  Breast / Formula / Breast+Formula / Weaned / Weaned+Breast 
 
Parental Smoking  Y / N / NR 
 
Clinical History: 
 
 Y/N Duration 
(hrs) 
Cough   
Difficulty 
breathing 
  
Wheeze   
Chest pain   
Sore throat   
Ear ache   
Seizures   
Neck Stiffness   
Parental 
concern 
  
 
 
Other   Y/ N   State other___________________ 
  
Immunisation 
2 months    DTaP/IPV / Hib    Y/N  PCV   Y/N   
3 months   DTaP/IPV / Hib    Y/N    MenC   Y/N   
4 months  DTaP/IPV / Hib    Y/N    MenC  Y/N 
          PCV   Y/N   
12 months   Hib      Y/N MenC  Y/N 
13 months   MMR   Y/N PCV  Y/N 
3-4 yrs    DTaP/IPV   Y/N MMR  Y/N 
Girls 12-13 years  HPV   Y/N 
13-18 years   dT/IPV   Y/N 
 Y/N Duration 
(hrs) 
Fever   
Vomiting   
Diarrhoea   
Drowsiness   
Headache   
Rash   
Myalgia   
Irritability/ 
Inconsolable crying 
  
Dysuria   
Abdo pain   
Decreased intake   
Dry nappies/ 
reduced UO 
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Clinical Examination 
 
 
Dehydration Y N If yes, mild Y   N, moderate Y   N, severe Y N 
Oedema Y N  Jaundice Y N 
 
Respiratory System 
Cyanosis   Y N  If no to the above:  
 Work of breathing  Y N  Normal air entry  Y N 
Stridor    Y N   Chest clear  Y N 
Decreased breath sounds Y N   
Crackles   Y N   
Wheeze   Y N   
Signs    RML / RLL / RUL / LLL / LUL  
Finger clubbing  Y N   
 
Cardiovascular System   Cyanosis Y N    
HS normal Y N      
If no,  Murmur / third sound / other 
 
Abdomen 
Oral thrush   Y N Mouth sores      Y      N 
Liver enlarged      Y N  If yes,  cm below RCM  
Spleen enlarged   Y N  If yes,  cm below RCM 
General appearance Very unwell/moderately unwell/mildly unwell 
Bulging fontanelle Yes/no/closed 
Rash Yes/no  
If yes petechial/purpuric/maculopapular/other 
If other, describe  
Abn ENT signs Y/N 
Sunken eyes Y/N 
Dry mucous membranes Y/N 
Pale skin Y/N 
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Lymphadenopathy Y / N   
If yes,  cervical / submandibular / axillary / inguinal / epitrochlear 
 
Neurological 
Mental state:  A / V / P/ U 
 
Pupillary reflex:   PERL/abnormal 
   If abnormal, describe:  
Neck stiffness:  Y / N    
Kernig’s sign:         Y / N  
 
 
Fundoscopy:  Done / Not done 
Fundoscopy:  Normal 
Blurred disc margins 
Papilloedema 
Haemorrhage 
Not visualised 
 
 
Overall clinical impression: 
 
Fever without source  Y / N 
 
Other:   
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Time Study: 
 
 
 
 
 
 
 
 
 
 
Time antibiotic given  (24 hr clock)   _ _:_ _ 
 
Fluids given in first 6 hours (circle all that apply) 
 
Normal saline / albumin / gelofusin / blood /platelets / fresh frozen plasma 
 
Please complete fluids form 
 
OUTCOME 
 
Duration of hospital stay (days): 
   
PICU admission  Y N   
If yes, date of PICU admission __________ date of PICU discharge________ 
 
HDU admission  Y N   
If yes, date of HDU admission __________ date of HDU discharge________ 
 
Dead/Alive Date of death: 
 
Final diagnosis 
ICD 10 code  1. Primary 
   2. Secondary  
 
Hr Temp SBP DBP MAP HR CR AVPU RR Sats 
0          
1          
2          
3          
4          
5          
6          
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Antibiotic form         Weight: 
 
Antibiotic Route Dose Frequency Start date 
dd/mm/yy 
Stop date 
dd/mm/yy 
      
      
      
      
 
Route: IV=intravenous, O=oral, Neb=Nebulised, IM=intramuscular, T=topical, 
IT=intrathecal, SDD= selective decontamination of digestive tract 
 
Intravenous Fluid Form 
 
Fluid Bolus (B) or 
Infusion (I) 
Infusion rate 
(ml/hr) 
Start time 
24 hr clock 
Stop time 
 24 hr clock 
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Appendix 4: Reproduced with permission from Pediatrics, Volume 135 (4), Pages 635-642. Copyright 
2015 by the AAP. 
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